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ABSTRACT 
Breast cancer (BC) is the most commonly diagnosed cancer in the UK 
and the second leading cause of cancer-related deaths in women 
worldwide. Limited treatment is available to patients with metastatic BCs, 
which are resistant to therapy. There is a strong link between metastatic 
BC and Epithelial Mesenchymal Transition (EMT). There is a need to 
target EMT, in order to prevent metastasis for which the therapy is not 
effective. Therefore, there is a need for improved pre-clinical models that 
will allow studying EMT in real-time. This study aimed to refine current in 
vivo models of BC, by incorporating inducible bioluminescent reporter(s) 
that will allow real-time read-out of EMT. The cell-lines used were 
classified according to their expression of EMT markers and cancer stem 
cell (CSC) profile. Inducible bioluminescent EMT reporters based on the 
S100A4 or E-cadherin or N-cadherin promoter driving firefly luciferase 
were constructed and used to transduce the cell lines. The activity of the 
S100A4 reporter was validated in hypoxic conditions in MCF-7 and 
BT549 cells, where it was shown that induction of S100A4-generated 
bioluminescence was associated with upregulation in S100A4.  In vivo it 
was shown that human mesenchymal stem cells promoted the tumour 
growth of MCF-7 cells and/or induced EMT-related traits, including 
downregulation/loss of E-cadherin, upregulation of Vimentin and/or 
upregulation of S100A4. The activity of the S100A4 reporter was tested 
in a similar in vivo model, where it was shown that S100A4-generated 
bioluminescence correlated with protein expression of S100A4. Taken all 
the data together, we generated an inducible bioluminescent EMT 
reporter that can detect the baseline levels and changes in the S100A4 
expression. The model can be potentially used for giving a real-time read 
out of EMT/early stages of EMT and subsequently for testing novel drugs 
targeted at the onset of EMT.  
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GLOSSARY 
 
 
ALDH=Aldehyde dehydrogenase 
BC=Breast cancer 
BCSCs=Breast CSC 
BrCAFs=Breast cancer CAFs 
BSA=Albumin from bovine serum 
CAFs=Cancer associated 
fibroblasts 
cDNA=Complementary DNA 
CSCs=Cancer stem cells 
dNTPs=Deoxynucleotides 
EGFR=Epidermal growth factor 
receptor 
EMT=Epithelial-mesenchymal 
transition 
EpCAM=Epithelial adhesion 
molecule 
ER=Oestrogen receptor 
FC=Flow cytometry 
FSP1(S100A4)=Fibroblast 
specific protein 
HBSS +DQN¶VEDODQFHGVDOW
solution 
HIF=Hypoxia-inducible factor 
hMSCs=Human MSCs 
IF=Immunofluorescence 
IgG=Immunoglobulin G 
IHC=Immunohistochemistry 
IL=Interleukin 
IRES=Internal ribosome entry site 
mAb=Monoclonal antibody 
MET=Mesenchymal-epithelial 
transition 
MFP=Mammary fat pad 
mRNA=Messenger RNA 
MSCs=Mesenchymal stem cells 
O/N=Overnight 
PBS=Phosphate buffered saline 
PCR=Polymerase chain reaction 
PDX=Patient-derived xenograft 
PR=Progesterone receptor 
qPCR=Quantitative PCR 
qRT-PCR=Quantitative reverse 
transcriptase PCR 
RT=Room temperature 
SC=Subcutaneous 
TAM=Tumour associated 
macrophages 
TF=Transcription factor 
TGF=Tumour growth factor 
TME=Tumour microenvironment 
TNF=Tumour necrosis factor 
VEGF=Vascular endothelial 
growth factor 
 
 
 
 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
1.1 Breast Cancer 
 
1.1.1 Incidence 
Despite the many advances in breast cancer (BC) therapy including 
improvements in the local management of breast cancer [1], 
implementation of screening, and introduction of adjuvant treatments [2], 
breast cancer is still the most commonly diagnosed cancer in the UK and 
the leading cause of cancer-related death in females worldwide [3]. In the 
UK, BC is the second most common cause of cancer death in women, 
accounted for 11,633 deaths in 2010, 1% of which were in men (latest 
statistics were obtained from www.cancerresearchuk.org). A new study 
revealed that most deaths occur in women who were not regularly 
screened [4]. Failure to detect and treat primary cancers at early stages 
could result in metastatic breast cancer, in which the cancer has spread 
to regional and distant sites including lymph nodes, lung, liver, brain and 
bones [5], and there is currently no effective treatment available.   
1.1.2 BC subtypes and clinical implications  
The clinical scenario is further complicated by the heterogeneity of breast 
cancers and their diversity in responsiveness to treatment. In an early 
study, Perou, C.M., et al. (2000) [6] analysed gene expression in 
specimens from human breast tumours, and demonstrated two different 
cancer types which were either oestrogen receptor positive (ER+) or 
negative (ER-$QDO\VLVRIWKH³LQWULQVLFJHQHH[SUHVVLRQ´VLJQDWXUHVRI
BCs, allowed further classification of breast cancer into five molecular 
subgroups defined as luminal A, luminal B, HER2+, basal-like and 
normal-like [7, 8]. The different subgroups could be explained by their 
cellular origin, originating from either luminal or basal/myoepithelial 
progenitors within the normal breast tissue (reviewed in [9]), although the 
cellular origin of BC is still unclear. Luminal subtypes are ER+ and PR+ 
and they express luminal markers.  While Luminal A tumours do not 
express HER2, Luminal B tumours are either HER2+ or HER2- [10]. The 
HER2+ subgroup is characterised by HER2 expression and may lack the 
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expression of ER and PR. The basal-like tumours are further subdivided 
into Basal-A and Basal-B tumours and are characterised by the lack of 
(535DQG+(57KH\DUHDOVRNQRZQDV ³triple-negative´ WXPRXUV 
Basal-% WXPRXUV DUH DOVR FKDUDFWHULVHG E\ D µFODXGLQ-ORZ¶ PROHFXODU
portrait. While Basal-A tumours have mixed luminal/basal features, 
Basal-B/ claudin-low tumours express markers that define the basal 
lineage. Finally, the normal-like group shows a genetic profile that 
resembles the normal breast tissue.  Different subgroups have different 
clinical outcomes, and depending on the molecular profile discussed 
above, a different therapeutic approach is taken; for example hormonal 
therapy can be used to treat those cancers that express the ER 
receptors. Limited treatment is available to patients with triple-negative 
breast cancers [11].  
1.1.3 Triple-negative cancers 
Triple-negative cancers, show a more aggressive phenotype compared 
to other subtypes [7, 12-14], and several studies have associated them 
with poor prognosis, high incidence of metastasis, and high rate of 
disease recurrence after therapy [11]. Although effective targeted 
therapies have been developed to target those patients with hormone 
receptor-positive tumours, the targeted therapy for triple-negative 
cancers is not effective. As triple-negative cancers share features with 
BRCA-1-related cancers (cancers carrying a mutation of the BRCA1 
tumour suppressor gene) including high nuclear grade, cytokeratin 5/6 
expression, Ki-67 staining, ER negativity and epidermal growth factor 
receptor (EGFR) expression, a shared therapeutic approach is 
suggested [15]. However, triple-negative cancers show reduced 
sensitivity to chemotherapy.  This can be explained by their aggressive 
phenotype: the morphological appearance of these tumours is 
consistently characterised by high proliferation, high rate of genetic 
aberration, high grade, central necrosis, frequent apoptotic cells and an 
advancing border of invasion [7, 12-14]. Furthermore, resistance to 
therapy can be explained by the fact that Basal-B and BRCA1-related 
cancers are enriched for cells with stem-cell like characteristics [16, 17], 
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and have enhanced invasive properties and a mesenchymal gene 
signature associated with epithelial-mesenchymal transition (EMT) [18].  
 
1.2 Cancer Stem Cells (CSCs) 
 
1.2.1 The Cancer Stem (CSC) Model 
The cancer stem cell (CSC) hypothesis has become a major focus in 
cancer research. It might explain why cancers are not curable, and 
promises new therapeutic strategies that target only the malignant cells 
[19].  
Cells within the tumour population demonstrate different proliferative and 
differentiative capacities known as tumour heterogeneity, which can be 
explained by two different models: the CSC [20, 21] and the clonal 
evolution model [22, 23]. The clonal evolution model proposes that most 
malignancies arise from a single normal cell through accumulation of 
mutations. This cell is characterised by genetic and epigenetic 
instabilities that are selected and passed to the offspring that also acquire 
mutations, forming a mass of genetically varied cancer cells. The CSC 
model comprises two distinct but related components [24]. The first 
proposes that cancers originate in cell populations that preserve or 
acquire the properties of normal stem cells to self-renew. These cells can 
be mutated normal stem cells, transit-amplifying cells, or differentiated 
cells (Figure 1). The second component holds that cancers are organised 
in a hierarchical fashion, in which stem cells both drive the malignant 
process and generate non-renewing cells that form the tumour bulk. The 
two models are not mutually exclusive in those cancers that are 
organised hierarchically into populations of tumorigenic and non-
tumorigenic cells; in these cells clonal evolution occurs in the CSCs.  
Evidence for the clonal evolution model came from different studies 
including (a) cytogenetic studies that showed that all cells within tumours 
had the same karyotype, suggesting that cells arose from the same 
origin, (b) studies of the isoenzymes of glucose-6-phosphate 
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dehydrogenase in neoplasms in heterozygous women indicated that the 
same member of the X chromosome pair is functional in all cells of a 
given tumour, indicating that cells descended from a single precursor and 
(c) studies that showed that the immunoglobulin produced by plasma cell 
tumours has in almost every case the homogeneity characteristic of a 
single clone [22]. Evidence for the CSC model arose from studies in 
leukaemia; for example, Dick and colleagues showed that adult human 
AML stem cells can be purified from patients and even though they 
comprised a very small proportion of AML cells, they were the only cells 
that could form tumours in immunocompromised mice [21]. This proved 
that not all the cells have the same tumourigenic capacity. Nonetheless, 
data over the past few years support the existence of CSCs in solid 
malignancies. The first evidence of CSCs in solid tumours came from 
breast cancer, and subsequently CSCs were isolated from brain tumours, 
colorectal and pancreatic carcinomas [25]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 Properties of CSCs  
CSCs share properties with normal stem cells: they can self-renew 
through symmetrical or asymmetrical divisions, they can differentiate, 
and colonise other parts of the body [26]. It is suggested that CSCs are 
resistant to treatment for many reasons including their low proliferative 
= Mutation 
Figure 1. The CSC model. Mutated stem cells, transit-amplifying cells 
or differentiated cells acquire the ability to self-renew and form tumours, 
composed of both tumorigenic and non-tumourigenic cells. 
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rate, quiescence, high efficiency of DNA repair, high levels of anti-
apoptotic molecules, and high levels of ATP-binding cassette drug 
pumps [26]. This could explain why local recurrence is so common after 
therapy, and unfortunately no effective treatment currently exists for 
metastatic breast cancer.   
1.2.3 Breast CSCs (BCSCs) 
Breast cancer stem cells have been identified based on the expression 
of cell surface markers. In an early study, Al-Hajj M. et al (2003) [27] 
isolated a cell population from breast cancer xenografts, able to form 
tumours in immunodeficient mice. This population, which only comprised 
1-35% of the total cell population, expressed the markers CD44+/CD24-
/low/lin-. In contrast to tens of thousands of cells with alternative profiles, 
as few as 100 cells with this profile formed tumours in NOD/SCID mice 
and they were able to reinitiate tumours in these mice and retained this 
ability; each time cells within this population were passaged they were 
able to form new tumours containing additional CD44+CD24í/low cells. 
Subsequent studies showed that the CD44+/CD24-/Low phenotype was 
characterised by radiation-resistance [28] and enhanced invasive 
properties [29]; it was enriched in basal-like cell lines [29-31] and BRCA1 
related cancers [32]. Aldehyde dehydrogenase 1 (ALDH1) has also been 
used to enrich for BCSCs; cells positive for ALDH1 have increased 
tumorigenicity, and patients with increased ALDH1 expression are 
resistant to treatment and have poor outcomes [33]. The main role of 
ALDHs is to detoxify aldehydes, that would otherwise be cytotoxic, 
through their oxidation to carboxylic acids (reviewed in [34]). 
Furthermore, they have other functions such as ester hydrolysis and 
production of retinoic acid.  The exact role of ALDH1 in CSCs still remains 
unknown, but it is thought to have a role in early differentiation of stem 
cells, through its role in oxidizing retinol to retinoic acid. CSC markers are 
also used in combination; for example, the CD44+/CD24-/low/lin- 
ALDEFLUOR-positive population was highly tumorigenic and could 
initiate tumours in immunodeficient mice. BCSCs are also enriched for 
the EpCAM (epithelial cell adhesion molecule, ESA) [30]. The 
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CD44+/CD24-/ESA+ phenotype in basal cancers represents cells capable 
of initiating tumours in immunodeficient mice.  
Emerging research suggests that BCSCs can be generated through the 
process of epithelial-mesenchymal transition (EMT) [35-37]. 
 
1.3 EPITHELIAL-MESENCHYMAL TRANSITION  
 
1.3.1 What is EMT? 
EMT is a complex biological process through which polarized epithelial 
cells are subjected to various changes, enabling them to acquire a 
mesenchymal cell phenotype [38]. Hallmarks of EMT include disruption 
of cell-cell adherence, loss of apico-basal polarity, extracellular matrix 
(ECM) remodelling, enhanced invasiveness and increased migratory 
capacity. At the molecular level, loss of expression of the cell adhesion 
molecule, E-cadherin, and upregulation of mesenchymal markers such 
as N-cadherin, Vimentin and Fibronectin are observed. During EMT, cells 
acquire a spindle-like morphology, resistance to apoptosis and stem-like 
traits. This process is, however, reversible, as cells can re-differentiate 
into epithelial cells through mesenchymal-epithelial transition (MET), or 
into other cell types, after migration to distant sites [39].  
1.3.2 Types of EMT 
EMT can occur in three different biological settings that carry very distinct 
functional consequences and is therefore classified into three types 
based on the biological context under which it occurs [40].  
1.3.2.1 Type 1 
Most adult tissues and organs arise from several rounds of EMT and MET 
referred to as primary, secondary and tertiary EMT [41]. These type 1-
EMTs are responsible for the transition of epithelial cells to motile 
mesenchymal cells during implantation, embryo formation, gastrulation 
and neural crest migration. Subsequently, these cells generate 
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secondary epithelia in mesodermal and endodermal organs via MET. At 
the biochemical level, EMT associated with gastrulation is regulated by 
the Wnt signalling, with the TFs Sox, Snail, FoxD3 being involved in EMT 
during embryonic development. In addition, signalling pathways 
mediated by Wnts, FGFs, BMPs, c-Myb and Msx-1 induce EMT during 
neural crest formation.  
132.2.2 Type 2 
Type 2 EMT is associated with organ fibrosis, wound healing and tissue 
regeneration [40]. Organ fibrosis occurs in a variety of fibrotic tissues, 
mediated by accumulation of myofibroblasts that secrete a number of 
inflammatory signals (collagen, laminins, elastin and tenascins) which 
are in turn deposited as fibres and eventually lead to organ failure. It has 
been shown that type 2 EMT generates myofibroblasts [42]. In fact, EMT-
induced organ fibrosis has been demonstrated in liver, lung, kidney and 
intestine. Similar processes to EMT occur as a physiological response to 
injury and tissue regeneration. For example, keratinocytes at the border 
of the wound recapitulate part of the EMT process during wound healing 
[42]. Furthermore, the ovarian surface epithelium undergoes an EMT-like 
process during postovulatory wound healing in each menstrual cycle.  
1.3.2.3 Type 3 
Type 3 EMT is associated with cancer progression and metastasis [40]. 
Many in vitro and in vivo studies have showed that cancer cells acquire 
a mesenchymal phenotype and express mesenchymal markers [42]. It is 
now clear that EMT is responsible for the acquisition of cell invasiveness 
and metastatic events. The invasive step involves epithelial cells that lose 
their polarity and detach from the basement membrane and undergo 
EMT (Figure 2). Through EMT, epithelial cancer cells at the invasive 
border of primary tumours become motile and invade and metastasise 
though the circulation, and finally generate metastatic lesions through 
MET to distant tissues or organs [40]. Even though it is now widely 
accepted that EMT is involved in metastatic events, its contribution in 
other events may also be highly relevant to cancer progression. EMT 
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confers resistance to cell death and senescence, immunosuppression, 
resistance to therapy and finally it generates cells with stem cell 
properties [40, 41]. 
 
 
 
1.3.3 Molecular mechanisms of EMT/EMT biomarkers 
Complex networks are engaged in order to facilitate EMT, including 
activation of transcription factors, changes in the expression of 
microRNAs, re-organisation and expression of cytoskeletal proteins, 
production of ECM-degrading enzymes and expression of                      cell-
surface proteins [40-46]. The first step of EMT involves the disassembly 
of epithelial cell-cell contacts (including tight, adherent and gap functions) 
and the loss of cell polarity. During this process, epithelial genes are 
repressed and mesenchymal genes are activated. A hallmark of EMT is 
the downregulation of E-cadherin, which is involved in the stabilisation of 
adherens junctions. The downregulation of E-cadherin is concomitant 
with the increased expression of the mesenchymal cadherin, N-cadherin. 
7KLVUHVXOWVLQµFDGKHULQVZLWFK¶ZKLFKSURPRWHVLQYDVLRQDQGPLJUDWLRQ
Figure 2. The contribution of EMT in cancer progression and 
metastasis. Progression from normal epithelium to invasive carcinoma 
goes through several stages. The invasive step involves epithelial cells 
losing their cell polarity and detaching from the basement membrane, 
where cell-ECM and signalling networks are being altered. The next step 
involves EMT (and other processes such as angiogenesis) that facilitate 
the tumour growth. Through EMT cells enter the circulation, and reach 
distant sites, where a secondary tumour might form, which may involve 
MET. 
Picture reprinted (permission granted) from: 
The basics of epithelial-mesenchymal transition 
Raghu Kalluri, Robert A. Weinberg 
Published June 1, 2009  
Citation Information: J Clin Invest. 2009;119(6):1420-1428. doi:10.1172/JCI39104. 
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The changes in the expression of the epithelial and mesenchymal genes 
are regulated through the activation of master transcription factors (TFs). 
The main TFs involved are SNAIL, TWIST and ZEB factors, which 
repress various epithelial genes and activate several mesenchymal 
genes (Figure 2). The involvement of these TFs is cell- and tissue-
specific, but often they cooperate with each other. The activity of the TFs 
involved in EMT, and, therefore, the EMT progression is regulated by 
different signalling pathways that are interlinked to facilitate a full EMT 
response (Figure 3). For example, the RAS-RAF-MEK-ERK MAPK 
signalling cascade contributes to EMT, by upregulating TFs involved in 
cell motility and invasion. Another example is the Wnt signalling pathway; 
Wnt activates ȕ-catenin which in turns activates several EMT-inducers 
including Slug, Twist and Goosecoid. Wnt and tyrosine kinase receptors 
(RTKs) can also regulate Snail through GSK3b. Similarly hypoxia, TGF-
ȕ, and Notch signalling pathway regulate a number of transcription 
factors that induce EMT through transcriptional regulation of E-cadherin, 
such as Twist, ZEB1, ZEB2, Snail, TCF3, FOXC1, and FOXC2. 
Coordination of EMT programs also results in upregulation of the 
expression of extracellular matrix (ECM) proteins, proteases, and other 
ECM remodelling enzymes. Furthermore, there is a crosstalk among the 
transcription factors that regulate EMT and their miRNAs level. For 
example, increased expression of RBFOX2 during EMT, promotes 
differential splicing of different transcripts (e.g. FGFR2), whose 
expression plays an important role in EMT promotion. Another example 
is the increased expression of miR-200 during EMT, which results in 
increasing the levels of the ZEB TFs.  
The different factors involved in EMT, are used in the literature as 
biomarkers, to define cells undergoing EMT. The most common 
biomarkers used to define/detect EMT are listed in Figure 5. As shown, 
some of them are common between the three different types of EMT, 
while others are restricted to specific types. 
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Figure 3. Main EMT transcription factors and their downstream 
targets. SNAIL, TWIST and ZEB are the main TFs involved in EMT 
initiation and progression, through repression of epithelial markers such 
as E-cadherin and activation of mesenchymal markers such as Vimentin. 
Picture reprinted (Licence number 3558171111103) from: 
Molecular mechanisms of epithelial-mesenchymal transition 
Samy Lamouille, Jian Xu, Rik Derynck 
Published Feb 21, 2014 
Citation information: Nature Reviews Molecular Cell Biology 15, 178±196 (2014) 
doi:10.1038/nrm3758 
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Figure 4. Signalling pathways involved in EMT progression. The 
TGFȕ, Ras-Raf-MEK-ERK, Wnt and Notch signalling pathways, as well 
as inflammation and hypoxia contribute to EMT progression, through 
regulation of different TFs.  
Picture reprinted (Licence number 3558171111103) from: 
Molecular mechanisms of epithelial-mesenchymal transition 
Samy Lamouille, Jian Xu, Rik Derynck 
Published Feb 21, 2014 
Citation information: Nature Reviews Molecular Cell Biology 15, 178±196 (2014) 
doi:10.1038/nrm3758 
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Figure 5. Biomarkers for EMT. The table lists the different 
factors involved in the different types of EMT that are 
commonly used in the literature to define/detect cells 
undergoing EMT.  
 
Picture adapted from: 
Biomarkers for epithelial-mesenchymal transitions 
Michael Zeisberg and Eric G. Neilson 
Published June 1, 2009 
Citation information: J Clin Invest. 119(6), 1429-1437±196 (2009)            
doi: 10.1172/JCI36183 
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1.3.4 EMT in BC  
In vitro and in vivo studies have provided much evidence of a role for 
EMT in breast cancer progression and metastasis, resistance to therapy 
and local recurrence. These include the expression of EMT-related 
markers, association of EMT markers with breast cancer histological 
grade, microRNA regulation of EMT in breast cancer, and the generation 
of breast cancer stem cells through EMT [45].  
EMT and its associated factors correlate with histological grade of breast 
cancer. Specifically, microarray gene expression profiles of breast cancer 
patients have demonstrated that up-regulation of genes involved in EMT 
is associated with poorly differentiated tumours [47].  
Changes in the histopathology of breast cancers associated with EMT 
correlate with high tumour grade, increased mitosis, and 
oestrogen/progesterone receptor negativity [48]. Moreover, high levels of 
the EMT-inducer Twist in patient samples associate with high-grade 
invasive carcinoma and chromosomal instability that promotes EMT and 
results in aggressive phenotype [49]. Furthermore, elevated levels of the 
EMT-inducer Snail correlate with higher risk of relapse and local 
recurrence in mouse models [50]. Other EMT markers (e.g. down-
regulation of E-cadherin, up-regulation of N-cadherin etc.) are associated 
with basal-like cancers [51].  
Association of expression of EMT markers and aggressive phenotypes 
have been demonstrated in breast cancer. Basal-like breast cancer 
tumours show high expression of EMT-related genes and EMT-inducers, 
including high expression of N-cadherin, Vimentin, ACTA2, laminin, 
fascin, and FOXC2 and low expression of E-cadherin [51, 52]. Such 
tumours have increased ability to metastasise to other distant sites and 
are associated with poor prognosis.  
Furthermore regulation of EMT by miRNAs has been observed in BC 
[45]. For example, Inhibition of the miR-200 and miR-250 family induces 
EMT in BC through upregulation of ZEB1 and ZEB2 [53]. In addition, 
Twist1 regulates miR-10b expression which is found to be expressed in 
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metastatic breast cancer cells and correlate with tumour progression [54]. 
Also, ectopic overexpression of mi-RNA74a in BC cell lines promoted 
EMT and metastasis through activation of the Wnt signalling pathway 
[55]. Furthermore, mi-RNA9 in BC has been shown to be associated with 
EMT, the stem cell phenotype and cancer progression [56].  
 
1.3.5 The link between BCSCs and EMT 
Emerging research suggests that there is a direct link between EMT and 
CSCs [35-37, 51, 52, 57-59]. EMT plays a critical role in cancer 
metastasis and local recurrence, which is tightly linked with the biology 
RI &6&V )XUWKHUPRUH D OLQN EHWZHHQ (07 DQG VWHPQHVV µDWWULEXWHV¶
have been observed in different studies. EMT and BCSCs are major 
areas of interest in breast cancer research. Most studies follow a 
common procedure: EMT is induced in human breast cancer cell lines 
(e.g. by over-expression of Twist, Snail or TGF-ȕ), cells are isolated 
based on co-expression of EMT and BCSC markers, and the tumorigenic 
and metastatic capacities of these cells are investigated using common 
assays (e.g. mammosphere assay) and animal models.  
Mani, S.A., et al. (2008) [52] provided the first evidence linking EMT to 
BCSCs by showing that induction of EMT in immortalized human 
mammary epithelial cells (HMLEs) by ectopic expression of Twist or Snail 
results in the acquisition of a mesenchymal phenotype and in the 
expression of stem cell markers. These cells were able to form 
mammospheres, soft agar colonies, and tumours more efficiently, 
compared to cells that have not undergone EMT. This was also 
supported by other groups [37, 57] and in mouse models [35]. 
Furthermore, EMT and stem cell markers were found to be associated 
with basal-like cancers which are more prone to metastasise [51]. Other 
evidence came from the similar miRNA expression profile in those cells 
undergoing EMT and BCSCs [36, 58]. Other interesting data showed that 
the CD44+/CD24-/low EUHDVWFDQFHUFHOOVVKRZHGDµFODXGLQ-ORZ¶PROHFXODU
subtype which is characterised by the expression of EMT- related 
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markers [59]. In addition, a recent study has shown that CD146, an EMT 
transcriptional inducer, generates cells with CSC properties and is 
associated with poor outcome, high tumour stage, and triple-negative 
breast cancers [60].  
When studying EMT and BCSCs, the role of the tumour 
microenvironment should be taken into consideration, as both are 
regulated by its components. 
 
1.4 The influence of the tumour microenvironment (TME) in cancer 
progression, EMT and BCSCs 
 
1.4.1 The TME 
In the TME there exists a complex interplay between the developing 
tumor and the host, which is thought to be mediated by three systems: 
angiogenesis/ vasculogenesis, cell-cell and cell-matrix interactions, and 
host immune response to tumor [61]. It is composed of multiple cell types 
(immune cells, inflammatory cells, stromal cells etc.) that all play a vital 
role in tumour growth, angiogenesis, invasion and metastasis and drug 
resistance (reviewed in [62]) (Figure 5). Similarly, the breast tumour 
microenvironment is comprised of a variety of cells that secrete a number 
of cytokines and growth factors that activate signaling pathways, 
promoting tumour progression and metastasis [63]. Examples include the 
cancer-associated fibroblasts (CAFs) and other stromal cells (e.g. 
macrophages) that can promote tumour onset and progression in 
different ways (reviewed in [64]). One of these ways is through promotion 
of EMT.  
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1.4.2 Influence on EMT and BCSCs 
During EMT, there is a communication between the extracellular matrix, 
the immune cells and fibroblasts, and interactions with host components 
influence cancer progression [65]. Inflammatory cells, hypoxia and stem 
cells can induce the EMT process [66].  
The inflammatory cells within the tumour microenvironment are 
fundamental for invasion and metastasis [67]. Tumour Associated 
Macrophages (TMAs) and their released cytokines (e.g. TNF-Į, IL1) are 
key mediators of all steps of these processes. For example, EMT was 
induced in MCF-7 cells treated with TNFĮ, as demonstrated by 
Figure 6. The tumour microenvironment. The TME is composed of 
multiple cells types that support tumour progression. (Picture reprinted 
from DF, Q. and J. JA, 2013). 
Picture reprinted (Licence number 3558170750281) from: 
Microenvironmental regulation of tumor progression and metastasis 
Daniela F Quail, Johanna A Joyce 
Published Nov 7, 2013 
Published June 1, 2009  
Citation Information: Nature Medicine 19, 1423±1437(2013)doi:10.1038/nm.3394 
. 
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decreased expression of E-cadherin, increased expression of Vimentin 
and Snail, and increased migratory capacities  [68].  
Another factor in the induction of EMT is hypoxia (the limited availability 
of oxygen and nutrients in the TME as a result of tumour growth) [66]. 
Hypoxia-induced EMT has been demonstrated in BC [69, 70]. Moreover, 
cancer cells can acquire stem-like properties under hypoxic conditions. It 
was demonstrated that hypoxia-selected subpopulation from human 
breast cancer lines could initiate tumours in immunodeficient mice and 
showed both stem-like and EMT phenotypes [71].  
Another possible inducer of EMT within the tumour microenvironment is 
the mesenchymal stem cells (MSCs). MSCs are recruited from the bone 
marrow to the tumour stroma; a process that is mediated by different 
chemokines, growth factors, and receptors found in the tumour 
microenvironment such as CCL2, EGF, CCL5, CXCL8 and CD44 [10]. 
Once in tumour sites, they can promote tumour growth by, for example, 
acting as precursors to CAFs, which in turn secrete a variety of growth 
factors, inflammatory cytokines and proteinases, all of which contribute 
to tumour progression. In a xenograft model, it has been shown that bone 
marrow-derived MSCs can cause cancer cells to metastasis via secretion 
of CCL5, which acts on the cancer cells to enhance their motility, invasion 
and metastasis [72]. Furthermore, there is growing evidence that MSCs 
stimulate EMT in the breast tumour microenvironment and therefore may 
facilitate tumour growth and metastasis; co-culturing MSCs with BC cells 
resulted in phenotypical changes of the tumour cells associated with EMT 
and constant downregulation of E-cadherin [73].  
Like EMT, BCSCs are also regulated by the players of the tumour 
microenvironment, through complex cytokine and growth factor networks 
[63]. MSCs, CAFs and TAMs are recruited to the tumour 
microenvironment and secrete IL-6, IL-8 and CXCL7, which activate the 
STAT3/NF-țǺ signalling pathway leading to self-renewal of BCSCs. 
MSC/BCSC interactions have been confirmed to exist in breast cancer 
patients by immunohistochemical analysis of biopsies [74] and serum 
levels of IL-1 and IL-8 have been associated with poor clinical outcome 
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of breast cancer patients [75, 76]. CAFs can also promote proliferation of 
tumour cells through secretion of SDF-1, the level of which have been 
associated with poor survival in breast cancer patients [77, 78]. 
The aforementioned are a few examples demonstrating the important 
role of the TME in cancer progression and metastasis, including the effect 
on EMT and BCSCs. Therefore, it is important that pre-clinical models of 
BC incorporate key elements of the TME in order to recapitulate human 
tumours as closely as possible, for patient-relevant drugs to be 
developed.  
 
 
 
1.5 Studying/modelling BC and EMT 
 
1.5.1 Cell lines  
Human BC cell lines in vitro and as xenografts in mice have been 
extensively used to study/model BC [79]. Human BC cell lines have been 
used to study the genes and signalling pathways that regulate 
proliferation, apoptosis and migration during breast cancer progression 
[80]. They are easily propagated, relatively tractable to genetic 
manipulations, give reproducible and quantifiable results, can be grown 
as xenografts, and are more relevant to human disease compared to 
rodent cells. However, no single cell line is truly representative of human 
tumours [81]. Furthermore, many of the cell lines have been derived from 
late-stage tumours and pleural effusion, and, thus, they may be 
representative of the most malignant phenotype that can be cultured [79]. 
A major limitation of human breast cancer cell lines is that they are 
cultured on plastic, and the conditions used to propagate these cells 
create an environment that differs from the breast microenvironment. 
When grown in a 2D culture, they do not allow the study of tumour-
stromal cell interaction. Methods of in vitro cell culture that mimic 
components found in human cancers have been developed, including 3D 
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cultures and co-cultures with stromal cells (e.g. human MSCs) [73, 82-
84].  Furthermore, growing breast cancer cell lines as xenografts enables 
investigation of cancer in the in vivo environment, which includes the 
interactions between the developing tumour and stromal cells [85].  
1.5.2 Mouse models 
Xenografts have given valuable insights about the role of the 
microenvironment, genetic alterations that contribute to tumour 
progression, and the events involved in metastasis [79]. For example, a 
xenograft model has been used to identify genes involved in BC 
progression and metastasis, which can have therapeutic implications and 
prognostic significance [86]. Briefly, a poorly metastatic and a highly 
metastatic BC cell line were injected in the MFP of immunodeficient mice 
and the tumours and metastases formed were stained for various 
proteins (e.g. bFGF). This, together with cDNA microarray analysis aided 
the identification of genes and proteins involved in BC metastasis.   
Xenograft models have several advantages including (a) they use human 
rather than mouse cell lines, which makes them more suitable for patient-
relevant drug testing (b) the tumours are formed quickly, are easily 
observable and can be followed, and (c) they are easy to use [87, 88]. A 
principal restriction is that cell lines transplanted may not be 
representative of the breast cancers observed in the clinic. Furthermore, 
xenografts are established in immunocompromised mice, and the 
absence of an immune system markedly affects tumour progression and 
metastasis [89]. Also, when the tumour cells are injected subcutaneously 
into the mouse, this microenvironment may change the growth and 
metastatic potential of the cells. While orthotopic transplantation of cells 
into the mammary fat pad should provide a more favourable environment, 
again there are differences between the mouse and human mammary 
stroma [90]. Finally, even though orthotopic models of BC metastasis to 
liver, brain, bone and lymph nodes have been reported [91-95], most 
models are poorly metastatic or they tend to metastasise only to the lungs 
[96, 97]. In contrary to xenografts from BC cell lines, patient-derived 
xenografts (PDXs) retain the morphology, heterogeneity and genomic 
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profile from the original patient and they have been proved to be more 
effective for predicting patient-relevant drug response (reviewed in [98]). 
But again, the PDXs have limitations, including the lack of an intact 
immune system in the host mice and the difference between the human 
and mouse microenvironment. For this reason, efforts have been made 
to humanize the BC xenograft models, by for example adding human 
stromal fibroblasts [99] or through implantation of human breast epithelial 
organoids [100].   
Others, have used syngeneic models (mouse tumour growing in mouse 
strain) to study BC, as they take into account anti-tumour immune 
response, cancer-stromal interactions, and maintain the mammary 
microenvironment, and have been shown to produce more efficient 
cancer progression and metastasis than xenografts [101, 102]. On the 
other hand, the tumour cells in syngeneic models are rodent, not human, 
so the question is whether the data from studies using such models can 
translate to humans. 
1.5.3 Imaging 
Tumour monitoring/ measurement of xenograft tumours is usually being 
performed by a calliper; a quick, non-invasive and cheap way [103, 104]. 
Other than WKLV³JROGVWDQGDUG´WHFKQLTXHa lot of other methods have 
been developed over the years to measure tumour including ultra sound 
[105], CT scan [106] and MRI [107]. Furthermore, techniques have been 
developed that allow live imaging/tracking of single cells, which are based 
on optical (fluorescent) reporters, including intravital microscopy, 
multiphoton microscopy and implantation of tissue window devices in the 
mice [108].  
In order to more specifically study different pathways and genes, involved 
in cancer progression and metastasis, a variety of reporter systems have 
been developed, which rely on the expression of a reporter-encoding 
gene driven by the promoter of interest (reviewed in [109]). The reporter 
activity, which is most commonly detected by fluorescent or 
bioluminescent imaging, can be then correlated with promoter activation. 
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One main advantage of fluorescent reporters is that the detection results 
from the intrinsic chromophore structure, which allows continuous 
monitoring of gene expression on a cell-by-cell basis. A main advantage 
of bioluminescent imaging is the high sensitivity. On the other hand, both 
methods have drawbacks. In the case of fluorescent reporters, most 
fluorescent proteins have slow turnover rates, which cause the signal to 
accumulate over time, and therefore they are not ideal for studying fast 
activation/inactivation of promoters. A main disadvantage of the 
bioluminescent reporters, is that the signal detected is an indication of 
the total quantity of the reporter expressed by the whole cell population, 
which means that it is not possible to know whether only a subset of cells 
are expressing the reporter.  Since reporters of this kind are based on 
promoter activity/gene expression, it is important that gene regulation is 
considered. Gene regulation is a biological process essential for all living 
organisms, which is achieved through interaction of regulatory elements 
with DNA sequences within the genes that they regulate [110]. It is 
controlled by various mechanisms including transcription, post-
transcriptional modification and processing, translation, transcript 
stability and localization. Therefore, when using an optical reporter to 
detect/image changes in gene expression, key players of gene regulation 
such as TF binding sites within the gene promoter and other regulatory 
elements (e.g. enhancer elements) should be considered.  
 
As discussed here, EMT is associated with BC progression, enrichment 
for therapy-resistant CSCs, and metastasis, for which there is currently 
no effective therapy. Therefore, there is a need for drugs to be developed 
to target those cells that are undergoing EMT, in order to prevent them 
from metastasising. Drug screening is most often performed in mouse 
models. Despite the fact that many BC metastasis models have been 
reported, as discussed previously, no model that detects EMT and/or 
early stages of metastasis has been reported. Therefore, in order to 
target this process, there is a need for improved models that will allow 
studying EMT in real-time in in vivo models.  
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1.6 Hypothesis & Aims 
It was hypothesised that the process of EMT and/or early metastasis can 
be visualised/ tracked in vivo in real-time by the use of the appropriate 
optical reporters. 
The aim of the research within this thesis was to produce effective EMT 
reporters using the expression vector pLVX (Clontech), and validate 
them in stably transduced basal and luminal BC cell-lines, both in vitro 
and in vivo. The reporter(s) will allow a real-time read-out of EMT in an 
orthotopic mouse model, which could be eventually used to test novel 
drugs developed to target the process of EMT and prevent invasion and 
metastasis, where the current treatment is not effective. 
1.7 Objectives 
The first objective was to develop inducible bioluminescent EMT 
reporters, consisting of an inducible firefly luciferase driven by the 
promoters of EMT genes (S100A4 or E-cadherin or N-cadherin).   
The second objective was to assess the activity of the reporters in in vitro 
models i.e. their ability to detect changes in the genes was assessed.   
The final objective was to develop in vivo models of EMT and/or 
metastasis and to validate the activity of the reporters in these models. 
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CHAPTER 2: Materials and Methods  
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2.1 Molecular cloning 
 
Kits for molecular cloning were purchased from Sigma Aldrich (Poole, 
UK) or Qiagen (Manchester, UK). The restriction enzymes, gel loading 
dye and DNA ladder were purchased from New England Biolabs (Hitchin, 
UK). The TOPO cloning vector and bacteria were purchased from 
Invitrogen (Paisley, UK). Other manufacturers are as stated.  
 
 
 
2.1.1 Plasmids 
Different plasmid vectors have been used for amplifying the gene of 
interest, cloning the gene/promoter of interest etc. All the plasmids used, 
including relevant figures, are described here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. pOTB7-Twist1 plasmid. Location of relevant features: (a) M13 
Forward priming site: 110-127, (b) Twist1 (Human TWIST1, exon 1 and 
2): 1171-1672, (c) M13 Reverse priming site. Purchased from 
Geneservice (Nottingham, UK). 
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Figure 8. pLightSwitch_S100A4promoter-Renilla. Location of relevant 
features: (a) Multiple cloning site (MCS): 1-1128, (b) S100A4 promoter 
(Human): 41-1101, (c) Renilla luciferase: 1168-2226 and (d) Ampicillin 
resistance gene: 3594-4454. Purchased from SwitchGear Genomics 
(Belgium, Germany).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. pLightSwitch_E-cadherin promoter-Renilla. Location of 
relevant features: (a) Multiple cloning site (MCS): 1-940, (b) E-cadherin 
promoter (Human): 35-917 and (c) Renilla luciferase: 980-2038. 
Purchased from SwitchGear Genomics.  
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Figure 10. pCR®4-TOPO® plasmid. Location of relevant features: (a) 
M13 Reverse priming site: 205-225, (b) TOPO® cloning site: 294-295, (c) 
M13 Forward priming site: 354-371, and (d) AmpR ampicillin resistance 
gene: 2206-2856. Purchased from Invitrogen. 
Figure 11. pLVX-IRES-tdTomato. Location of relevant features: (a) 
CMV IE (human cytomegalovirus immediate early promoter): 2185±
2787, (b) MCS: 2803±2840, (c) IRES (encephalomyocarditis virus 
internal ribosome entry site): 2842±3416, (d) tdTomato: 3417±4844 
and (e) AmpR (ampicillin resistance gene): 7578±8574. Purchased 
from Clontech (Saint-Germain-en-Laye, France).  
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2.1.2 Genomic DNA extraction  
'1$ ZDV LVRODWHG IURP PDPPDOLDQ FHOOV XVLQJ WKH *HQ(OXWH
0DPPDOLDQ *HQRPLF '1$ 0LQLSUHS .LW DFFRUGLQJ WR PDQXIDFWXUHU¶V
instructions. Briefly, mammalian cells were lysed with a salt-containing 
buffer to ensure denaturation of macromolecules. DNA was bound to the 
spin column membrane and the remaining lysate was removed by 
centrifugation. A filtration column was used to remove cell debris. After 
washing to remove contaminants, the DNA was eluted with 100µl distilled 
water.  
2.1.3 Polymerase Chain Reaction (PCR)  
2.1.3.1 Primers  
Primers were GHVLJQHG XVLQJ WKH 2OLJR3HUIHFW 'HVLJQHU WRRO
(Invitrogen, Paisley, UK) and their specificity was checked using the 
NCBI/ Primer-BLAST tool. Table 1 summarises the sequence of the 
primers. 
Figure 12. pLVX-CMV-fLuc. It was made by Teresa Coughlan based 
RQµS/9;-tdTomato¶. The CMVIE promoter of this plasmid was replaced 
with the EMT promoters for the purposes of this study, in order to 
construct the inducible bioluminescent EMT reporters. Location of 
relevant features: (a) ClaI restriction site: 2179, (b) CMV: 2201-2727, 
(c) Xhol restriction site: 2816, (d) Firefly Luciferase: 2917-4569, (e) 
PuroR: 5110-5709 and (f) AmpR: 8442-9101.  
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2.1.3.2 HotStarTaq® DNA Polymerase (Qiagen) 
The reaction mix was composed of 1x PCR buffer, 1x Q solution, dNTP 
mix (200µM of each), 250nM of forward and reverse primer, 1.25U/rnx of 
polymerase, 15ng of plasmid DNA and distilled water (up to 50µl). The 
cycling conditions were set up as described in Table 2.  
 
Table 1. Primers used for the amplification of PCR products 
 
PRIMER                       6(48(1&(¶-¶$1')($785(6 
 
Twist1 Forward    EcoRI     Twist 1 (exon1) 
                      CCGG^AATTCGAGGTATAAGAGCCTCCAAGTCTG  
Twist1 Reverse         BamHI    Twist 1 (exon 2) 
                           CGCG^GATCCCCCCTCAGAGGAAGGATGA  
S100A4 promoter  Forward        ClaI   S100A4 promoter 
                                             CCAT^CGATAACTCCCCTATTT  
S100A4 promoter Reverse    XhoI       S100A4 promoter  
                                     GATC^TCGAGCAACACAACTCACCAAT 
E-cadherin promoter   ClaI         E-cadherin promoter 
Forward         GCGTACAT^CGATAAATTAGGCTGCTAGCTCAG 
 
E-cadherin promoter             XhoI     E-cadherin promoter 
Reverse                                GCAAATCTCGAGAATGCGTCCCTCGCA 
N-cadherin promoter  ClaI   N-cadherin promoter                       Forward   
AAATTTAT^CGATGGCTCTAGGGGCTGGATT 
N-cadherin promoter         XhoI            N-cadherin promoter 
Reverse               GGTTGGC^TCGAGTGTTGTTCGGGCGTGTAA 
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Table 2. Cycling conditions for PCR amplification using the 
HotStarTaq DNA polymerase.  
 
 
 
7HUUD3&5'LUHFW3RO\PHUDVH0L[(Clontech) 
The reaction mix was composed of 1x Terra PCR Direct Buffer (with 
Mg2+ and dNTP, 0.3µM of the forward and reverse primer, 100ng of template 
   Additional comments 
Initial activation 
step 
 15 min 95°C HotStarTaq DNA polymerase 
was activated by this heating 
step 
3-step Cycling 
Denaturation          30 sec 94°C 
 
Annealing 30 sec Gradient: 
50°C to 68°C 
(Twist1) 
47°C to 60°C 
(S100A4 
promoter) 
50°C to 70°C 
(E-cadherin 
promoter) 
The gradient covered a variety 
of temperatures below and 
above Tm of primers 
Extension 1 min 72°C For PCR products longer than 1 
kb, an extension time of 
approximately 1 min per kb DNA 
was used 
Number of 
cycles 
30   
Final extension 10 min 72°C  
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DNA, 1.25 of the Terra PCR Direct Polymerase Mix and distilled water (up to 
50µl). The cycling conditions were set up as follows:  
3-Step PCR (for amplification of standard targets < 2 kb): 
98°C 2 min 
98°C 10 sec 
50°C-68°C 15 sec             30 cycles         
68°C 1 min/kb 
 
2.1.4 Agarose gel electrophoresis 
Agarose gels were made 0.8% agarose (Eurogentec, Southampton, UK) 
dissolved in 150ml of 1x Tris/Acetate/EDTA (TAE) electrophoresis buffer. 
0.8% is suitable for size ranges of 500bp to 10,002bp, which cover the 
size of all the PCR products amplified in this study. Gel loading dye (6x) 
was added to the samples and the 1kb DNA ladder was used as a 
reference to estimate the size of DNA molecules (Figure 12). The nucleic 
acid stain SafeView (NBS Biologicals, Huntingdon, UK), was used for the 
detection of DNA. After loading samples, DNA was separated using a 
constant voltage of 80V for approximately 1 hour or until the loading dye 
had reached the end of the gel. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. 1kb DNA ladder.  The DNA includes fragments range from 
0.5-10.0 kilobases (kb).  
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2.1.5 PCR CLEAN-UP  
PCR products were purified using QIAquick PCR purification kit, 
DFFRUGLQJWRPDQXIDFWXUHU¶VUHFRPPHQGDWLRQV 
2.1.6 TOPO Cloning (TOPO TA CLONING® FOR SEQUENCING) 
The reaction mixture for the TOPO® cloning reaction was composed of 
1µl of salt solution, 10ng/µl of the TOPO vector, variable amount of PCR 
product (or no PCR product for the empty control) and distilled water (up 
to 6µl). The reaction incubated for 5 minutes at RT and stored at -Û&
The amount of the PCR product was calculated as follows: ng of PCR 
product need (1:1 Insert: Vector) = 1 x Length of insert in bp x (ng of 
vector/length of vector in bp) 
2.1.7 Transformations  
Plasmids were transformed into SUBCLONING EFFICIENCYTM '+ĮTM 
competent cells. The cells were thawed on ice, gently mixed with the 
pipette tip, and 50µl of cells for each transformation was aliquoted into a 
1.5ml microcentrifuge tube. 1µl-5µl (1-10ng) of DNA was added to the 
cells and mixed gently. For the pUC19 control DNA, 2.5µl (250pg) was 
added to the cells and mixed. The cells were incubated on ice for 30 
minutes. After that, the cells were heat shocked for 20 seconds in a 42°C 
water bath without shaking, and immediately transferred on ice for 2 
minutes to allow cooling down. 950µl of pre-warmed Luria Broth (LB) 
medium was added to each tube, and cells were incubated at 37°C for 1 
hour shaking. Different volumes from each transformation were spread 
on pre-warmed agar plates containing ampicillin (100µg/ml). Plates were 
incubated overnight (O/N) at 37°C.  
2.1.8 Plasmid minipreps  
Plasmids were isolated from bacteria using the GenEluteTM plasmid 
miniprep NLW DFFRUGLQJ WR PDQXIDFWXUHU¶V UHFRPPHQGDWLRQV %ULHIO\
bacterial cells were harvested via centrifugation, subjected to a modified 
alkaline-SDS lysis procedure and the DNA adsorbed onto silica in the 
presence of high salts. Contaminants were then removed by a simple 
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wash step. Bound DNA was eluted in 30µl water. DNA yield and quality 
were determined using the NANODROP 2000 Spectophotometer 
(THERMO SCIENTIFIC, Loughborough, UK). Quality of DNA was 
determined by the ratio of spectrophotometric absorbance of the sample 
at 260nm to that of 280nm (A260/A280 ratio). Values above 1.6 were 
considered acceptable.  
2.1.9 Plasmid maxipreps  
Plasmids were isolated from bacteria using the QIAGEN Plasmid Maxi 
.LW DFFRUGLQJ WR PDQXIDFWXUHU¶V UHFRPPHQGDWLRQV '1$ \LHOG ZDV
determined using the NANODROP 2000 Spectophotometer and DNA 
quality was determined by the A260/A280 ratio. Values above 1.6 were 
considered acceptable.  
2.1.10 Cleavage of DNA with restriction endonucleases  
The PCR products and the vectors were digested with restriction 
endonucleases with compatible ends. Digestions were also performed for 
selection of clones with the insert incorporated. The enzymes used in this 
study are the following: EcoRI (G^AATTC), BamHI (G^GATCC), ClaI 
(AT^CGAT) and XhoI (C^TCGAG). The digestion reactions were 
composed of 150-200ng of DNA, 1ȝl of each enzyme, 2ȝl of the 
appropriate buffer (EcoRI NEB or NEBuffer 4 + BSA) and distilled water 
(up to 20ȝl). The reactions were incubated at 37°C for 2 hours or ON.                          
2.1.11 Gel extraction (QIAquick gel extraction kit) 
After separation on agarose gel, the DNA fragment was visualised using 
a 312nm UV transilluminator (MODEL TVC-312A) and the relevant band 
cut out. It was extracted using QIAquick gel extraction kit according to 
PDQXIDFWXUHU¶V LQVWUXFWLRQV '1$ ZDV HOXWHG LQ ZDWHU DQG \LHOG ZDV
determined using the NANODROP 2000 Spectophotometer.  
2.1.12 Ligations 
The gel-extracted digested PCR products and vectors were ligated using 
the DNA ligation kit (Agilent Technologies, Santa Clara, USA). The 
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following mix was prepared for different insert: vector ratios and 
incubated at 4°C ON: 
                                           Vector + Insert    Vector only control 
Digested vector                     50ng                  50ng 
Digested insert                      -                        * 
10 x Ligase Buffer                 1µl                      1µl 
10 mM rATP (pH 7.5)            1µl                      1µl 
T4 DNA ligase (4 U/ȝl)          0.5µl                   0.5µl 
H2O                                     Up to 10µl           Up to 10µl 
 
 
* Calculated as follows:  
ng of PCR product need (1:1 Insert: Vector) = 1 x Length of insert in bp x 
(ng of vector/length of vector in bp) 
 
ng of PCR product need (3:1 Insert: Vector) = 3 x Length of insert in bp x 
(ng of vector/length of vector in bp) 
 
ng of PCR product need (6:1 Insert: Vector) = 6 x Length of insert in bp x 
(ng of vector/length of vector in bp) 
 
2.1.13 DNA sequencing 
The DNA sequence of the plasmid constructs was analysed using a 
3130xl ABI PRISM Genetic Analyzer by the DNA sequencing facility 
(University Of Nottingham). The sequencing primers for each construct 
are listed in Table 3. The primers were either provided by the sequencing 
facility (M13), or designed for the purposes of this project as explained 
above (See section 3.1.3.1). The sequence was aligned to 
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the original sequence of the plasmid construct using the ApE (A plasmid 
Editor) software Version 1.1 
 
Table 3. Sequencing primers for plasmid constructs. F=Forward, 
R=Reverse, M=Middle primer 
 
 
CONSTRUCT PRIMER 6(48(1&(¶-¶ 
 
pCR4-TOPO-Twist1 
M13 F TGGCCGTCGTTTTACA 
M GGCGCCCCGCTCTTCTCC 
M13 R CAGGAAACAGCTATGACCATG 
 
pCR4-TOPO-S100A4prom 
M13 F TGGCCGTCGTTTTACA 
M CCCCCTAGCTTTTGTGTCAC 
M13 R CAGGAAACAGCTATGACCATG 
 
 
pCR4-TOPO-Ncadprom 
M13 F TGGCCGTCGTTTTACA 
M AGAGCCAGCGAGCCTTTT 
M CTAGACGGTCGTGGGCCG 
M13 R CAGGAAACAGCTATGACCATG 
 
pCR4-TOPO-Ecadprom 
M13 F TGGCCGTCGTTTTACA 
M13 R CAGGAAACAGCTATGACCATG 
 
pLVX-Twist1-IRES-tdTom 
F TATATAAGCAGAGCTCGTTTAG
TGAAC 
M  GGCGCCCCGCTCTTCTCC 
R TATGGTGGAAAATAACATATAG
ACAAACG 
 
pLVX-S100A4prom-fLuc 
F GGACCCGACAGGCCCGAA 
M CCCCCTAGCTTTTGTGTCAC 
R  GCTTCATGGCTTTGTGCAG 
 
pLVX-Twist1-IRES-tdTom 
F TATATAAGCAGAGCTCGTTTAG
TGAAC 
M GGCGCCCCGCTCTTCTCC 
R TATGGTGGAAAATAACATATAG
ACAAACG 
 
pLVX-Ncadprom-fLuc 
F TCAAAATTTTCGGGTTTATTACA
GG 
M AGAGCCAGCGAGCCTTTT 
M CTAGACGGTCGTGGGCCG 
R GAACGCTCATCTCGAAGTACTC 
 
pLVX-Ecadprom-fLuc 
F GGGGGGTACAGTGCAGGG 
R TGGGCCCTTCTTAATGTTTTT 
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2.2 CELL-BASED STUDIES 
 
The chemicals used were purchased from Sigma Aldrich (Poole, UK), 
unless otherwise stated. All the NuPAGE® products for western blot were 
purchased from Invitrogen (Paisley, UK).  
 
2.2.1 Cell culture conditions  
The cells used in the study were incubated at 37°C in a humidified 5% 
CO2 incubator. They were split in ratios ranging from 1:2 to 1:5. Briefly, 
they were detached from the flask using sterile trypsin/EDTA solution, 
they were centrifuged at 415g for 5 minutes, and the pellet was re-
suspended in the appropriate medium. Table 4 summarises the source 
and the growth medium used for each cell line. The lentivirally transduced 
cell lines were selected weekly with 4µg/ml puromycin in the appropriate 
growth media. The amount of puromycin for each cell line was previously 
determined in the lab.  
2.2.2 Cell plating 
For plating, cells were washed with HBSS, detached with Trypsin/EDTA, 
collected with medium and pelleted for 5 minutes at 415g, re-suspended 
in culture medium and counted using Trypan Blue (Life Technologies). 
For counting 50µl of re-suspended cells were mixed with 50µl of Trypan 
Blue and counted using a haemocytometer. 
2.2.3 Alamar Blue readings 
Cell growth was monitored with Alamar Blue® (Life Technologies). Alamar 
Blue was diluted in TGA media, at 1:10 dilution, and 100µl/well was 
added. The cells were incubated DWÛ&IRUPLQXWHVH[DFWO\DQG the 
readings were performed on the FlexStationII384 (Molecular Devices) at 
ȜH[ QPȜHP QPDQGȜFXWRII . Cell viability was plotted as 
relative fluorescent units (RFU).  
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Table 4. Source and growth conditions of cell lines. 
 
 
2.2.4 Stable transductions 
Lentiviruses were produced in-house using the Lenti-; /HQWLYLUDO
([SUHVVLRQ6\VWHP&ORQWHFKDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV
7KHTXDOLW\RIWKHOHQWLYLUXVVWRFNZDVDVVHVVHGXVLQJ&ORQWHFK¶V/HQWL-
X GoStix. The cell-lines were transduced with the lentiviral vector at a 
MOI (multiplicity of infection) of 1 or 3 IFUs (infectious unit)/ cell using the 
VDPHV\VWHPDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV 
CELL LINE SOURCE GROWTH MEDIUM 
MCF-7 
NCI60 or 
ECACC 
Phenol red-free RPMI with 10% 
Fetal bovine serum (FBS) and 
200nM l-glutamine 
MDAMB231 NCI60 
RPMI with 10% FBS and 200nM l-
glutamine 
BT549 NCI60 
RPMI with 10% FBS, 200nM l-
glutamine and 5µg/mL insulin 
 
BrCAFs 
Age of patient:67 
Tumour grade:2 
Type: Invasive lobular 
carcinoma 
ER/PR and Her2 status: 
ER8/8, PR8/8, Her2 
negative 
Kindly 
provided by 
Professor 
Val Speirs 
(University 
of Leeds) 
DMEM, high glucose, GlutaMAXTM 
Supplement, GIBCO (Paisley, UK) 
Human Mesenchymal 
Stem Cells-bone marrow 
(HMSC-bm) 
ScienCell 
(Carlsbad, 
USA) 
Mesenchymal Stem Cell Medium 
(MSCM), supplemented with 5% 
FBS and 1% MSC growth 
supplement 
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2.2.5 Bioluminescent readings 
Bioluminescent readings of the cells transduced with luciferase-
expressing constructs were taken using the Ivis Spectrum from Caliper 
Life Sciences. D-Luciferin (Caliper Life Sciences) was added to the cells 
to a final concentration of 150ȝg/ml and firefly luciferase expression was 
measured as average radiance (photons/sec/cm2). 
 
2.2.6 Flow cytometry 
Flow cytometry is based on the principles of light scattering, light 
excitation and emission of fluorochromes, in order to obtain specific multi-
parameter data from cells. The cells were separated according to their 
size, granularity and fluorochrome emission.  
For each antibody, 50,000 cells were harvested and re-suspended in 
50µl PBS 2% BSA.  The antibody was added at the appropriate 
concentrations and mixed. Cells were stained with CD44 (Alexa Fluor® 
mouse Anti-KXPDQ&'&ORQH,0RQO\&'%'3KDUPLQJHQ3(
Mouse Anti-Human CD24) only, and with both antibodies (dual staining). 
Cells were also stained with the isotype controls (Alexa Fluor® 488 Rat 
,J*E ț ,VRW\SH DQG 3( 0RXVH ,J*Į ț ,VRW\SH WR WKH VDPH ILQDO
concentration as the matched test antibody. Also, unstained cells were 
used for the analysis. After addition of the antibodies, cells were 
incubated on ice for 30 minutes in the dark. They were washed with PBS 
2% BSA and were fixed with 500µl PBS 3.7% Formaldehyde. At least 
10,000 cells per test were analysed using a FC500 flow cytometer 
(Beckman Coulter) and data was analysed using Weasel Software 
Version 3.0.2 (The Walter and Eliza Hall Institute of Medical Research, 
Melbourne Australia). 
 
56 
 
2.2.7 Western Blot 
2.2.7.1 Preparation of protein samples 
Cells were washed in cold PBS (pH 7.6). 1ml of PBS was added to the 
flask and the cells were detached using a cell scraper. The cells were 
transferred to a 1.5ml micro centrifuge tube and pelleted at 417g for 5 
minutes. The cell pellet was washed again in PBS and pelleted. 50-100µl 
lysis buffer was added to the cells and the cells were mechanically 
resuspended by pipetting up and down. Lysis buffer was composed of 
RIPA buffer, 1/100 phosphatase inhibitor cocktail 2 and 3 and 1/50 
protease inhibitor. The cells were lysed on ice for 20 minutes. The lysates 
were centrifuged at 3600g for 5 minutes at 4ƕC to pellet the cell debris. 
The protein lysate was transferred to a clean 1.5ml micro centrifuge tube. 
The cells were stored at -80ƕC or used immediately. The protein 
concentration was determined by a Bradford assay (section 2.2.5.6) and 
20µg of protein was mixed with 4µl of 4x NuPAGE® LDS Sample Buffer, 
2µl of 10x NuPAGE® Sample Reducing Agent and RIPA buffer (up to 
16µl). The samples were heated for 5 minutes at 96ƕC, cooled down on 
ice and centrifuged to collect any condensation. 
2.2.7.2 Preparation of apparatus for electrophoresis 
The combs were removed from the gels (NuPAGE® Novex® 4-12% Bis-
Tris Protein Gels, 1.0 mm, 12 well) and the wells were rinsed with 1 x 
SDS buffer (NuPAGE® MOPS SDS Running Buffer (20X) from Life 
Technologies diluted in distilled water). The gels were placed in the 
electrophoresis tank and 1 X SDS buffer was added to the wells and tank. 
The protein samples were loaded to the wells. Two different size markers 
were also added. The markers were the SeeBlue® Plus2 Pre-stained 
Protein Standard and 0DJLF0DUN;3:HVWHUQ3URWHLQ6WDQGDUG from 
Life Technologies. 500µl of NuPAGE® Antioxidant was added in to top 
of the tank and the gel was run at 80V initially and then 200V, until the 
samples were at the bottom of the gel. 
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2.2.7.3 Transfer of samples 
The gels were removed from the tank and washed and transferred to the 
iBlot Anode (iBlot® Transfer Stack, nitrocellulose), placed in the iBlot gel 
transfer device. A soaked blotting paper was added on top and then the 
iBlot Cathode was placed on top of that. Finally, a sponge was added on 
the lid of the device and the transfer was performed for 7 minutes.  
2.2.7.4 Binding of antibodies 
The membranes were transferred to 15ml tubes and they were blocked 
for 1 hour in 5ml of 3.5% blocking buffer (Membrane blocking agent, GE 
Healthcare) diluted in TBS with 0.1% Tween (TBS-Tween) for 1 hour at 
room temperature on the roller. The blocking buffer was replaced with the 
primary antibody diluted in blocking buffer at the appropriate 
concentration and incubated O/N in the cold room on the roller, followed 
by 1 hour incubation at RT on the roller. The blots were washed with the 
wash solution, 1 x TBS-Tween, (3 x 5 minutes). The wash solution was 
replaced by the secondary antibody which was incubated for 1 hour at 
RT on the roller. The blots were washed with TBS-Tween (3 x 5 minutes). 
The antibodies used are listed in Table 5. B-actin was used as a 
reference protein.  
2.2.7.5 Imaging 
The blots were visualised in the ChemiGenius2 Bio imaging system, after 
addition of Amersham ECL Prime Western Blotting Detection Reagent 
(GE Healthcare). Different exposure times were used for each protein as 
appropriate.  
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Table 5. Antibodies used for western blot. 
 
 
 
 
2.2.7.6 Bradford assay 
BSA (Albumin from bovine serum) was diluted in distilled water to prepare 
the following protein standards: 0.25mg/ml, 0.50mg/ml. 0.75mg/ml, 
1mg/ml, 1.15mg/ml, 1.25mg/ml and 1.50mg/ml. 5µl of each standard, of 
the protein and of a negative control (lysis buffer; section 2.2.5.1) was 
added to a 96 well clear, polystyrene plate (Corning incorporated, CoStar, 
London, UK) in triplicates. 250µl of Bradford reagent was added to each 
Primary antibody Secondary antibody MW 
(kDa) 
Dilution 
TWIST1 monoclonal 
antibody (M03), 
clone 2F8, Mouse, 
Anti-human, Abnova 
Polyclonal Goat Anti-Mouse 
Immunoglobulins/HRP, Dako 
(Cambridgeshire, UK), 1:2000 
22 1:500 
E-Cadherin (24E10) 
Rabbit mAb, Anti-
human, Cell 
Signalling 
Technology 
Anti-rabbit IgG, HRP-linked 
Antibody, Cell Signalling 
Technology (1:1000) 
 
135 1:1000 
Vimentin (D21H3) 
XP® Rabbit mAb, 
Reacts with human, 
mouse, rat and 
monkey, Cell 
Signalling 
Technology 
Anti-rabbit IgG, HRP-linked 
Antibody, Cell Signalling 
Technology (1:1000) 
 
57 1:100 
Mouse monoclonal 
to ȕ-actin (AC-15), 
abcam (Cambridge, 
UK) 
Polyclonal Goat Anti-Mouse 
Immunoglobulins/HRP, Dako, 
1:2000 
40 1:2000 
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well, and the plate was gently mixed and incubated for 10 minutes at RT. 
The absorbance at 595nm was measured using an illuminometer (MRX 
Revelation, Thermo Labsystems, Cheshire, UK). The absorbance of the 
protein standards was used to plot a standard curve. The equation of 
linear regression was calculated in Graph Pad Prism, and the 
concentration of the protein samples was determined based on this, after 
subtracting the absorbance value of the lysis buffer (negative control).  
 
 
2.2.8 Immunofluorescence 
2.2.8.1 Cell plating 
Cells were harvested and counted as before (section 2.2.5.6). Coverslips 
and tweezers were dipped in absolute ethanol for 5-10 minutes before 
use. After drying, they were placed on the bottom of the plate. 100µl of 
cells (~400,000 cells/ ml) were carefully added, and the plate was 
transferred to the incubator. Each well was topped up with normal 
medium when the cells were attached to the coverslip.  
2.2.8.2 Staining 
The next day, the medium was carefully removed and the cells were 
washed twice with PBS. The cells were fixed in 1ml of 3.7% formaldehyde 
for 30 minutes at RT. The cells were washed twice with PBS. The slides 
were covered with 1ml of permeabilsation solution (2% BSA, 0.2% Triton 
X-100 and 0.005% Tween-20 in PBS) for 15 minutes at RT. The 
permeabilisation solution was removed and the wells and the cells were 
stained with the primary antibody diluted in 100µl of permeabilisation 
buffer for 2 hours at RT. A piece of parafilm was added on the coverslips 
to avoid evaporation. The primary antibody was washed three times with 
PBS and the cells were incubated with the secondary antibody 
(conjugated with a fluorochrome) diluted in 100µl of permeabilisation 
solution for 1 hour in the cold room. After 3 washes with PBS, the 
coverslips were mounted on poly-L-lysine coated glass slides (Polysine® 
slides, Thermo Scientific, Loughborough, UK) with Prolong gold 
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(Prolong® Gold antifade reagent with DAPI, Invitrogen) and left to harden 
for 24 hours in the cold room. For each primary antibody, an isotype 
FRQWURODQGDµVHFRQGDU\RQO\¶FRQWUROZHUHLQFOXGHG7KHDQWLERGLHVXVHG
are listed in Table 6. The pictures of staining were taken with the Nikon 
Eclipse Ti-U microscope. 
 
 
Table 6. Antibodies used for immunofluorescence. 
 
Primary 
antibody 
Secondary 
antibody 
Isotype control Dilution 
E-cadherin, 
Mouse, Anti-
human, DAKO 
(Clone NCH-
38) 
Goat anti-mouse 
Alexa Fluor 488, 
Invitrogen, used at 
1:50 dilution 
Mouse IgG1, 
DAKO,  matched 
to the 
concentration of 
the primary 
antibody 
1:25 
Vimentin, 
mouse, anti-
human, DAKO, 
clone V9 
Goat anti-mouse 
Alexa Fluor 488, 
Invitrogen, used at 
1:50 dilution 
Mouse IgG1, 
DAKO,  matched 
to the 
concentration of 
the primary 
antibody 
1:50 
 
 
2.2.9 Gene expression analysis 
RNA was isolated from cells, cDNA was synthesised and gene 
expression levels were assessed using quantitative PCR (qPCR).  
2.2.9.1 RNA isolation 
RNA was extracted using the TRI-reagent isolation protocol. Harvested 
cells were re-suspended in 1mL TRI-reagent and allowed to stand at R/T 
for 5 minutes to ensure complete dissociation of nucleoprotein 
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complexes. 200µl of chloroform were added per mL of TRI-reagent and 
samples were vigorously shaken for 15 seconds. After standing at RT for 
15 minutes, cells were centrifuged at 3600g for 15 minutes at 4°C. 
Centrifugation separated the mixture into 3 phases: a red organic phase 
(containing protein), an interphase (containing DNA), and a colourless 
upper aqueous phase (containing RNA). The aqueous phase was 
transferred to a fresh tube containing 500µl isopropanol and mixed 
gently. The sample was allowed to stand at R/T for 10 minutes and then 
centrifuged at 3600g for 15 minutes at 4°C.  The supernatant was 
removed and the RNA pellet was washed with 1mL 70% ethanol. After 
centrifugation at 3600g for 5 minutes at 4°C, the supernatant was 
removed and the samples were re-centrifuged for an additional minute. 
Excess ethanol was removed without disturbing the pellet. The RNA 
pellet was air-dried and re-suspended in 50µl nuclease-free water.  
2.2.9.2 cDNA synthesis  
cDNA was synthesised from the mRNA isolated from the cells using the 
6XSHU6FULSW ,, 5HYHUVH 7UDQVFULSWDVH ,QYLWURJHQ )RU HDFK F'1$
made, a cDNA negative that contained all the reagents, except the 
reverse transcriptase and primers, was also prepared. This allowed the 
degree of genomic contamination in each RNA preparation to be 
checked. In order to check contamination of any of the reagents used, a 
cDNA control was included in which a complete cDNA synthesis was 
carried out using water instead of RNA.  
Two 0.5mL tubes were labelled cDNA+ve and cDNA-ve. 1µl of random 
hexamers (stock diluted 1:3) and 1µl water were added to the cDNA+ve 
and cDNA-ve respectively. 10µl of RNA was added to the tubes and 
mixed. The samples were incubated at 70°C for 10 minutes.  
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The following master mixes were made: 
                                           cDNA+ve (x1)          cDNA-ve (x1) 
Water                                        3µl                          3.4µl 
5xBuffer                                    4µl                             4µl 
0.1M DTT                                  2µl                             2µl 
10mM dNTPS                          0.6µl                          0.6µl 
SuperScript                             0.4µl                             - 
 
10µl of the appropriate reaction mix was added to each RNA sample. The 
samples were mixed and incubated for 10 minutes at 25°C and 1 hour at 
42°C. The enzyme was heat inactivated for 5 minutes at 95°C. The 
samples were stored at -20°C or used immediately.  
2.2.9.3 Quantitative PCR (qPCR) 
2.2.9.3.1 The reaction 
The qPCR reactions were carried out in 96 well plates (Applied 
Biosystems) containing 5µl cDNA and 15µl reaction mixture. The reaction 
mixture contained 10µl of 2X Master Mix (SYBR green I and polymerase, 
Applied Biosystems), 4 µl nuclease-free water and 1µl primers (forward 
DQG UHYHUVH SULPHUV PL[HG XVXDOO\ ȝ0 HDFK 7KH UHDFWLRQV ZHUH
performed in a StepOnePlus Real Time PCR machine (Applied 
Biosystems) using the following reaction cycle protocol: one holding 
VWDJHÛ&IRUPLQXWHVRQHF\FOLQJVWDJHF\FOHVDWÛ&IRU
VHFDQGÛ&IRUVHFDQGRQHPHOWFXUYHVWDJHÛ&IRUPLQXWHV
Û&IRUPLQXWHDQGÛ&IRUPLQXWHV)RUHYHU\VDPSOHDQDO\VHG
a negative cDNA control (H2O instead of cDNA) was run to detect any 
contamination during the preparation.  
2.2.9.3.2 Primers 
The sequences of the primers are listed in Table 7. 
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Table 7. Sequence of primers used in qRT-PCR. 
 
 
 2.2.9.3.3 Data analysis 
 The data obtained from the qPCR were analysed based on the cycle 
threshold (Ct) value, the minimum number of cycles necessary in order 
to detect SYBR green fluorescence incorporated into the DNA. The 
higher the Ct value, the lower the gene expression level. All samples 
were analysed in triplicates and each Ct value was normalised to the 
Gene Forward primer  
¶-¶ 
Reverse primer  
¶-¶ 
HPRT 
ATTATGCTGAG
GATTTGGAAAG
GG 
GCCTCCCATCTCCTTCATCAC 
VEGF 
CCAAGTGGTCC
CAGGCTGCA 
TGGATGGCAGTAGCTGCGCT 
TWIST1 
CAAGCTGAGCA
AGATTCAGACC
C 
AGACCGAGAAGGCGTAGCTGA 
S100A4 
GGATGGATGGT
GTCCT 
CATCTGTCCTTTTCCCCAAGAA
G 
CDH1 
GAACAGCACGT
ACACAGCCCT 
GCAGAAGTGTCCCTGTTCCAG 
CDH2 
GACGGTTCGCC
ATCCAGAC 
TCGATTGGTTTGACCACGG 
VIM 
AAAACACCCTG
CAATCTTTCAGA 
CACTTTGCGTTCAAGGTCAAGA
C 
SNAI2 
CTGCGGCAAGG
CGTT 
GCAGTGAGGGCAAGAAAAAGG 
ZEB1 
GAAAGGAAGGG
CAAGAAATCCT 
TGCATCTGACTCGCATTCATC 
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triplicate Ct values obtained for the housekeeping gene Hypoxanthine-
guanine phosphoribosyl transferase (HPRT) expression in the same 
cDNA sample. Gene expression was expressed as 2-¨&W[111] in which 
¨Ct = Ct target gene-Ct reference gene (HPRT).  
 
2.2.10 Cell culture assays 
2.2.10.1 Hypoxia  
1x104 cells/ml were seeded in black 24-well plates in a total volume of 
1ml, in quadruplicates. Cells were cultured in normal oxygen (normoxia) 
conditions (see section 2.2.1) or in low oxygen conditions (1%) in a 
humidified hypoxia chamber (Invivo2 Hypoxia Workstation 400, 
RUSKINN) for 4 days. At the end of the assay, bioluminescent readings 
were performed (see sections 2.2.3) and the activity of the reporter was 
calculated as follows: (Average signal of EMT reporter in hypoxia / 
Average signal of control vector in hypoxia) / (Average signal of EMT 
reporter in normoxia / Average signal of control vector in normoxia). 
Following bioluminescent readings, the medium was aspirated and the 
cells were collected with 1ml of TRI-reagent (all four wells in 1ml) for 
subsequent gene expression analysis. 
2.2.10.2 Culture with EMT inducing media supplement 
5x103 cells were seeded in 10cm culture dish in 6ml of culture medium 
with or without 1X (60µl) StemXVivo EMT Inducing Media Supplement 
(R&D systems, Abingdon, UK). The medium was replenished after 3 
days. After 5 days the cells were collected with TRI-reagent and/or were 
lysed as described before (section 2.2.5). 
2.2.10.3 3D cultures 
Cultrex® Basement Membrane Extract (BME) was defrosted on ice 
overnight. Cells were pelleted for 5 minutes at 835g in phenol free, serum 
free RPMI supplemented with 1% l ±glutamine (Tumour growth assay 
medium; TGA), and resuspended in TGA medium; an equal amount of 
BME was added and mixed. These steps were performed on ice, to avoid 
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solidification of BME. In a 96 well plate black with clear bottom, 100µl per 
well (2x104 cells/well, 4-6 wells per day) were added with the plate on 
Û&SODWHZDUPHU, to allow immediate setting of the BME. The plate was 
placed in the incubator and after about 6 hours (when the BME was 
completely settled) 50µl of TGA was added on top. Cell growth was 
monitor with Alamar Blue (section 2.2.3). Cells were collected with TRI-
reagent using a blue tip, in which the tip was cut. 
2.2.10.4 Co-cultures with MSCs 
Approximately 3300 MCF-7 cells per well were mixed with approximately 
1750 MSCs (2:1 ratio) or 1750 MCF-7 cells and plated on coverslips in 
6-well plates in a total volume of 3ml MCF-7 medium (Table 4). For each 
condition (MCF-7 only or MCF-7 + MSCs), 5 wells were included for the 
IF analysis: 1) No staining, 2) Isotype control, 3) Secondary antibody 
only, 4) E-cadherin and 5) Vimentin. The cells were cultured for 7 days. 
At the end of the assay, the co-cultures were analysed for the expression 
of E-cadherin and Vimentin by IF, as described before (section 2.2.6). 
2.2.10.5 Cultures with IL6 supplementation 
1x104 cells were seeded in 10cm culture dishes with or without 50ng/ml 
recombinant human IL-6 (Life Technologies) in a total volume of 6ml 
MCF-7 medium (Table 4). The cells were incubated for 7 days. The 
medium was replenished every 2-3 days. At the end of the experiment, 
cells were collected with TRI-reagent for gene expression analysis.  
2.2.10.6 Trans-wells with BrCAFs 
Cells were collected and counted as before (2.2.8.1) in the appropriate 
medium. 2x103 MCF-7 cells were plated in the well of the transwell plates 
(Corning incorporated, CoStar) in 600µl MCF-7 medium (Table 4). Cells 
were added in the insert in their growth medium (MCF-7 medium or CAFs 
medium; Table 4) as follows: 2x103 MCF-7 (1:1 ratio; control), 6x103 
MCF-7 (1:3 ratio; control), 2x103 BrCAFs (1:1 ratio), and 6x103 BrCAFs 
(1:3 ratio).  
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2.3 IN VIVO STUDIES 
 
The studies were conducted under the UK Home Office Licence number 
PPL 40/3559. NCRI guidelines for the welfare and use of animals in 
cancer research, LASA good practice guidelines, and FELASA working 
group on pain and distress guidelines were followed. To see an example 
of a full study protocol, including adverse effects, see appendix 1. The 
chemicals used were purchased from Sigma Aldrich, unless otherwise 
stated.  
 
2.3.1 Cell maintenance 
On day of initiation of the study, cells were harvested from semi-confluent 
monolayers. Cells with viability of >90% were re-suspended, for in vivo 
administration, in sterile standard formulation matrigel (BD MatrigelTM 
Matrix Basement Membrane) or in culture medium at 2x106 
cells/100µl/mouse. In the studies in which MSCs were co-implanted, 
1x106 MSCs were mixed with 2x106 MCF-7 cells or BT549 and re-
suspended in 100µl of sterile standard formulation matrigel. Cells were 
aliquoted into sterile tubes and transported on ice to the in vivo facility for 
initiation within 30mins of arrival. The same cell number of MSCs was 
used for re-injecting with MSCs in some studies. 
2.3.2 Animals (species, strain, sex, identification and diet) 
MF1 female nude mice (HsDOla:MF1-Foxn1nu) at 4 to 6 weeks of age 
were obtained from Harlan Laboratories (Leicester, UK). Female Rag2-
/-
 ȖF-/- mice (C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J) were bred in house under 
a breeding licence (PPL40/3576). Each animal was earmarked and 
assigned a cage number which appeared on the data sheets. Ear 
markings were as follows; pl (plain or no marking), 1r (1 notch in right 
ear), 1l (1 notch in left ear), 1r1l, 2r etc. For the mice injected with MCF-
7 cells, estradiol (Sniff, Germany) was added to their diet.  
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2.3.3 Tumour initiation (site of implantation)  
Mice were injected with 100µl of the cells in the mammary fat pad (MFP); 
under the skin of the left upper nipple of the mouse. Otherwise, they were 
injected with the cells subcutaneously, under the skin on the left flank of 
the mice. For those studies where D³06&VERRVW´ZDVLQFOXGHd, 100µl 
of MCF-7/MSCs mixture were injected at initiation and then an additional 
100µl of MSCs (same number as at initiation) were injected intratumorally 
upon tumour formation.  
2.3.4 Monitoring/tumour measurement 
Tumour establishment was monitored by calliper measurements weekly. 
The length and width of tumours were measured, and the tumour 
volumes were calculated as follows: (length x (width2))/2. Tumour growth 
was monitored weekly, or once every two weeks, by optical imaging, 
carried under anaesthesia in an IVIS Spectrum. For the bioluminescence 
imaging, D-luciferin (Caliper Life Sciences) was injected in the mice and 
the imaging was carried out 15 minutes after injection. The 
amount/volume of D-luciferin added dependent on mouse weight (for 
example 200µl of 15mg/ml D-luciferin were injected in a mouse weighted 
20g, 250µl were injected in a mouse weighted 25g and so on). The 
imaging was carried out at different exposure times (1 second, 10 
seconds, 30 seconds and 60 seconds). To analyse the bioluminescence 
imaging, the most representative image (i.e. not overexposed) was 
selected, regions of interest were drawn around the tumours, and the 
signal was calculated as total flux (photons/second) using the Living 
Image (4.3.1 build) software. For the fluorescent (mCherry) imaging, 
pictures were taken at three different excitation/emission filters 
(570ex/520em, 605ex/660em and 430ex/660em) to allow accounting for 
any crossover between the different filters. Regions of interests were 
drawn around the tumours and at a different site on the mice, for 
background control, and the total flux was calculated (605ex/660em). 
The total flux was calculated, and the background signal 
(autofluorescence) was subtracted from each value. To check for any 
spill-over between the different emission filters, the background signal 
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from the mice at other exposures/emissions was also subtracted.  To 
avoid crosstalk between the high levels of bioluminescence and weaker 
levels of fluorescent signal, the fluorescent reads were performed prior 
to luminescent reads. 
2.3.5 Termination 
The studies continued until the tumours reached the maximum size 
(1.2cm2), as specified by the Home Office licence, or other clinical signs 
necessitate removal of a particular mouse for the study. After the final 
imaging, the mice were sacrificed and the terminal imaging was carried 
out with the skin and muscle layers open to expose the primary site and 
adjacent lymphatics, as well as distant organs. The lymph nodes and 
spleens were resected and imaged individually. After imaging, the 
tumours and other organs of interest were weighed and preserved in 
fixative solution and/or in RNAlater (Ambion® Life Technologies).  
2.3.6 Ex vivo analysis 
2.3.6.1 Tissue and cell fixation, processing and sectioning 
2.3.6.1.1 Fixation 
The tissues were immersed in at least 20 volumes of fixative solution 
(Neutral Buffered Formalin, Thermo Scientific) for at least 24 hours 
before processing. For storage, the samples were transferred to 70% 
methanol. Cells cultured in vitro, were fixed in 500µl of 2% 
paraformaldehyde (diluted in PBS) for 10 minutes. They were mixed with 
1% agarose and placed into 1.5ml micro centrifuge tubes containing an 
agarose plug. After the cells had settled, the plug was removed and 
placed in 70% methanol ON.   
2.3.6.1.2 Processing 
The tissues (or cells) were placed in embedding cassettes with 
disposable lid, and processed in the tissue processor (TP1020, Leica 
Microsystems UK). The chemical-station layout of the tissue processor 
was set as follows:  
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1. 70% Methanol diluted in distilled water 
2. 90% Methanol diluted in distilled water 
3. 100% Methanol 
4. 100% Methanol 
5. 100% Methanol 
6. 100% Methanol 
7. 100% Methanol 
8. Xylene  
9. Xylene 
10. Xylene 
11. Paraffin wax (VWR BDH Prolabo, West Sussex, UK) 
12. Paraffin wax 
The tissues were placed in stations 1-10 for 60 minutes at RT under 
vacuum and agitation and in stations 11 and 12 for 20 minutes at 60ƕC 
under vacuum and agitation. After the processing cycle, the cassettes 
were removed and placed in the embedding station was reservoir 
(EG1160 Leica Microsystems UK), which was pre-ZDUPHG WR ƕ&
Molten paraffin wax was dispensed in pre-heated moulds, and the tissues 
were placed into the wax and oriented as required. The moulds were 
allowed to set/cool and the cassette was removed for trimming the 
excess wax with a pen knife.  
2.3.6.1.3 Sectioning 
The tissues were chilled at around 4ƕC for optimum cutting. The 
sectioning was performed using a microtome (LEICA RM2135). The 
blocks were fixed into the chuck and were trimmed in at 10-micron 
intervals until the required depth was attained. Tissues were cut at 4-
microns and the tissue sections were allowed to form a continuous 
ribbon, which was transferred to a water bath (distilled water at 37ƕC) 
using forceps. The tissue was allowed to stretch out and then transferred 
to poly-L-lysine coated glass slides (Polysine® slides, Thermo Scientific). 
The tissue was allowed to air dry ON before use. 
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2.3.6.2 Immunohistochemistry 
All sections were de-waxed in 2 xylene baths for 5 minutes each, then 
rinsed in 2 100% methanol baths, for 1 minute each, and then rinsed in 
running tab water for 1 minute. After the staining process, the sections 
were incubated with DAB (1 drop of iquid DAB+Chromogen per ml of 
DAB+Substrate buffer) for approximately 3 minutes. After the sections 
were rinsed in running tap water, WKH\ZHUHFRXQWHUVWDLQHGZLWK0D\HU¶V
Haemalum for 3 minutes and then rinsed in running tap water. The 
sections were dehydrated in 3 100% methanol baths (1 minute each) and 
cleared in 2 xylene baths (5 minutes each). The slides were mounted to 
glass coverslips with DPX. Pictures were taken with the LEICA DMLB 
microscope (Leica Microsystems).   
2.3.6.2.1 H and E staining 
Following de-waxing, sections were incubated with pre-ILOWHUHG0D\HU¶V
Haemalum (RAYMOND A LAMB Ltd., Eastbourne, UK) for 3 minutes. 
Sections were rinsed in running tab water for 1 minute and then incubated 
with pre-filtered Eosin (RAYMOND A LAMB Ltd.) for 3 minutes. The 
sections were stained with DAB, counterstained with Haemalum, 
dehydrated, cleared and mounted, as described above.  
2.3.6.2.2 Cytokeratin, E-cadherin and Vimentin staining 
Following de-waxing, the sections were immersed in cold citric acid from 
SIGMA® (10mM in distilled water, pH6) and heated in a microware at 
98ƕC for 30 minutes (antigen retrieval step for E-cadherin) or 20 minutes 
(antigen retrieval step for Vimentin), or incubated with Proteinase K 
(Dako) for 5 minutes at RT (antigen retrieval step for cytokeratin).After 
that, the sections were immediately quenched in running tap water for 1 
minute. Sections were incubated for 5 minutes in peroxidase block and 
then washed in PBS (2 times, 5 minutes each). The primary antibodies 
E-cadherin (mouse anti-human E-cadherin, clone NCH38, Dako) and 
Vimentin (anti-human Vimentin, clone V9, Dako) and the isotype control 
(mouse IgG1, Dako) were mixed mouse with biotinylation reagent and 
PBS, and incubated for 15 minutes to a final concentration of. 5 minutes 
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before use, the blocking reagent was added to the mix. The volumes 
were calculated using the ARKulator (Dako). The sections were 
incubated with the primary antibody or the control for 30 minutes at room 
temperature.  The sections were rinsed in PBS (2 times, 3 minutes each) 
and then incubated with the secondary avidin:biotin peroxidase for 15 
minutes. The sections were again rinsed in PBS and then incubated with 
DAB and rinsed. The sections stained with E-cadherin, were intensified 
in copper sulphate (0.5% CuS04 and 0.9% NaCl in distilled water) for 10 
minutes. The sections were stained with counterstained with Haemalum, 
dehydrated, cleared, mounted, and imaged, as described above. The 
reagents used were provided in the form of a kit (Dako ARKTM (Animal 
Research Kit), Peroxidase for Mouse Primary Antibodies). 
2.2.6.2.4 S100A4 staining 
After de-waxing,  were immersed in sodium citrate buffer (10mM in 
distilled water, pH6) and heated in a microware at 98ƕC for 30 minutes 
and left to cool down to RT for 30 minutes (antigen retrieval step). The 
sections were rinsed in TBS with Tween (137mM Sodium Chloride, 5mM 
Trizma, 0.1% Tween-20 in distilled water). The next steps were 
performed sections in a humidified chamber. The endogenous 
peroxidase was inactivated by covering the tissues with 3% hydrogen 
peroxide (diluted in 1XTBS) for 5 minutes. The slides were washed in 
TBS-Tween. The sections were incubated with the blocking solution 
(10% swine serum (Vector labs, Peterborough, UK) diluted in PBS), for 1 
hour. The primary antibody (rabbit polyclonal anti-humanS100A4 
antibody, EPR2761(2), C-term, GeneTex) was diluted in 5% swine serum 
(in PBS) at a final concentration of approximately 3µg/ml. The sections 
were incubated with the primary antibody or the control (rabbit serum, 
Vector labs) in the cold room ON. To avoid evaporation, the sections 
were covered with a piece of parafilm. The sections were washed with 
TBS-Tween and incubated with the secondary antibody (polyclonal swine 
anti-rabbit immunoglobulins/HRP, Dako), which was diluted in 5% swine 
serum at a final concentration of 10µg/ml, for 1 hour at RT. The sections 
were washed in TBS-Tween for 5 minutes and incubated with DAB. The 
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sections were then stained counterstained with Haemalum, dehydrated, 
cleared, mounted, and imaged, as described above. 
2.3.6.3 Tumour homogenisation for gene expression analysis 
Tumours stored in RNAlater were mechanically homogenised using a 
mortar and pestle and collected with TRI-reagent. RNA extraction, cDNA 
synthesis and qRT-PCR were performed normally as previously 
described (section 2.2.7).  
  
2.4 STATISTICAL ANALYSIS 
 
Statistical analysis of the data was performed using Graph Pad Prism 
Version 6 (San Diego, California). The linearity of bioluminescent signal 
against cell number was analysed by linear regression (R2 coefficient). 
The correlation between baseline bioluminescent signal and baseline 
gene expression levels in the transduced cell lines, and other correlation 
DQDO\VHV ZDV DQDO\VHG E\ WKH 3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW 7KH
significant changes in gene expression or bioluminescent signal between 
different conditions (e.g. normoxia versus hypoxia) was analysed by a 
ratio paired t-test. Changes in gene expression were also assessed by 
an unpaired t-test when necessary. Finally, differences between two 
groups (e.g. average tumour volumes) were also assessed by an 
unpaired t-test. 
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CHAPTER 3: RESULTS 1 ± Development and 
validation of the activity of EMT reporters in vitro 
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This chapter describes the development and validation of the activity of 
EMT reporters in vitro.  
The cell lines used in this study were initially selected based on previous 
studies performed in-house and the literature that defined MCF-7 as 
epithelial (luminal) and MDA-MB-231 and BT549 as mesenchymal (Basal 
B/triple-negative) [112]. MCF-7 cells were included in the study to be 
used as a model for inducing EMT, in order to test the EMT reporters 
upon induction of EMT, both in vitro and in vivo. The mesenchymal cell 
lines, MDA-MB-231 and BT549, were included in the study to be used in 
in vivo metastatic models, in order to test the activity of EMT reporters 
before and after metastasis. Metastasis of MDA-MB-231 in mouse 
models has been previously reported [92, 95, 113] 7R WKH DXWKRU¶V
knowledge, no previous in vivo models of spontaneous metastasis using 
the BT549 cells have been reported; therefore a metastatic in vivo model 
of BT549 would be a novel model. As BT549 belong to the same subtype 
as the MDA-MB-231 cells, it is expected that they will be highly 
tumourigenic and metastatic. Finally, as the selected cell lines represent 
different subtypes of BC (luminal and basal/triple negative) they will be 
used to assess the activity and the patient-relevance of the EMT 
reporters in the different BC subtypes.  
In the first part of the chapter, to confirm the phenotype of the cell lines, 
epithelial or mesenchymal, and to determine which cell line(s) were the 
best to use to test the EMT reporters, the baseline expression of common 
EMT biomarkers (reviewed in [114]) was analysed in the cell lines. The 
markers included the epithelial marker E-cadherin, which is 
downregulated in EMT, and the mesenchymal markers N-cadherin, 
Vimentin, ZEB1, Twist, Slug and S100A4 (FSP1), which are acquired in 
EMT. The baseline expression of the EMT markers was detected by 
qPCR (gene expression) and western blot (protein expression).  
It has been reported that EMT generates cells with stem-like properties 
[52], therefore the ³CSC population´ of the cell lines was investigated, to 
further characterise the cell lines and to determine which cell lines were 
best to use to test enrichment of cells with stem-like properties upon 
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induction of EMT. The markers used were CD44 and CD24, to detect the 
CD44+/CD24low/- population, which has been previously defined as CSCs 
in BC [29-31]. To identify this population, the cells were stained with 
CD44 and CD24, and the reported CD44+/CD24low/- population was 
quantified by flow cytometry, which has been used for identifying the 
CD44+/CD24low/- population in different BC cell lines [29-31].  
The second part of the chapter describes the development and validation 
of inducible EMT reporters driven by the promoters of the EMT 
genes/markers (S100A4, E-cadherin or N-cadherin) upstream of a 
bioluminescent reporter, firefly luciferase. Bioluminescent reporters have 
been extensively used for studying gene expression at the transcriptional 
level [115] and were therefore used for the purposes of this study to 
measure the changes in the reporter transcription levels. As the reporters 
would be eventually tested in vivo, choosing bioluminescent rather than 
fluorescent reporters would have advantages, including high sensitivity 
and low background levels, which would allow the detection of a smaller 
number of cancer cells [116, 117]. This would allow detecting even a 
small proportion of cells in which changes in the activity of the reporters 
will occur. 
Briefly, the reporters were constructed by conventional molecular cloning 
(information on molecular cloning can be found at 
http://www.molecularcloning.com/). Stable cell lines expressing the 
reporters were generated, using a commercially available lentiviral 
expression system (Lenti-; /HQWLYLUDO ([SUHVVLRQ 6\VWHP The 
linearity between the cell number and the bioluminescent signal was 
analysed, and the ability of the reporters to detect the baseline levels of 
the reporter genes was investigated. Finally, the ability of the reporters to 
detect the changes in the expression of the reporter genes was explored. 
The planned reporters were based on a lenti-viral expression vector. 
Lentiviral vectors have been widely used in research as a tool of 
transferring genetic material in mammalian cell lines, and will be used in 
this study due to their ability to integrate in both dividing and non-dividing 
cells and sustain long-term expression [118].  
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A bioluminescent reporter measuring the transcription of Vimentin has 
been previously reported, which was used to measure EMT in BC cell 
lines [83]. In this study, the reporter was used to screen for EMT inhibitors 
in MDAMB231 3D spheroids using a small compound library by 
measuring inhibition of Vimentin transcription/decrease in the 
bioluminescence signal. In this thesis, bioluminescent EMT reporters 
were developed in order to detect EMT in real-time, that could be 
subsequently be used for screening for inhibitors of EMT in early and late 
stages of EMT.  
The S100A4 reporter was used in this study, in order to detect EMT at 
early stages and mark the cells with prometastatic properties. S100A4 
(also known as fibroblast specific protein 1;FSP1) is a small ubiquitous 
calcium-binding protein that is involved in increasing cell mobility to allow 
invasion and migration [119]. It targets different proteins that are involved 
in cytoskeletal rearrangement and cell motility and it has many 
extracellular functions, including remodelling of the extracellular matrix, 
cell motility, differentiation and survival [119, 120]. S100A4 has been 
shown to have an early role in EMT [121] and has been used as an early 
marker of EMT [122, 123]. In cancer, EMT has been linked to 
metastasising cells, and it was therefore hypothesised that some of the 
prometastatic roles of S100A4 are due to its role in EMT (reviewed in 
[124]). There is evidence in the literature linking S100A4 and EMT in 
cancer, such as its inverse correlation with epithelial markers and its 
ability to activate transcription factors involved in the process of EMT. In 
breast cancer, S100A4 correlates with experimental metastasis, and 
metastasis and poor prognosis in BC patients [124].  
E-cadherin and N-cadherin are both common markers of EMT, as they 
mark fundamental changes in the cytoskeleton and cell motility 
characteristic for EMT, and will be therefore used in this study to 
investigate these changes. Cadherins are transmembrane cell-cell 
adhesion molecules that have different functions in morphogenesis, 
including the control of cell contact and cell signalling (reviewed in [125]). 
E-cadherin has an important role in epithelial cells [126], while N-cadherin 
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is a neural cadherin [127]. Downregulation of E-cadherin is a hallmark of 
EMT and the downregulation of E-cadherin is concomitant with the 
upregulation of N-cadherin, resulting LQ D µFDGKHULQ VZLWFK¶ [128]. This 
switch results in increasing motility and invasion of the cells, by 
weakening the affinity of cells epithelial cell interaction and acquisition of 
the ability to interact with mesenchymal cells.  
The activity of the reporters was validated in vitro in stable cell lines 
expressing the reporters. The ability of the reporters to detect changes in 
the gene expression of the reporter genes was investigated in a model in 
which activation or repression of the reporter genes would be later 
induced. This induction was via hypoxia (culture of the cells in low oxygen 
culture conditions). During hypoxia, the Hypoxia Inducible Factor (HIF)-1 
is activated and controls different processes including tumour 
proliferation and apoptosis and activation or repression of different 
pathways (reviewed in [129]). Briefly, in normoxia HIF-1Į protein binds to 
the E3 ubiquitin ligase VHL complex leading to its degradation, while in 
hypoxia HIF-1Į protein is stabilised and translocate to the nucleus to bind 
to HIF-1ȕ, and together they bind to target genes (reviewed in [130]). A 
major role of HIF-1 is to promote angiogenesis by directly binding to the 
VEGF (vascular endothelial growth factor) promoter leading to its 
expression, which in turn promotes the migration of endothelial cells 
towards a hypoxic area. As VEGF is a downstream target of HIF-1, VEGF 
will serve as a hypoxia marker in this study, to confirm that hypoxia was 
induced in the different assays. As the activity of HIF-1Į is dependent on 
protein stabilisation as discussed above, analysing the gene expression 
levels of HIF-1Į wouldQ¶WEH UHOHYDQW LQ WKLVVWXG\XSUHJXODWLRQRI WKH
gene will not necessarily mean activation of the protein and downstream 
targets. S100A4 has also been reported as a direct target of HIF-1, which 
increased its expression [131, 132]. Therefore, the activity of the S100A4 
reporter was assessed in hypoxia, where it was expected that the gene 
expression of S100A4 would be increased, resulting in increase in the 
bioluminescent signal. HIF-1 also regulates the expression of E-cadherin 
and N-cadherin indirectly via the activation of different TFs (e.g. TWIST) 
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[133-135].  Thus, hypoxia was used as a model to induce changes in the 
gene expression of E-cadherin and N-cadherin and test the activity of the 
reporters. The changes in the gene levels of the EMT genes were 
assessed by qPCR. The changes in the bioluminescent signal were 
assessed by luciferase assays, where the signal from the reporter line 
was normalised to the signal from the control line (cells transduced with 
a vector that allows constitutive expression of firefly luciferase). This 
allowed normalisation of the differences in the growth rate of the cells in 
the different conditions, accounting for any factors that could have 
affected luciferase expression (oxygen, ATP, cell density, viability and 
pH). Emission of light, upon administration of the D-luciferin, requires 
oxygen and ATP [136] and it has been shown that changes in the oxygen 
levels and pH can significantly reduce the bioluminescent signal in in vivo 
models [137].  
 
3.1 Choice of cell lines 
 
3.1.1 Gene and protein levels of EMT markers  
3.1.1.1 Gene expression of EMT markers 
The baseline gene expression of EMT markers was analysed in the cell 
lines. RNA was extracted from the cells, cDNA was synthesised and the 
gene expression was determined by qPCR. The average 2-¨CT values are 
summarised in Table 8. The 2-¨CT values for each gene were plotted for 
all the cell lines, to allow comparison across all cell types for each gene 
(Figure 13). MCF-7 expressed higher levels of the epithelial marker 
CDH1 and lower expression of the mesenchymal markers compared to 
MDA-MB-231 and BT549. MDA-MB-231 expressed higher levels of 
SNAI2 and S100A4 compared to BT549. BT549 expressed higher levels 
of CDH2, VIM, ZEB1 and TWIST1 compared to MDA-MB-231.  
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3.1.1.2 Protein expression of EMT markers 
The protein expression of the most common EMT markers reported in 
the literature, E-cadherin and Vimentin, was analysed in the cell lines. 
Cell lysates were collected, the protein concentration was determined by 
a Bradford assay, and protein expression was detected by a Western 
Blot. MCF-7 cells expressed high levels of E-cadherin and undetectable 
levels of Vimentin (Figure14). E-cadherin could not be detected in either 
MDA-MB-231 or BT549 (Figure 14), while both the cell lines expressed 
Vimentin, with MDA-MB-231 showing higher expression compared to 
BT549. 
 
 
 
 
 
 
 
 
 
Table 8. Baseline gene expression of EMT markers in BC cell lines. 
The values represent the average 2-¨&7 values, from three or more 
biological replicates, as analysed by qPCR. 
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ǃ-actin 
E-cadherin (135 kDa) 
A 
Vimentin (57 kDa) 
B C 
 
  
Figure 14. Western blot of E-cadherin and Vimentin in BC cell 
lines. Analysis of E-cadherin (135kDa) and Vimentin (57kDa) are 
shown in the top two lanes in MCF-7 (A), MDA-MB-231 (B) and BT549 
(CǺ-actin (42kDa) was used as protein loading control.  
Figure 15. Gene expression of EMT markers in BC cell lines.  The 
graph represents the average 2-ǻCT values from three or more biological 
replicates, as analysed by qPCR. 
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3.1.2 CSC POPULATIONS  
The cell lines were stained with CD44 and CD24, and the reported CSC 
population (CD44+/CD24low/-) was quantified using flow cytometry. The 
cells were identified according to their size (Forward Scatter; FS) and 
their granularity (Side Scatter; SS). The appropriate compensations were 
applied based on single colour staining and level of background 
fluorescence measured on matched isotype controls for both test 
antibodies for each individual cell line (Figure 15A, 15C &15E). The 
compensations were applied individually for each cell line, to account for 
differences in the staining efficiency and autofluorescence.  
MCF-7 cells displayed uniform low level (dim) CD44 staining combined 
with uniform high CD24 staining (Figure 15B). Conversely, MDA-MB-231 
displayed uniformly high CD44 staining combined with negative CD24 
staining (Figure 15D). BT549 contained two populations, both of which 
expressed CD44, but 61.4% also expressed CD24 and 39.6% were 
CD44+/CD24 negative (Figure 15F). The CSC population was low in the 
MCF-7 (0.97%), higher in the BT549 (38.6%) and very high in the MDA-
MB-231 (98.5%). The percentage of CD44+/CD24low/- staining is 
summarised in Table 9.  
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Figure 16. Flow cytometry analysis of BC cell lines stained with 
CD44 and CD24 and their isotype controls. A. MCF-7 isotype 
controls. B. MCF-7 CD44/CD24 dual staining. C. MDA-MB-231 isotype 
controls. D. MDA-MB-231 dual staining. E. BT549 isotype controls. F. 
BT549 dual staining. The percentage of cells in each Quadrant is 
indicated. N=2 (Figure shows representative example) 
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Table 9. Summary of flow cytometry data of BC cell lines stained 
with CD44 and CD24. The numbers represent an average of two 
replicates. 
CELL LINE CD44+/CD24low/- 
MCF-7 0.97% 
MDA-MB-231 98.5% 
BT549 38.6% 
 
 
Summary and discussion 
MCF-7 expressed high levels of the epithelial marker E-cadherin (both at 
gene and protein levels) and did not express the mesenchymal markers. 
Conversely, MDA-MB-231 and BT549 did not express E-cadherin but 
expressed higher levels of the mesenchymal markers compared to the 
MCF-7. The data FRQILUPHG WKH µ(SLWKHOLDO (-cadherin-H[SUHVVLQJ¶
phenotype of MCF-DQGWKHµ0HVHQFK\PDO¶ phenotype of MDA-MB-231 
and BT549 [112]. Also, high expression of E-cadherin and no or low 
expression of  N-cadherin, Vimentin, Twist, Slug and ZEB1 in MCF-7 has 
previously been reported [112]. As S100A4 is involved in the early stages 
of EMT [138], it is expected that it is not expressed in epithelial cell lines 
like MCF-7. 
MDA-MB-231 had the highest CSC population, as defined by 
CD44+/CD24low/-, followed by the BT549 and finally the MCF-7 which had 
a very small CSC population. The data showed that the CSC population 
was 0.97% in MCF-7, 98.5% in MDA-MB-231 and 38.6% in BT549. 
Previous studies have shown similar data, where it was demonstrated 
that the CD44+/CD24- population was 0% in MCF-7 [29-31], between 80 
and >90% in MDA-MB-231 [29-31] and ~36% in BT549 [31]. It is 
important to note that other CSC markers have also been identified in 
BC, including ALDH1, CD133 and ESA [16, 30, 33, 139]. Also, it has been 
proposed that no single CSC markers exists and that it is more relevant 
to focus on the fundamental properties of the stem cells (e.g. tumour 
initiation) rather than in the expression of a single CSC marker [140].  
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The planned EMT reporters will measure the transcriptional activity of 
S100A4 or N-cadherin or E-cadherin promoters. E-cadherin is expected 
to be downregulated upon EMT, while N-cadherin and S100A4 are 
expected to be upregulated. As MCF-7 cells were confirmed as epithelial 
and their CSC population is very low, they will be used as a model to 
induce EMT and enrich for CSCs, and test the reporters upon induction 
of EMT. The MDA-MB-231 and BT549 were defined as mesenchymal 
with high CSC populations. Therefore, they will be used to test the 
S100A4 and N-cadherin reporters in in vivo metastatic models, in order 
to test the activity of the reporters in the cells before they metastasise. 
As these cell lines do not express E-cadherin, they will not be used to 
test that reporter; downregulation of E-cadherin will not be possible and 
no upregulation of E-cadherin is expected in EMT or metastasis.  
 
3.2 Development and validation of reporters 
 
3.2.1 Molecular cloning of EMT reporters 
3.2.1.1 Optimisation of cloning strategy 
In the attempt to generate the various plasmid constructs used in this 
study, the cloning method was designed and optimised as appropriate. 
Briefly, the gene of interest was amplified from plasmid or genomic DNA, 
gel extracted and purified, cloned into a TOPO vector for DNA 
sequencing, digested from the TOPO vector with the appropriate 
restriction enzymes, ligated with the digested cloning vector, and the 
ligation products were transformed into bacteria from which the DNA was 
isolated and sequenced. The primers used for the amplification were 
carefully designed to introduce unique and compatible restriction enzyme 
sequences, as well as additional bases upstream and downstream of the 
restriction sites for sufficient digestion of the PCR products, as suggested 
by New England Biolabs. During this process different kits were used 
(e.g. different polymerases to amplify the different genes) and many of 
the steps involved were optimised/amended including, the PCR 
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conditions, the incubation times of digestions, the intensity and time of 
exposure to UV light during gel extraction, and the amount of ligation 
products transformed into the bacteria, More details about each construct 
will be described in the next section.  
3.2.1.2 PCR amplification 
The S100A4 promoter (1078bp) was amplified from the commercially 
available plasmid, pLightSwitch_S100A4prom (Figure 7), using the 
HotStarTaq® DNA polymerase, at different annealing temperatures 
UDQJLQJ IURP Û& DQG Û& (Figure 16A). The promoter was 
identified by the company using sophisticated algorithms for gene model 
construction and transcription site prediction. The N-cadherin promoter 
(2434bp)/regulatory sequence was amplified from genomic DNA 
extracted from MCF-7 (ENSG00000170558: 1312-3721bp), using the 3-
6WHS7HUUD3RO\PHUDVH0L[at three different annealing temperatures; 
62.5Û& Û& DQG Û& (Figure 16B). The sequence of the 
amplification primers has been previously reported [141]. Finally, the E-
cadherin reporter (882bp) was amplified from the commercially available 
plasmid pLightSwitch_Ecadprom (Figure 8), using the HotStarTaq® DNA 
SRO\PHUDVHDWGLIIHUHQWDQQHDOLQJWHPSHUDWXUHVUDQJLQJIURPÛ&DQG
Û& (Figure 16C). As with the S100A4 promoter, the E-cadherin 
promoter was identified by the company. The primers used to amplify the 
promoters, were designed to introduce ClaI and XhoI restriction sites at 
WKH¶DQG¶ of the promoters accordingly, for subsequent replacement 
RIWKHµClaI/XhoI¶&09SURPRWHULQWKHS/9;-CMV-fLuc plasmid (Figure 
11).  
3.2.1.3 TOPO cloning 
Bright and clear PCR products (indicating high yield and purity) were 
purified and cloned into a TOPO vector (indicated by arrows; Figure 16). 
Following bacterial transformations of the TOPO vectors, a few colonies 
were selected and the plasmids were isolated using plasmid minipreps. 
The plasmids were digested with ClaI and XhoI, to select those clones 
with the insert incorporated, for subsequent DNA sequence analysis 
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(Figure 17). Digest of the clones was expected to reveal different size 
fragments depending on whether the PCR product was successfully 
cloned into the TOPO vector or not.  
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Figure 17. PCR amplification of the EMT promoters. A. 
Amplification of S100A4 promoter (1073 bases). Lanes: 1 = 1 kb DNA 
ladder, 2-13 = PCR products at different annealing temperatures 
(Gradient: 47.0°C ± 60.0°C). Size of the product = 1078 bases. B. 
Amplification of N-cadherin promoter (2410 bases). Lanes: 1 = 1 kb 
DNA ladder, 2-13 = PCR products at different annealing temperatures 
(Gradient: 50.0°C ± 68.0°C). C. Amplification of E-cadherin promoter 
(883 bases). Lanes: 1 = 1 kb DNA ladder, 2-13 = PCR products at 
different annealing temperatures (Gradient: 50.0°C ± 70.0°C). The 
arrows indicated the PCR products that were used to generate the 
plasmid constructs. Agarose gels 0.8%.  
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The restriction digests showed that only three out of the six clones had 
incorporated the S100A4 promoter, while all the clones had incorporated 
the N-cadherin and E-cadherin promoters (Figure 17). The clones were 
sequenced and the sequence was aligned to the original sequences of 
the designed plasmid constructs. The alignment of the S100A4 clones 
showed that, unlike the rest of the clones, one of the clones contained 
only a single mismatch (A>T; position in the promoter 1045bp), and it was 
therefore selected for constructing the reporter. Similarly, for the N-
cadherin promoter, the clone that contained a single mismatch (T>C; 
position in the promoter 912bp) was selected for constructing the 
reporter. No evidence were found in the literature suggesting that these 
mutations could change the activity of the promoters i.e. none of the 
known TF binding sites (will be discussed later) were affected by these 
mutations. The clone selected for constructing the E-cadherin reporter 
had one single mismatch from the original sequence (C>T; position in 
promoter 854bp), which was previously reported to be a variant 
(Ensemble Genome Browser).  
3.2.1.4 Construction of reporters  
The pLVX-CMV-fLuc plasmid (Figure 19D) was digested with ClaI and 
XhoI, so that the CMV promoter was removed (data not shown), and the 
plasmid DNA was gel-extracted. The digested plasmid was ligated with 
the EMT promoters, which were digested and gel extracted from the 
TOPO vectors with the same enzymes, to replace the CMV promoter. 
Following transformations, colonies were selected, the plasmids were 
isolated and following diagnostic digests (Figure 18), clones were 
selected for DNA sequencing, which confirmed that the EMT reporters 
were successfully generated (Figure 19). Throughout the thesis the 
constructs will be referred to as S100A4, E-cadherin and N-cadherin 
reporters. For the DNA sequence of the reporter constructs, see 
appendices 2-4.  
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Figure 18. Diagnostic digests of TOPO clones with ClaI/XhoI. A. 
Digests of TOPO-S100A4 clones. Expected size fragments: (a) Empty 
vector=3956bp and (b) With insert=3967+1067. B. Digests of TOPO-
N-cadherin clones. Expected size fragments: (a) Empty 
vector=3956bp, (b) With insert=3974+2416. C. Digest of TOPO-E-
cadherin clones. Expected size fragments: (a) Empty vector=uncut and 
(b) With insert=3974+889. DNA ladder = 1kb DNA ladder. Agarose gels 
0.8%.  
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Figure 19. Diagnostic digests of clones of plasmid constructs of 
EMT reporters with ClaI and XhoI. A. Digests of S100A4 reporter 
construct. Expected size fragments: (a) Empty vector=9970bp, (b) With 
insert 9164+1067bp and (c) Insert in opposite direction=10231. B. 
Digests of N-cadherin reporter construct. Expected size fragments: (a) 
Empty vector=9165bp, (b) With insert 9164+2419bp and (c) Insert in 
opposite direction=11580. C. Digests of E-cadherin reporter construct. 
Expected size fragments: (a) Empty vector=uncut, (b) With insert 
9164+889bp and (c) Insert in opposite direction=uncut.   DNA 
ladder=1kb ladder. Agarose gels 0.8%.  
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Figure 20. Plasmid constructs of EMT reporters. A. S100A4 
reporter (pLVX-S100A4prom-fLuc). B. N-cadherin reporter (pLVX-N-
cadprom-fLuc).  C. E-cadherin reporter (pLVX-E-cadprom-fLuc). The 
constructs DUHEDVHGRQµS/9;-CMV-I/XF¶(D). Expression of firefly 
luciferase is under the control of the S100A4 (A), or N-cadherin (B) 
or E-cadherin (C) human promoters. They were made by removing 
WKHµ&OD,;KR,¶&09IUDJPHQWIURPWKHRULJLQDOYHFWRUDQGUHSODFLQJ
LWZLWKWKHµ&OD,;KR,¶SURPRWHUVGLJHVWHGIURPWKH7232YHFWRUV 
2179 ClaI (1)
AmpR 9531..8872
pLVX-S100A4prom-fLuc
10231 bp
PuroR 5540..6139
S100A4 promoter 2185..3245
3246 XhoI (1)
Firefly luciferase 3347..4999
AmpR 9270..8611
pLVX-E-cadherinprom-fLuc
9970 bp
2985 XhoI (1)
Firefly luciferase 3086..4738
PuroR 5279..5878
2179 ClaI (1)
E-cadherin promoter 2185..2984
2179 ClaI (1)
4595 XhoI (1)
Firefly luciferase 4696..6348
PuroR 6889..7488
AmpR 10880..10221
pLVX-N-cadherin prom-fLuc
11580 bp
N-cadherin promoter 2185..4594
A  
B  
C  
D 
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3.2.2 Generation of stable cell lines expressing the EMT reporters 
Cell lines stably expressing the EMT reporters or the control vector, 
pLVX-CMV-fLuc (Figure 19D), were generated by lentiviral transductions 
in-house. Stable transductants were selected weekly with 4µg/ml 
puromycin; the amount of puromycin was previously determined in- 
house. To test the baseline activity of the reporters and assess whether 
the signal increased proportionately to the cell number, the correlation 
between the bioluminescent signal and cell number was tested. Cells 
were plated in black 24 well plates at different cell densities (serial 
dilutions) and following addition of D-luciferin, the bioluminescent signal 
was detected with the IVIS Spectrum, and the cell number against 
bioluminescent signal was plotted. The same cell numbers were seeded 
and the same batch of D-luciferin was used, for subsequent comparisons. 
Linear regression analysis confirmed that the bioluminescent signal 
emitted from the cells was proportional to the cell number in all the cell 
lines tested (Figure 20). As expected, the signal emitted from the cell 
lines expressing the control vector was higher than the signal detected in 
the cell lines expressing the EMT reporters; the control vector allows 
constitutive expression of luciferase, while the signal from the EMT 
reporters is inducible and dependent on the expression of the reporter 
genes. Throughout the thesis, the stable cell lines expressing the control 
vector and the EMT reporters will be referred to as control and reporter 
lines respectively. The cell lines will be denoted by /fLuc, /S100A4, /E-
cadherin or /N-cadherin.  
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the patterns of signal and gene expression were compared.  
 
 
Figure 21. Linear regression of bioluminescent signal and cell 
number of control and reporter lines. A. Control cell lines. B. MCF-
7/E-cadherin. C. S100A4 reporter lines. D. N-cadherin reporter lines. 
Red=MDA-MB-231, blue=BT549 and green=MCF-7. R2=coefficient 
determination. N=2. 
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3.2.3 Initial correlation of signal levels with gene levels 
The next step was to analyse whether the baseline bioluminescent 
signals corresponded to the baseline levels of gene expression of the 
reporter genes. First, the baseline levels of the reporter genes in the 
reporter lines were compared with the baseline levels of gene expression 
in the wild type cell lines (Table 8), to ensure that the transductions did 
not affect their expression. As shown in Table 10, the gene levels were 
very similar between the wild type and the transduced cell lines. Once it 
was confirmed that the expression of the reporter genes was not affected, 
the baseline bioluminescent signal previously detected at a particular cell 
density (1x104 cells/ml) across the reporter lines (Figure 20), was plotted 
according to the reporter gene (Figure 21A), and the patterns observed 
were compared with the baseline levels of gene expression in the 
reporter lines (Table 10), plotted in the same way (Figure 21B).  
 
 
Table 10. Comparison of baseline gene expression of reporter 
genes between wild type and reporter lines. The values represent 
average 2-ǻ&7YDOXHVIURPWKUHHRUPRUHELRORJLFDOUHSOLFDWHV 
 
 
 
 
Gene                         Cell line 
 
MCF-7 wild type MCF-7/S100A4 
S100A4 0.1602 0.3720 
 
MCF-7 wild type MCF-7/E-cadherin 
CDH1 (E-cadherin) 20.4520 20.9816 
 
MCF-7 wild type MCF-7/N-cadherin 
CDH2 (N-cadherin) 0.0005 0.0001 
 
MDA-MB-231 wild type MDA-MB-231/S100A4 
S100A4 2.5949 2.7171 
 
MDA-MB-231 wild type MDA-MB-231/N-cadherin 
CDH2 (N-cadherin) 0.0064 0.0055 
 
BT549 wild type BT549/S100A4 
S100A4 1.3967 1.0379 
 
BT549 wild type BT549/N-cadherin 
CDH2 (N-cadherin) 3.1332 2.2276 
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It was observed that the highest signal amongst the N-cadherin reporter 
lines was observed in BT549 cells, and this corresponded to the highest 
baseline gene expression of N-cadherin amongst the cell lines. Low 
signals were detected in the MCF-7 and MDA-MB-231, which 
corresponded to low gene expression levels. Similarly, the higher signal 
amongst the S100A4 reporter lines was observed in the MDA-MB-231, 
followed by the BT549 and finally the MCF-7. The same pattern was 
observed for the baseline gene levels of S100A4 in these cell lines. 
Looking at each cell line individually, it was shown that the MCF-7/E-
cadherin cells emitted the highest bioluminescent signal compared to the 
MCF-7/S100A4 and MCF-7/N-cadherin. This corresponded with high 
baseline gene levels of E-cadherin and low gene levels of N-cadherin and 
S100A4. In the MDA-MB-231, the signal was high in the MDA-MB-
231/S100A4 and lower in the MDA-MB-231/N-cadherin cell lines, which 
corresponded to high baseline gene levels of S100A4 and low levels of 
N-cadherin. Finally, in the BT549, high signal was observed in the 
BT549/N-cadherin and low signal in the BT549/S100A4, which again 
corresponded with high baseline gene levels on N-cadherin and lower 
levels of S100A4.  
To further validate the reporter lines, the bioluminescent levels detected 
were correlated with the baseline gene levels of the matched reporter 
genes across all the reporter lines generated. A significant positive 
correlation was observed, as analysed by the Pearson correlation 
coefficient (Figure 22).  
In summary, the analysis revealed that the EMT reporters can detect the 
baseline gene levels of the reporter genes. 
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Figure 22. Comparison of baseline bioluminescent levels and gene 
levels in reporter lines. (A) Baseline bioluminescent levels of reporter 
lines at the same cell density (1x104). Each bar represents the mean 
Average Radiance ± SEM previously detected (Figure 20B-D) (B) 
Baseline gene expression levels of reporter genes in reporter lines. Each 
bar represents the mean 2-¨&7 values± SEM previously detected (Table 
10).  
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3.2.4. Validation of the activity of the reporters in vitro 
The next step was to analyse whether the EMT reporters would 
successfully identify changes in the reporter genes. The reporter and 
control lines were seeded in black 24-well plates and cultured in normal 
(normoxia) or hypoxic conditions (hypoxia; 1% O2) for four days. The 
experiments were repeated at least four times. An extra replicate was 
included when the results were not consistent and/or comparable. At the 
end of the experiment, D-luciferin was added to the wells and the 
bioluminescent signal was detected using the IVIS Spectrum. The cells 
were then collected with TRI-Reagent and, following RNA extraction and 
cDNA synthesis, the gene expression of VEGF and of the reporter genes 
was analysed by qPCR. The changes in the bioluminescent signal in 
reporter lines between normal conditions and hypoxia were assessed 
UHODWLYHO\ WR WKHVLJQDO LQ WKHFRQWURO OLQHVDV IROORZ ³$YHUDJHVLJQDO LQ
reporter line in K\SR[LD  $YHUDJH VLJQDO LQ FRQWURO OLQH LQ K\SR[LD´ RU
³$YHUDJHVLJQDO LQUHSRUWHU OLQH LQQRUPR[LD$YHUDJHVLJQDO LQFRQWURO
Figure 23. Correlation of baseline bioluminescent signal and 
baseline gene expression levels or reporter genes in reporter cell 
lines. Each point represents the average signal and average gene 
levels of the matched reporter gene in individual cell lines previously 
identified (Figure 21). r=0.8411, P=0.0177. 
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OLQHLQQRUPR[LD´7KHFKDQJHVRIWKHJHQHVDQGELROXPLQHVFHQWVLJQDO
between normoxia and hypoxia were plotted for each individual biological 
replicate, and the significance of the changes amongst the replicates was 
assessed by a ratio paired t-test. The different biological replicates were 
plotted and analysed individually in order to account for the variability 
between the experiments arising from various factors including 
differences in the sensitivity of the D-luciferin (different batch or vial) and 
different cell numbers (pipetting errors and different growth rates).   
3.2.4.1 S100A4 reporter 
In the MCF-7/S100A4 cells, VEGF was significantly upregulated in all the 
replicates (Figure 23A), confirming that hypoxia was induced. The 
S100A4 gene expression and the bioluminescent signal was also 
significantly upregulated in all the replicates (Figures 23B and 231C). 
Similar data were observed in the BT549/S100A4 cells (Figure 24). In the 
MDA-MB-231/S100A4 cells, VEGF was only upregulated in three 
replicates, showing that hypoxia was not induced in all the biological 
replicates (Figure 25A). As a result, the changes in the S100A4 gene and 
the bioluminescent signal were not consistent (Figure 25B and 25C). 
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Figure 24. Validation of the S100A4 reporter in MCF-7 in hypoxia. 
A. Gene expression of VEGF in normoxia and hypoxia. B. Gene 
expression of S100A4 in normoxia and hypoxia. C. Reporter signal in 
normoxia and hypoxia calculated as follows: Average reporter 
signal/Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=4 
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Figure 25. Validation of the S100A4 reporter in BT549 in hypoxia. 
A. Gene expression of VEGF in normoxia and hypoxia. B. Gene 
expression of S100A4 in normoxia and hypoxia. C. Reporter signal in 
normoxia and hypoxia calculated as follows: Average reporter 
signal/Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=4 
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Figure 26. Validation of the S100A4 reporter in MDA-MB-231 in 
hypoxia. A. Gene expression of VEGF in normoxia and hypoxia. B. 
Gene expression of S100A4 in normoxia and hypoxia. C. Reporter 
signal in normoxia and hypoxia calculated as follows: Average reporter 
signal/ Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=4 
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3.2.4.2 E-cadherin reporter 
VEGF was significantly upregulated (Figure 26A), confirming that 
hypoxia was induced in all the replicates. The changes in the E-cadherin 
expression and the bioluminescent signal were not consistent (Figure 
26B and 26C). In three of the replicates the direction of the change was 
the same for the gene and the signal. Specifically, when the gene was 
downregulated (blue point), the signal was also downregulated and when 
the gene was upregulated (yellow and red points), the signal was also 
upregulated. In the other two replicates (grey and green points), the gene 
was downregulated but the signal was upregulated.   
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Validation of the E-cadherin reporter in MCF-7 in 
hypoxia. A. Gene expression of VEGF in normoxia and hypoxia. B. 
Gene expression of E-cadherin in normoxia and hypoxia. C. Reporter 
signal in normoxia and hypoxia calculated as follows: Average reporter 
signal/ Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=5 
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3.2.4.3 N-cadherin reporter 
In the MCF-7/N-cadherin cells, VEGF was significantly upregulated 
(Figure 27A). The changes in the gene and the signal were not consistent 
(Figure 127B-C). As shown, the direction of the change was the same for 
the gene and the signal in four of the replicates. Specifically, when the 
gene was downregulated (blue point), the signal was also downregulated 
and when the gene was upregulated (yellow, red and green points), the 
signal was also upregulated. On the contrary, in one of the replicates 
(grey point), the gene was upregulated, but the signal was 
downregulated.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Validation of the N-cadherin reporter in MCF-7 in 
hypoxia. A. Gene expression of VEGF in normoxia and hypoxia. B. 
Gene expression of N-cadherin in normoxia and hypoxia. C. Reporter 
signal in normoxia and hypoxia calculated as follows: Average reporter 
signal/ Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=5 
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In the BT549/N-cadherin cells VEGF was significantly upregulated 
(Figure 28A). Neither the N-cadherin gene nor the bioluminescent signal 
was significantly upregulated (Figure 28B-C), and the direction of change 
in the gene was comparable with the change in the signal only in two 
biological replicates (yellow and red point). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Validation of the N-cadherin reporter in BT549 in 
hypoxia. A. Gene expression of VEGF in normoxia and hypoxia. B. 
Gene expression of N-cadherin in normoxia and hypoxia. C. Reporter 
signal in normoxia and hypoxia calculated as follows: Average reporter 
signal/ Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=5 
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Finally, in the MDA-MB-231/N-cadherin cells, VEGF was not significantly 
upregulated (Figure 29A) showing that hypoxia was not induced in all the 
biological replicates. As would be anticipated, the gene and signal 
changes were neither consistent nor significant (Figure 29B-C).  
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Figure 30. Validation of the N-cadherin reporter in MDA-MB-231 in 
hypoxia. A. Gene expression of VEGF in normoxia and hypoxia. B. 
Gene expression of N-cadherin in normoxia and hypoxia. C. Reporter 
signal in normoxia and hypoxia calculated as follows: Average reporter 
signal/ Average control signal. Each point represents a different 
biological replicate (colour matched in all the graphs). The significance 
of the different changes between normoxia and hypoxia was assessed 
by a ratio paired t-test. N=5 
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In summary, the analysis showed that the S100A4 reporter in MCF-7 and 
BT549 could effectively detect the direction of the changes in the reporter 
genes, and that was statistically significant. To investigate the ability of 
the reporter to detect the degree of changes, the fold change in the gene 
levels was correlated with the fold change in the bioluminescent signal 
between normoxia and hypoxia. No significant correlation was found in 
either the MCF-7/S100A4 or the BT549/S100A4 (Figure 30), as 
assessed with the Pearson correlation coefficient. This implied that the 
fold change in the bioluminescent signal did not correspond to the fold 
change in the gene levels.   
Figure 31. Further validation of the S100A4 reporter in hypoxia. 
Correlation of the fold change in the bioluminescent signal and the gene 
levels of the reporter genes between normoxia and hypoxia in (A) MCF-
7/S100A4 and (B) BT549/S100A4. The fold change in the signal was 
calculated as follows: (Average signal in reporter line in hypoxia / 
Average signal in control line in hypoxia) / (Average signal in reporter 
line in normoxia / Average signal in control vector in normoxia). The 
change in the gene levels was expressed as a relative gene expression 
(2-¨¨&7).Correlation was assessed by the Pearson correlation 
coefficient. N=4. 
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Summary and discussion 
Inducible bioluminescent EMT reporters measuring the transcription of 
S100A4, E-cadherin or N-cadherin alongside firefly luciferase were 
successfully generated by conventional molecular cloning. 
Stable cell lines expressing the reporters or the control vector were 
generated by lenti-viral transductions, and it was confirmed that the 
bioluminescent signal was proportional to the cell number. 
The baseline levels of the bioluminescent signal in the reporter lines 
significantly correlated with the baseline gene expression of the 
corresponding reporter genes. This confirmed that the EMT reporters can 
detect the baseline levels of the reporter genes. 
To validate the activity of the reporters, the ability of the reporters to 
detect changes in the gene expression of the reporter genes was 
assessed in hypoxic assays:  
Induction of hypoxia was assessed by analysing the gene 
expression of the hypoxia marker, VEGF, a downstream target of HIF-1. 
It was shown that VEGF was significantly upregulated in all the MCF-7 
and BT549 reporter lines, but not in the MDA-MB-231 cell lines. The 
expression of VEGF is dependent on all the different conditions involved 
in the activation and stabilisation of HIF-1 (reviewed in [142]). These 
include, amongst others, growth factors and cytokines such as EGF, 
FGF2 and insulin. Furthermore, it was shown that the Ras-Raf-MEK-ERK 
pathway is essential for the trans-activation of the VEGF promoter. 
Substitution mutations in the EGF receptor and KRAS have been 
previously reported in the MDA-MB-231 cells (COSMIC), suggesting a 
possible explanation as to why VEGF was not activated in these cells. 
Furthermore, it has been shown that the levels of HIF-1 expression are 
dependent on the cell density in the MDA-MB-231 cells [143], suggesting 
that these cells should have been seeded at a higher cell density in order 
to allow activation of HIF-1, and subsequent activation of VEGF. In order 
for HIF-1 to bind to target genes, its two subunits, HIF-1Į and HIF-1ȕ 
need to form dimers [130]. It has been reported that HIF-1Į was unable 
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to form heterodimers with HIF-1ȕ in MDA-MB-231 [144], which is another 
possible explanation as to why VEGF was not upregulated in this cell line. 
Furthermore, the baseline gene levels of VEGF are higher compared to 
the other cell lines, implying that there is already a degree of HIF-1 
activity within the cell line, and suggesting that possibly all the HIF-1Į 
proteins present are already activated and no more activation would be 
expected. Finally, the synthesis, stability and degradation of HIF-1 are 
not only regulated due to changes in oxygen levels, but also through 
other mechanisms that are independent of oxygen levels, including 
growth factors (e.g. IGF) and acetylation status [130, 145]. 
The ability of the reporters to detect changes in the reporter genes 
was assessed by comparing the direction of change of the gene with the 
direction of change of the bioluminescent signal. The activity of the 
S100A4 reporter was validated in the MCF-7/S100A4 and 
BT549/S100A4 lines, where it was shown that both the S100A4 gene and 
the bioluminescent signal were significantly upregulated in hypoxic 
conditions. Upregulation of the S100A4 gene was expected in hypoxia, 
since S100A4 has been shown to be a direct target of HIF-1 [131, 132]. 
Five hypoxia response elements (HRE) sequences have been detected 
LQ WKH6$JHQHDQG LQ IDFWDQ+5(VHTXHQFH¶&$&*&¶ LV
present in the promoter of the S100A4 reporter, suggesting the direct 
regulation of the S100A4 reporter by HIF-1 (annotated in Figure 31). It is 
important to mention though, that the fact that the sequence is present 
does not necessarily mean that is functional, and that many other TFs 
control the gene expression of S100A4, as will be discussed later on.  
The changes of the E-cadherin and N-cadherin genes were not 
consistent in hypoxia i.e. in some biological replicates the gene was 
upregulated and in others it was downregulated. Unlike S100A4, the 
expression of N-cadherin in hypoxia is not regulated directly by HIF-1, 
but through other TFs (Twist1, Snail, TCF3 and others) which are directly 
regulated by HIF-1 and induce EMT, in which N-cadherin upregulation is 
observed [134, 135].  Thus, changes in the N-cadherin expression, at 
least the ones associated with hypoxia-induced EMT, will be dependent 
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on the activation of factors other than HIF-1 or VEGF. Two HRE 
VHTXHQFHV ¶GGA ATC AGA ACC GTG CAG GTC CCA T ¶DQG¶
GTG GCC GGC AGG TGA ACC CTC A ¶SUHYLRXVO\GHWHFWHGLQWKH(-
cadherin promoter [146], are present in the promoter of the E-cadherin 
reporter (annotated in Figure 32). It would be therefore expected that E-
cadherin is directly regulated by HIF-1. In BC it has been shown that HIF-
1 binding to the HRE of the E-cadherin promoter was enhanced by the 
transcriptional co-activator with PDZ-binding motif (TAZ) or the 
WWdomain-containing oxidoreductase (Wwox) [146], suggesting that 
other factors are needed for HIF-1 to interact with and downregulate E-
cadherin, which might not have been activated in all the different 
experiments performed in this study. But again, it is not certain that the 
HRE sequence in the E-cadherin promoter is functional. Furthermore, 
many other TFs are involved in regulating the E-cadherin expression, 
including TFs that upregulate the gene expression (reviewed in [147]) 
(annotated in Figure 32). For example, SP1, a protein that has been 
shown to be activated in MCF7 in hypoxia [148], is a positive regulator of 
E-cadherin [147],QIDFWWKHVHTXHQFHIRUWKH63ELQGLQJVLWH¶GGG 
***&**7*&¶[149], is present in the promoter of the E-cadherin 
reporter. Assuming that the sequence is functional, it could explain why 
E-cadherin expression was upregulated in some biological replicates  
The inducible bioluminescent EMT reporters were designed so that the 
expression of the luciferase gene would be driven by the promoters of 
the S100A4, E-cadherin or N-cadherin genes.  But, the direction of the 
changes in the E-cadherin and N-cadherin genes was not always 
comparable with the direction of the change of the bioluminescent signal. 
Furthermore, no significant correlation between the fold change in the 
gene and the fold change in the bioluminescent signal was observed in 
the cell lines expressing the S100A4 reporter. The factors that could have 
affected the expression of luciferase were controlled in this study, by 
normalising the signal in the reporter lines to the control lines, as 
discussed before. Therefore, the data could have been compromised due 
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to artifacts in the quantification of the gene expression of the reporter 
genes. Possible explanations for this are the following: 
a) The gene expression of the reporter genes was analysed by qPCR, 
which quantified the expression of the reporter genes found in the cell 
lines tested. It was anticipated that when the promoters of the reporter 
genes in the genome were activated or repressed, then the promoter in 
the EMT reporters would have the same fate. But, this might not have 
been the case, since the promoters in the reporters may be missing 
regulatory elements found in the promoters of the genes in the genome, 
which could have affected their gene expression. For instance, S100A4 
expression has been shown to be regulated by C/EBPĮ [150], and c-Myb 
[150], whose binding sites are not found in the promoter of the S100A4 
reporter; they are found approximately 240 and 220 bases upstream the 
promoter respectively (annotated in Figure 31). Similarly, the gene 
expression of E-cadherin has been shown to be regulated by LUN [151] 
and CREB1 [149], and the gene expression of N-cadherin has been 
shown to be regulated by, Sp1/Sp3 and MZF-1 [152], whose binding sites 
are not found in the promoter of the E-cadherin and N-cadherin reporter 
respectively (annotated in Figure 32 & 33). It is worth noting though, that 
variation of the binding sites of these TFs might be present in the 
promoters of the EMT reporters, and that other TFs, whose role has not 
yet been studied, might be playing an important role in the regulation of 
the reporter genes. It is not expected that all of the TFs mentioned will be 
relevant to BC and/or hypoxia, but it is clear that the control of gene 
expression is not dependent on a single factor.  
b) Post-transcriptional RNA modification and processing, transcript 
stability and localisation, are also very important for gene regulation 
(reviewed in [153]). Briefly, various sequence elements found within an 
mRNA can determine its stability and turnover by associating with other 
proteins or small non-coding RNAs. Examples include the internal 
ribosome entry sites (IRES) element, the c-Jun amino terminal kinase 
(JNK) responsive element (JRE) and the A+U rich elements (AREs). The 
turnover of mRNAs is controlled by various stimuli, one of which is 
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hypoxia (reviewed in [154]), in which various RNA-binding proteins 
(RBPs) facilitate changes in the mRNA stability and turnover. Therefore, 
mRNA stability and turnover in hypoxia can explain the variations 
observed in the gene changes (direction and fold change) in the various 
biological replicates. Also, it can explain why the changes in the reporter 
genes did not compare/ correlate with the signal, since different 
sequence elements that control the mRNA stability and turnover are 
present in the mRNA of the genes in the genome from the ones present 
in the transcribed luciferase mRNA in  the EMT reporters.      
c) qPCR detected the gene expression levels of the reporter genes in all 
the cells seeded. Even though the cells were selected prior to setting up 
the experiments, the selection process might not have been completely 
efficient resulting in the survival and expansion of untransduced cells. If 
that was the case, the bioluminescent signals would have been detected 
only from the transduced cells whereas qPCR would have detected the 
gene expression in all the cells. This would have resulted in bigger fold 
changes in the gene expression than in the bioluminescent signal; a 
phenomenon which was frequently observed in this study. One way to 
check this would be the use of fluorescent EMT reporters in order to 
check the percentage of transduced cells by fluorescent microscopy. The 
reporters could express either a fluorescent reporter or both a fluorescent 
and bioluminescent reporter. The latter could be achieved by transducing 
the cells with two different plasmids (i.e. the bioluminescent EMT reporter 
and a plasmid that allows constitutive expression of a fluorescent marker) 
or by a single plasmid construct that allows the simultaneous expression 
of the two proteins (fluorescent marker and luciferase). Another way to 
test for this would be to identify the copy number of the virus in the cells 
by absolute qPCR and normalise the gene expression data to the amount 
of virus present. 
In further in vitro and in vivo experiments the S100A4 reporter in the 
MCF7 and BT549 (i.e. MCF-7/S100A4 and BT549/S100A4 cell lines) will 
be validated upon induction of EMT in vitro, and/or in in vivo models, in 
which changes in the S100A4 expression (gene and/or protein) will be 
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correlated with generated bioluminescent levels. Since the activity of the 
E-cadherin and N-cadherin reporters was not validated in this setting, 
other methods to induce changes in the E-cadherin and N-cadherin 
genes will be investigated in the next chapter. Once a model in which 
consistent changes in the gene expression will be identified, the activity 
of the reporter will be tested and the reporters will be validated upon 
induction of EMT.   Testing the E-cadherin and N-cadherin reporters were 
made depending on data in the following chapters i.e. if significant and 
consistent changes in their expression (gene and/or protein) will were 
observed in in vitro and/or in vivo models of EMT.  
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Figure 32. Diagrammatic representation of the human S100A4 gene displaying the location of the S100A4 promoter and 
other relevant features. The blue box shows the gene of interest located at chromosome 1, location 153711315-153717838. The 
purple box show the sequence of the S100A4 promoter, cloned into the S100A4 reporter. The orange boxes demonstrate the 
different exons of the gene. Anything between the exons is introns. The orange arrow represents the translational start site/start 
FRGRQ$7*DVLGHQWLILHGLQHQVHPEORUJZKHUHWKHLV³7´LQWKH³$7*´7KHRWKHUDUURZVUHSUHVHQWWKHORFDWLRQRI7)ELnding 
sites, as identified in the literature. The locations of the TFs were calculated manually, having as reference the start codon. The 
HIF-1Į sequences are colour coded i.e. each colour represents a different HRE sequence.  
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Figure 33. Diagrammatic representation of the human CDH1 gene displaying the location of the promoter and other relevant 
features. The blue box shows the gene of interest located at chromosome 16, location 16:68737225-68835548:1. The purple box 
show the sequence of the CDH1 promoter, cloned into the E-cadherin reporter. The orange box demonstrates exon 1 of the gene. 
The orange arrow represents the translational start site/staUWFRGRQ$7*DVLGHQWLILHGLQHQVHPEORUJZKHUHWKHLV³7´LQWKH
³$7*´7KHEOXHDUURZVKRZVWKHWUDQVFULSWLRQVWDUWVLWHDVLGHQWLILHGLQYN, L., et al., 2005. The other arrows represent the location 
of TF binding sites, as identified in the literature. The locations of the TFs were calculated manually, having as reference the start 
codon. The HIF-1Į sequences are emphasised.  
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Figure 34. Diagrammatic representation of the human CDH2 gene displaying the location of the promoter and other relevant 
features. The blue box shows the gene of interest located at chromosome 18, location 27,950,966-28,177,446. The purple box show the 
sequence of the CDH2 promoter/regulatory sequence, cloned into the N-cadherin reporter. The orange box demonstrates exon 1 of the 
gene. The orange arrow represents the translational start site/start codon (ATG), as identified in ensembl.org, where the +1 LV³7´LQthe 
³$7*´7KHEOXHDUURZVKRZVWKHWUDQVFULSWLRQVWDUWVLWHDVLGHQWLILHGLQ6/0)2DQG03-, 2005. The other arrows represent the 
location of TF binding sites, as identified in the literature. The locations of the TFs were calculated manually, having as reference the start 
codon. The HIF-1Į sequences are emphasised. 
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CHAPTER 4: RESULTS 2 ± Development of an in 
vitro EMT model  
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This chapter describes the different methods tested to induce EMT (or 
EMT-like traits) in epithelial cell lines, in order to establish an in vitro EMT 
model, which could be used to test the activity of EMT reporters upon 
induction of EMT. Furthermore, the work in this chapter aimed to find a 
model, in which significant and consistent changes in the expression of 
E-cadherin and N-cadherin would be achieved, in order that it could be 
used for validating the E-cadherin and N-cadherin reporters. 
The different methods used were an adaptation of the methods reported 
to induce EMT and/or enhance for metastatic and stem-like properties in 
the current literature.  
Induction of EMT was assessed by analysing the gene expression or 
protein levels of EMT markers, and the morphological changes of the 
cells. Briefly, during EMT, cells undergo changes in their shape (acquire 
a spindle-OLNH ³ILEUREODVWLF´ VKDSH ORVH WKHLU H[SUHVVLRQ RI HSLWKHOLDO
markers (e.g. E-cadherin), and acquire a mesenchymal phenotype 
(motility and expression of mesenchymal markers e.g. Vimentin) 
(reviewed in [46]). The morphology of the cells was assessed by 
microscopy, and the expression of EMT markers (attenuation/loss or 
upregulation) was analysed by qPCR (gene levels) and 
immunofluorescence (IF) staining (protein levels). 
The first method used to induce EMT was the overexpression of Twist1. 
Twist1 is a main TF driving EMT, whose expression downregulates 
epithelial markers like E-cadherin and activates mesenchymal markers 
like N-cadherin (reviewed in [46]). Twist-expressing vectors have 
previously been reported to induce EMT in BC cells [52, 141, 155]. A 
plasmid construct allowing the simultaneous expression of Twist1 and a 
red fluorescent protein (tdTomato) was constructed by molecular cloning. 
The vector was designed to express the two proteins from a bicistronic 
mRNA transcript utilising an internal ribosome entry site (IRES) [156] that 
allowed tdTomato (downstream of TWIST1) to be used as an indicator of 
transduction efficiency and a marker for selection. MCF-7 cells 
expressing the Twist1 expression vector, or a control plasmid 
constitutively expressing tdTomato, were generated by lenti-viral 
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transductions and stable transductants were purified by Flow Cytometric 
Cell Sorting.  
Induction of EMT was also attempted by culturing the cells in hypoxia. 
Cells are typically cultured in atmospheric oxygen levels, but when 
cultured in hypoxia, they have been shown to undergo EMT through a 
variety of mechanisms, including upregulation of Twist1, Snail and the 
Notch signalling pathway (reviewed in [157]). Furthermore hypoxia can 
help in stabilising the mesenchymal state of the cells by activating 
positive-feedback loops and by maintaining the expression of the various 
EMT-inducing TFs. 65-70% sub confluent MCF-7 cells cultured in 3% O2 
underwent morphological changes associated with EMT and lost the 
expression of E-cadherin after 72 hours [69]. In another instance, BC 
cells cultured in 1% O2, lost their cell-cell contact, became spindle-like 
and acquired expression of the mesenchymal marker Vimentin after 50 
hours [70].  
Another method used was the culture of the cells in a commercially 
available EMT-Inducing Media Supplement, which contains a cocktail of 
EMT-inducing recombinant proteins and neutralizing antibodies for the 
straightforward induction of EMT. Induction and analysis of EMT in 
different cell lines using this product has been described [158]. The 
supplement is designed to enhance the Wnt and TGF-ȕVLJQDOOLQJ and to 
block E-cadherin-based cell adhesion. Loss of E-cadherin is a hallmark 
of EMT and both TGF and Wnt signalling pathway have been shown to 
induce EMT (reviewed in [46],QDGGLWLRQWKHFROODERUDWLRQRIWKH7*)ȕ
canonical and non-canonical Wnt signalling to induce EMT in BC and 
maintain the acquired mesenchymal phenotype of the cells in an 
autocrine signalling, has been previously described [159]. The 
supplement specifically contains recombinant human Wnt-Į
recombinant human TGF-ȕ DQWL-human E-cadherin, anti-human 
Secreted Frizzled Related Protein-1 (sFRP-1) and anti-human Dickkopf-
1 (Dkk-1). Both sFRP-1 and Dkk-1 downregulate the Wnt signalling 
pathway; the former inhibits Wnt receptor binding [160] and the latter is 
a Wnt antagonist [161].  
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In order to induce EMT, cells were also cultured in a 3D assay. A 3D 
multicellular tumour growth assay (TGA) has been developed in order to 
mimic the in vivo scenario of tumours [82]. As opposed to a 2D monolayer 
culture, in which the cells are cultured in plastic, the 3D culture mimics 
different conditions present in human cancers, including cell-matrix 
interactions, stiffness, acidic pH, dimensionality, and secreted factors 
that affect cell function, behaviour and drug response. The cells were 
cultured in a laminin-rich Basement Membrane Extract (BME) gel, which 
was derived from murine chondrosarcoma that was grown in mice and 
therefore includes tumour matrix and mouse immune modulators. 3D 
cultures and 3D-related systems have been used for induction of EMT in 
BC cells, where it was shown that cells have undergone morphological 
changes and acquired mesenchymal markers [83, 162].  
In a further attempt to induce EMT, the MCF-7 cells were co-cultured with 
human bone marrow-derived mesenchymal stem cells (MSCs). MSCs 
are non-haematopoietic cells that can self-renew and differentiate into 
different cell types (reviewed in [163]). Through their interaction with the 
cells, including BC cells, and the secretion of paracrine factors and 
cytokines, they have an effect both on the morphology and proliferation 
of the cells. MSCs are recruited by tumours and they have a significant 
role in tumour progression and metastasis. Co-cultures of bone marrow 
and human placenta-derived MSCs with BC epithelial cells induced traits 
associated with EMT [73, 84]. In this study, MSCs expressing a red 
fluorescent protein (mCherry) were used. EMT was assessed by IF 
staining of E-cadherin and Vimentin.   
It has been shown that the cytokine Interleukin-6 (IL-6) induced EMT in 
BC [164], therefore culture of cells in a medium supplemented with IL-6 
was used in this study to induce EMT. Elevated levels of IL-6 have been 
shown in BC patients and it correlated with disease stage, metastasis 
and poor prognosis. The authors showed induction of EMT in MCF-7 cells 
exposed to 50ng IL-6 in a 3D system and in MCF-7 cells constitutively 
expressing ectopic IL-6. In a different paper, IL-6-induced EMT promoted 
the generation of BC stem-like cells [165].  
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Another method used is the indirect co-culture of epithelial cells with BC 
associated fibroblasts (BrCAFs), in which the epithelial cells were seeded 
in a well as normally and the BrCAFs were seeded in transwell insert. 
The insert contains a microporous membrane that will allow secreted 
factors to migrate and interact with the epithelial cells. CAFs, a distinct 
cell type, are found in the tumour stroma and facilitate tumour 
progression through secretion of inflammatory cytokines, growth factors 
and proteinases [166]. It has been shown that MCF-7 and MCF10A cells 
have undergone EMT, after being exposed to CAF-conditioned medium, 
as assessed by increased expression of Vimentin, and enhanced 
invasive abilities [167].  Furthermore, MCF-7 cells cultured in CAF-
conditioned medium have undergone EMT, which was dependent on the 
secretion of IL6 [168].  
Finally, some of the methods were used in combination, for example 3D 
cultures were performed in hypoxia.  
 
4.1 Overexpression of Twist1  
 
4.1.1 Molecular cloning of the Twist1 expression vector 
TWIST1 was amplified from plasmid DNA in order to construct a lentiviral 
vector that allows constitutive dual expression of Twist1 and tdTomato. 
The sequence covered exon 1 and part of exon 2 of the gene, which gives 
rise to the full transcript which in turns translates to a 202 amino acid 
protein. TWIST1 (1492bp) was amplified from the pOTB7-Twist1 plasmid 
(Figure 6) using the HotStarTaq® DNA polymerase (Figure 34). The 
annealing temperatures used ranged from 50.2°C to 68.3°C; the product 
was successfully amplified at 50.2°C and 50.8°C. The primers used for 
the amplification, were designed to introduce restriction sites for EcoRI 
and BamHI DW WKH¶DQG¶HQGRITWIST1 accordingly. The amplified 
product (indicated by arrow; Figure 34) was purified and cloned into the 
pCR4-TOPO vector (Figure 9), in order to confirm its sequence before 
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proceeding to generating the expression vector. Following transformation 
of the TOPO vectors, plasmids were isolated. In order to select those 
clones with the gene incorporated, diagnostic digests were performed. 
The plasmids were digested with EcoRI and BamHI (data not shown) and 
it was shown that all the clones had incorporated TWIST1. This was 
confirmed by DNA sequencing. A clone with no mutations introduced was 
selected for generating the expression vector.  TWIST1 was then 
digested from the TOPO vector with EcoRI/BamHI. pLVX-IRES-
tdTomato (Figure 10) was also digested using the same enzymes, so that 
TWIST1 would be cloned in to the Multiple Cloning Site (MCS) of this 
plasmid.  The digested TWIST1 and vector were gel extracted and 
ligated. The ligation pURGXFWVZHUHWUDQVIRUPHGLQWR'+ĮDQGSODVPLGV
were isolated. Following diagnostic digests of the clones with EcoRI and 
BamHI (Figure 35), the clone with the insert incorporated (Indicated by 
arrow; Figure 35) was selected for DNA sequencing. The analysis the 
DNA sequence showed that the Twist1 reporter was successfully 
constructed (Figure 36). For the full DNA sequence, see appendix 5.  
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 1         2       3        4       5        6       7        8       9     10       11  12    13 
Ladder 50.2°C  50.6°C  51.6°C   53.3°C   55.3°C  57.7°C  60.0°C 62.5°C  65.2°C  66.8°C  67.7°C  68.3°C 
 
 1.5Kb     
Figure 35. Amplification of TWIST1 with HotStarTaq® DNA 
Polymerase. Lane 1=1 kb DNA ladder. Lanes 2-13=Samples at 
different annealing temperatures (Gradient: 50.2°C ± 68.3°C). Size of 
the product=1492 bases. Agarose gel=0.8%. 
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Figure 37. pLVX-Twist1-IRES-tdTomato plasmid construct (Twist1 
expression vector). 7KLVFRQVWUXFWLVEDVHGRQµS/9;-IRES-WG7RPDWR¶
(Figure 11). Expression of Twist1 is constitutively driven by the CMV 
promoter. It was made by removing the inserting EcoRI/BamHI µTWIST1¶
into the MCS of EcoRI/BamHI µS/9;-IRES-WG7RPDWR¶ 
    1              2            3               4           5         
 1.5Kb     
 10Kb      
 8Kb        
Figure 36. Diagnostic digests of plasmids with EcoRI and BamHI. 
Lane 1=kb DNA ladder. Lanes 2- GLJHVWHG µS/9;-Twist1-IRES-
WG7RPDWR¶ (Twist1 expression vector) clones. Expected size of 
fragments of the clones with the insert incorporated=8860+1499. 
Gel=0.8%.  
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4.1.2 Stable cell lines expressing the vector 
The Twist1 expression vector was packaged into lentiviral particles and 
MCF-7 cells expressing the Twist1 reporter or a control vector (pLVX-
CMV-tdTomato) were generated in-house by lenti-viral transductions, 
using the Lenti-;/HQWLYLUDO([SUHVVLRQ system from Clontech. Stable 
transductants were selected by Flow Cytometric Cell Sorting (Beckman 
Coulter MoFlo XDP Cell Sorter). The sorting efficiencies ranged from 90-
95%. Pictures of the cells after sorting are shown in Figure 37. To confirm 
that the Twist1 was successfully overexpressed in the stable cell lines 
and that the expression was maintained, the gene expression and protein 
levels of Twist1 were analysed at different cell passage numbers. RNA 
was isolated from the transduced cell lines, cDNA was synthesised and 
the gene expression of TWIST1 was analysed by qPCR. It was shown 
that Twist1 was significantly up-regulated in the cells expressing the 
Twist1 vector compared to the control cell lines at the gene level, as 
assessed by a ratio paired t-test (Figure 38). The average gene 
expression in the cells expressing the Twist1 vector was about 560 times 
higher than the expression of TWIST1 in the cells expressing the control 
vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%ULJKWILHOGWG7RPDWR 
A B 
x10 x10 
Figure 38. Pictures of transduced MCF-7 cells. Pictures showing the 
cells expressing the control vector, pLVX-CMV-tdTomato (A), or the 
Twist1 expression vector, pLVX-Twist1-IRES-tdTom (B). Pictures are a 
merged image of pictures taken in brightfield and with DsRed filter. The 
red fluorescence (tdTomato) is emitted from the vectors and represents 
the cells that have successfully uptaken the vectors. Pictures were taken 
at x10 magnification.  
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To test whether the protein was overexpressed, cell lysates were 
collected and the protein expression was analysed by western blot. Cell 
lysates from the BT549 and MSCs cells were included in the analysis to 
serve as a positive control for Twist1 expression, as both cell lines have 
been shown to express Twist1, at least at the gene levels, in previous in-
KRXVHH[SHULPHQWVǺ-actin was used as a reference/ loading protein. In 
the western blot gel, multiple bands were detected. To overcome this, 
different optimisations have been attempted including use of fresh 
lysates from earlier passaged cells, use of fresh ingredients (e.g. fresh 
reducing agent), use of different antibodies, different concentrations of 
the antibody and longer incubation times, but in all of the experiments the 
results were similar. One representative example is shown in Figure 39. 
The expected size of the protein was 21kDa. Single bands sized ~40kDa 
were detected in the MSCs and BT549 (Figure 39 lanes A&B). In the 
MCF-7 control cells (cells transduced with the control vector) three main 
bands were detected sized, 14kDa, ~21kDa and ~40kDa (Figure 39 lane 
C). The same sized bands were detected in the MCF-7 cells (Figure 39 
lane D), where the ~40kDa band appeared to be much more 
Figure 39. Gene expression of TWIST1 in MCF-7 stably expressing 
the Twist1 expression vector or a control vector. Each bar 
represents the mean gene expression (2-¨&7) ± SEM on a logarithmic 
scale. Statistical significance was assessed with a ratio paired t-test. 
*35 and **31. N=4. 
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concentrated in these cells, compared to the control cells. In addition, 
extra bands of >40kDa were detected in these cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3 Analysis of EMT-like traits in cell lines expressing the vector  
Even though, the protein level of Twist1 was not determined in the cells, 
EMT-like traits were examined. No changes in the morphology of the cells 
were observed between the cells expressing the control vector and the 
Twist1 vector. Furthermore, while the TWIST1 expression was 
upregulated (average fold change 3500), no changes in the gene 
expression of the EMT markers were observed (Figure 40).  
 
 
A 
ȕ-actin (40kDa) 
14kDa 
~21kDa 
~40kDa 
B C D 
Figure 40. Western blot analysis of Twist1 in MCF-7 cells expressing 
the Twist1 expression vector. The different cells, MSCs (A), BT549 
(B), MCF-7 control (C) and MCF-7/ Twist1(D) were stained with anti-
human Twist1 (21kDa). The arrows indicate the size of the bands. B-
actin (40kDa) was used as a reference protein.  
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4.2 Hypoxia 
Cells were seeded in a 24-well plate and cultured in a hypoxia chamber 
(1% O2) or in normoxia (21% O2) for four days. At the end of the assay 
the morphology of the cells was assessed by microscopy and the cells 
were collected for gene expression analysis of the EMT markers. The 
experiment was repeated three times. No obvious morphological 
changes associated with EMT were observed in the NCI60 MCF-7 cells 
(a representative example is shown in Figure 41). In these cells VEGF 
was upregulated in all biological replicates (average fold increase 3.2), 
implying a degree of hypoxia (Figure 42). The upregulation of VEGF was 
statistically significant as assessed by a ratio paired t-test (Figure 43A). 
S100A4 was also upregulated in all biological replicates (average fold 
increase 9.76; Figure 42), but the difference was not statistically 
significant, as assessed by a ratio paired-test (Figure 43B). VIM was also 
upregulated in all biological replicates (average fold increase 1.2; Figure 
Figure 41. Relative gene expression of EMT markers in MCF-7 cells 
expressing the control vector or the Twist1 expression vector. 
Each bar represents the relative mean gene expression (2-¨¨&7) ± SEM 
of matched biological replicates, on a logarithmic scale.  
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42). While VIM was significantly upregulated (Figure 43C), the changes 
in the actual 2-¨CT values were relatively small to be considered 
substantial (i.e. from 0.008 to 0.009, from 0.009 to 0.011 and from 0.01 
to 0.013). No consistent changes were observed in the other EMT genes 
tested (Figure 42).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 42. Pictures of MCF-7 cells cultured in normoxia or hypoxia. 
A. MCF-7 (NCI60) normoxia. B. MCF-7 (NCI60) hypoxia. Pictures were 
taken at x10 magnification. 
 
Figure 43. Relative gene expression of EMT markers in hypoxic 
assay of MCF-7 cells. Each bar represents the mean relative gene 
expression (2-¨¨&7) ± SEM of matched biological replicates on a 
logarithmic scale. N=3. Pictures were taken at x10 magnification. 
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4.3 EMT-inducing media supplement 
Cells were cultured in their normal medium or in a medium containing the 
commercially available EMT-inducing media supplement. The 
recommended cell density (0.9 - 1.0 x 104 cells/cm2) resulted in cells 
being over-confluent at the end of the assay; therefore, the cell density 
was optimised (5x103 cells per dish). In this experiment, the MCF-7 cells 
from NCI60 and ECACC were included. The latter were included in the 
study at later stages, in order to investigate the EMT potential of different 
MCF-7 cells, and use as alternatives.  
The MCF-7 cells stably expressing the Twist1 vector (MCF-7/Twist1) 
were also included. It was shown before, that even though the TWIST1 
gene was overexpressed in these cell lines, EMT was not induced. Since, 
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Figure 44. Gene expression of VEGF, S100A4 and VIM in hypoxic 
conditions. Each bar represents the mean gene expression (2-¨CT) ± 
SEM of matched biological replicates for VEGF (A), S100A4 (B) and 
VIM (C). Significance was assessed by a ratio paired t-test. *35. 
N=3. 
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it was not possible to determine for certain whether Twist1 protein was 
overexpressed and/or activated, it was assumed that the protein was 
inactive and that was the reason why EMT was not induced. It has been 
shown, that TGFȕ phosphorylates Twist1 on Ser68, which is required for 
EMT induction [169] and that Wnt-1 upregulates Twist1 [170]. Since the 
EMT inducing media supplement was designed to induce the Wnt and 
TGF-ȕ VLJQDOOLQJ WKHVH FHOOV ZHUH LQFOXGHG LQ WKLV H[SHULPHQW LQ DQ
attempt to phosphorylate/activate Twist1. 
At the end of the experiment, the morphology of the cells was assessed 
by microscopy and the cells were collected for gene expression analysis 
of the EMT markers. The experiment was repeated 3 times for the NCI60 
MCF-7 cells, 2 times for the ECACC MCF-7 cells and 1 time for the MCF-
7/Twist1 cells. For the MCF-7/Twist1 cells, half of the cells were collected 
for gene expression analysis and half of the cells were lysed for western 
blot. No morphological changes associated with EMT were observed in 
either of the cell lines tested (a representative example is shown in Figure 
44). In the NCI60 MCF-7 cells, a small downregulation of CDH1 was 
observed (average fold change 0.82), but no consistent changes were 
observed in the mesenchymal genes (Figure 45A). Upregulation of 
S100A4, CDH2 and SNAI was observed in the ECACC MCF-7 cells 
(average fold change 4.5, 12.4 and 5.2 respectively; Figure 45B). As no 
morphological changes and no changes in the epithelial gene CDH1 were 
observed in these cells, the experiment was not pursued further. In the 
MCF-7/Twist1 cells, TWIST1 was not upregulated (Figure 45C). The 
proteins from the two different samples appeared exactly the same on a 
western blot, suggesting that the media supplement did not have an 
effect on the expression of Twist1 (Figure 46). A small downregulation of 
CDH1 was observed in these cells (fold change 0.64), but the 
mesenchymal markers were either downregulated or retained similar 
levels of expression (Figure 45C). Since no changes were observed in 
the expression of Twist1 (gene and protein levels), or the morphology of 
the cells, or the mesenchymal markers tested, the experiment using 
these cells was not pursued further. 
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A B 
C D 
E F 
Figure 45. Pictures of cells cultured in EMT inducing media 
supplement. NCI60 MCF-7 cells without supplement (A) and with 
supplement (B). ECACC MCF-7 cells without supplement (C) and with 
supplement (D). MCF-7/Twist1 cells without supplement (E) and with 
supplement (F). Pictures were taken at x10 magnification. 
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Figure 46. Relative gene expression of EMT markers in cells 
cultured in a medium containing the EMT-inducing media 
supplement. The graphs show the analysis of EMT markers in NCI60 
MCF-7 (n=3) (A), ECACC MCF-7 (n=2) (B) and MCF-7/Twist1 (n=1) (C) 
cells. Each bar represents mean 2-¨¨CT values ± SEM of matched 
biological replicates on a logarithmic scale.  
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4.4 3D cultures 
The NCI60 MCF-7 cells were seeded a 96-well plate in quadruplicate and 
cultured in a 3D TGA for up to 7 days both in normoxia and hypoxia. The 
experiment was performed once. The cell density, the concentration of 
the BME, and the length of the assay had been previously determined in-
house. The growth of the cells was monitored every 1-2 days with the 
Alamar Blue (AB) cell viability assay. As shown in Figure 47, the cell 
number increased over the first six days of the assay and remained 
stable/started declining by the end of the assay. Furthermore, the growth 
rate of the cells was similar in normoxia and hypoxia.  
 
 
ȕ-actin (40kDa) 
14kDa 
~21kDa 
~40kDa 
A B 
Figure 47. Western blot analysis of Twist1 in MCF-7/Twist1 cells, 
cultured with EMT-inducing media supplement. The cells cultured 
without the supplement (A) or with the supplement (B), were stained 
with anti-human Twist1 (21kDa). The arrows indicate the size of the 
bands. B-actin (40kDa) was used as a reference protein.  
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The gene expression of the EMT markers and the hypoxia marker 
(VEGF) at the end of the assay (Day 7) was compared with the gene 
expression at the first day of the assay (Day 1). VEGF was upregulated 
both in normoxia and hypoxia (fold change 2.9 and 29.7 respectively), 
suggesting a degree of hypoxia in both conditions (Figure 48). VIM was 
upregulated in normoxia (fold change 11.1) and S100A4 was upregulated 
in hypoxia (fold change 30.3) (Figure 48). Even though, upregulation of 
the mesenchymal markers was observed, upregulation of the epithelial 
marker CDH1 was also observed both in normoxia and hypoxia (fold 
change 3 and 1.9 respectively) therefore, the experiment was not 
pursued further.  
 
 
 
 
Figure 48. Growth curves of cells cultured in a 3D TGA assay in 
normoxia and hypoxia. Each point shows the average fluorescent 
units, as detected by AB ± SEM. N=1. 
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4.5 Co-cultures with MSCs 
NCI60 MCF-7 cells were cultured with (co-culture) or without (mono-
culture) mCherry MSCs on coverslips in 6-well plates for 10 days, at a 
ratio of 2MCF-7:1MSCs. The cell density and length of the assay was 
optimised, so that the cells reached ~80% confluence at the end of the 
assay (suitable for immunofluorescence (IF) staining). At the end of the 
experiment the morphology of the cells was assessed by microscopy and 
the protein expression of E-cadherin and Vimentin was assessed by IF. 
In this experiment, the changes in the EMT markers was assessed at the 
protein level (by IF) rather than by gene expression, in order to avoid 
separating the cells and risking ending up with a cell population that is 
not completely pure.  
The appropriate controls were included to control for nonspecific, 
background and autofluorescence, and the pictures were taken at the 
same exposure times for each dye.  
MCF-7 cells cultured in mono-cultures expressed high levels of 
membranous E-cadherin (Figure 49A&B). MCF-7 cells co-cultured with 
hMSCs also expressed E-cadherin (Figure 49C&E), showing that the 
expression of E-cadherin was not downregulated as it would be expected 
Figure 49. Relative gene expression of EMT markers in cells 
cultured in a 3D TGA assay in normoxia and hypoxia. Each bar 
shows the 2-¨¨&7 value. N=1.   
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upon EMT induction. While high expression of Vimentin was observed in 
the mCherry MSCs, no expression/upregulation of Vimentin was 
observed in the MCF-7 cells co-cultured with MSCs (Figure 50). 
Furthermore, from both pictures, it can be seen that the morphology of 
the MCF-7 cells remained epithelial-like. In summary, EMT-related traits 
were not induced in this setting. The experiment was performed twice; 
the results were the same at both times. For all the controls and individual 
images, see appendices 6-9. 
 
 
                               Dapi/FITC (E-cadherin)/ HcRed (mCherry MSCs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
                                    
 
B A 
D C 
Figure 50. IF staining of co-cultures for E-cadherin. (A) E-cadherin 
staining in mono-cultures. (B) Merge picture of staining in mono-cultures. 
(C) E-cadherin staining in co-cultures. (D) Merge image of staining in co-
cultures Blue (Dapi) = nuclei, green (FITC) = E-cadherin, and pink 
(HcRed) = mCherry MSCs.  Pictures were taken at x10 magnification. 
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                             Dapi/FITC (Vimentin)/ HcRed (mCherry MSCs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6 Supplementation with IL-6 
Cells were seeded at low densities and cultured in normal medium or 
medium supplemented with 50ng/ml human recombinant IL-6 for up to 7 
days. The experiment was performed twice (the gene expression of EMT 
markers was analysed once, while the morphology of the cells twice). 
The medium, with or without IL-6, was replenished every 2 or 3 days. No 
morphological changes were observed in either the NCI60 MCF-7 or the 
ECACC MCF-7 cells (representative examples are shown in Figure 51). 
D 
B A 
C 
Figure 51. IF staining of co-cultures for Vimentin. (A) Vimentin 
staining in mono-cultures. (B) Merge picture of staining in mono-cultures. 
(C) Vimentin staining in co-cultures. (D) Merge picture of staining in co-
cultures.  Blue (Dapi) = nuclei, green (FITC) = E-cadherin, and pink 
(HcRed) = mCherry MSCs.  Pictures were taken at x10 magnification. 
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TWIST1 and CDH2 were upregulated in the NCI60 MCF-7 cells (fold 
change 6.9 and 2.6 respectively; Figure 52A). However, the difference in 
the actual 2-¨&7values was small to be considered substantial; therefore, 
the experiment was not pursued further (i.e. from 0.0042 in normoxia to 
0.0291 in hypoxia for TWIST1 and 0.00007 to 0.0002 for CDH2). The rest 
of the EMT markers did not change. In the ECACC MCF-7 cells, S100A4 
was slightly upregulated (fold change 2.5), but the other markers 
remained unchanged (Figure 52B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Figure 52. Pictures of cells cultured in medium supplemented with 
IL6. A. NCI60 MCF-7 cells no IL6. B. NCI60 MCF-7 cells with IL6. C. 
ECACC MCF-7 cells no IL6. D. ECACC MCF-7 cells with IL6. Pictures 
were taken at x10 magnification. Pictures were taken at x10 
magnification. 
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4.7 Indirect co-cultures with BrCAFs 
NCI60 MCF-7 cells were seeded in a trans-well 24-well plate and either 
MCF-7 or BrCAFs were seeded in the insert in the appropriate culture 
medium. While the number of the MCF-7 cells in the well was kept 
constant, the number of cells in the insert was altered so that different 
cell ratios were used. The ratios used included the following: (a) 1MCF-
A 
B 
Figure 53. Relative gene expression of EMT markers in cells 
cultured with IL-6. Gene expression analysis in NCI60 MCF-7 cells 
(A) and in ECACC MCF-7 cells (B). Each bar represents the relative 
2-¨¨&7 values. N=1.  
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7:1MCF-7, (b) 1MCF-7:1BrCAFs, (c) 1MCF-7:3MCF-7 and (d) 1MCF-
7:3BrCAFs. The experiment was performed twice (the gene expression 
of EMT markers was analysed once, while the morphology of the cells 
twice). The cell density and morphology of the cells was monitored daily 
by microscopy and at day 10, the cells were collected for analysis of the 
EMT genes. No obvious morphological changes associated with EMT 
were observed (representative images are shown in Figure 53) and no 
substantial differences in the expression of the EMT markers were 
detected (Figure 54). 
 
 
 
 
 
 
 
 
 
 
 
 
GENE EXPRESSION ALL  
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Figure 54. Pictures of MCF-7 cells cultured in trans-well plates with 
BrCAFs. The pictures show the MCF-7 cells in the well cultured with 
MCF-7 cells in the insert at 1MCF-7:1MCF-7 (A) or 1MCF-7:3MCF-7 (B) 
ratios or with BrCAFs in the insert at 1MCF-7:1BrCAFs (C) or 1MCF-
7:3BrCAFs (D) ratios. Pictures were taken at x10 magnification. 
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Summary and discussion 
In this chapter, different methods were attempted to induce EMT-related 
traits, including change in the morphology of the cells and change in the 
expression of EMT markers. While in some of the methods attempted, 
some of the mesenchymal genes were upregulated, none of the 
techniques resulted in a complete EMT phenotype. Therefore, it was 
impossible to test the activity of the EMT reporters upon induction of EMT 
in vitro.  Furthermore, no consistent changes in E-cadherin or N-cadherin 
were observed; hence, a different system to validate the activity of the E-
cadherin and N-cadherin in vitro was not established. 
The different methods used were an adaptation of the methods used in 
the literature, or were based on commercial products, suggesting that 
technical/methodological aspects could have affected the induction of 
Figure 55. Relative gene expression of EMT markers in MCF-7 cells 
cultured in transwell plates with BrCAFs, or MCF-7 at different 
ratios. Each bar represents the 2-¨¨&7 value (1MCF7:1BrCAFs relative to 
1MCF7:1MCF7 and 1MCF7:3BrCAFs relative to 1MCF7:3MCF7). N=1.  
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EMT. These include differences in the cell density, length of the assay, 
dimensionality, and the origin, batch and passage number of the cell lines 
used. Furthermore, some specific issues arose. For example, when 
attempting to overexpress Twist1 in MCF-7 cells, the gene was 
successfully upregulated but it was not shown whether the protein was 
upregulated and/or activated.  
The process of EMT is controlled by different regulatory networks, which 
are interconnected (reviewed in [171]). In addition to different TFs 
activating different signalling pathways, non-coding RNAs, differential 
splicing, and translational and post-translational control which affect the 
SURWHLQV¶VWDELOLW\DQGORFDOLVDWLRQDOVRUHJXODWHWKH(07SURJUDP,W LV
clearly demonstrated that EMT is a complicated process and hence not 
straightforward to achieve experimentally. Also, it can be referred that 
maybe only some of these regulatory mechanisms were activated by the 
methods attempted, but were not sufficient to induce a complete EMT 
alone.  
Finally, human tumours and cell lines are heterogeneous, composed of 
cell with different plasticity and tumourigenic potential (reviewed in [172]). 
This means that not all cells will behave the same way; for example some 
cells are responsive to drugs and others are resistant. As a consequence, 
in breast cancer, and in most cancers, EMT rarely occurs 
homogeneously [173].  Only a portion of cells will undergo EMT, which 
implies that maybe EMT was induced in a few cells, but was not 
detectable.  
EMT was not induced in vitro, due to all the aforementioned issues. This 
further stresses the need of improved models and detection of EMT, both 
in vitro and in vivo, which is the aim of this study.  
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CHAPTER 5: RESULTS 3 ± In vivo model(s) 
development  
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This chapter will describe the studies performed, in order to establish in 
vivo model(s) of EMT and/or metastasis, for testing the activity of the 
EMT reporters in real-time. In the previous chapters, the activity of the 
S100A4 reporter was validated in vitro in MCF-7 and BT549 cells, 
therefore, these studies were performed using these two cell lines. The 
work aimed to test the tumourigenecity of these cell lines, induction of 
EMT, changes in the expression of the reporter markers and metastatic 
potential. 
As earlier discussed, EMT is thought to be involved in the early stages of 
metastatic BC, where cells in the invasive border of the tumour undergo 
EMT which allows them to metastasise. It is not clear though when EMT 
is happening, which cells are involved and what happens to those cells 
after they metastasis, and to our knowledge this has not been shown in 
real-time. This project aimed to study this by the use of EMT reporter that 
will allow this real-time read out of EMT. MCF-7 cells are not thought to 
be metastatic, but they were chosen for this study in an attempt to 
experimentally induce EMT in an in vivo setting and capture the early 
stages of EMT. As previously discussed, the MSCs play an important role 
in tumour progression and metastasis and MSC-induced EMT-related 
traits have been reported in BC cell lines in vitro. So, MSCs were used to 
induce EMT in the low metastatic MCF-7 cells. Furthermore, the use in 
human-derived MSCs makes the xenograft model more clinically 
relevant.  
Mouse models have been extensively used for studying human cancer, 
and they comprise one of the best models due to different features 
including small size, easy breeding, and most importantly, extensive 
physiological and molecular similarities to humans (reviewed in [174]). 
Different mouse models exist, including genetically engineered mice 
(transgenic or endogenous) and xenografts. In this study, xenograft 
models were established, in which the cell lines were propagated in 
immunodeficient/immunocompromised mice in ectopic or orthotopic 
sites. One main advantage of using xenograft models is the fact that they 
use cell lines derived from human cancers, and are hence a good model 
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for testing the efficacy of drugs against human cancers. In 
immunodeficient/immunocompromised mice, various breast cancer cells 
lines have been xenotransplanted and shown to be able to form tumours 
and metastasise into other organs, including lungs, liver, brain, bone and 
lymph nodes (reviewed in [175]). In this project two different mouse 
strains were used; the HsdOla:MF1-Foxn1nu (aka MF1 nude mice) and 
the C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J (aka Rag2-/- ȖF-/- mice). The MF1 
nude mice carry the nude (nu/nu) mutation and are therefore hairless and 
completely lack a thymus [176]. Therefore, they are T-cell deficient and 
their lymphocyte population is composed mostly of B-cells. They have a 
very poor response to thymic-dependent antigens, including failure to 
reject xenografts. Rag-2 mice carry a germline mutation in which most of 
the RAG-2 (recombinant-activating gene) coding region is depleted, 
whose protein function is to initiate V(D)J recombination, which is 
important for the maturation of pre-B and pre-T cells [177]. The particular 
strain also has mutations in the X-linked IL2RG gene, which encodes the 
FRPPRQ Ȗ FKDLQ ȖF of the leukocyte receptors for interleukin-2 and 
multiple other cytokines that regulate the growth and maturation of 
lymphocytes, and its mutation results in severe combined 
immunodeficiency (SCID) [178]. Hence, these mice lack T, B and NK 
cells; their immunodeficiency makes them particularly useful as 
transplant hosts.  
To support/maintain the growth of the cell lines, the cells were mixed with 
matrigel prior to implantation, and, in the case of the studies with the 
MCF-7 cells, the mice were receiving oestrogen (estradiol). Matrigel is a 
soluble form of basement membrane matrix extracted from Engelbreth-
Holm-Swarm (EHS) mouse tumour, which is rich in proteins of the 
extracellular matrix (laminin, collagen IV and others) and growth factors 
(FGF, TGFȕ and others) [179]. Tumour growth enhancement of a variety 
of BC cell lines, including MCF-7, with the addition of matrigel has been 
reported [180]. In the same study, it was shown that sustained growth of 
MCF-7 xenografts was maintained in the presence of oestrogen, 
confirming the well-documented hormone dependency of these cells.  
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While mouse models are the main tools for screening for drug efficacy, 
most drugs fail when tested in clinical trials in humans [181-183]. We 
anticipate that a major reason for this, is the fact that the mouse models 
lack the relevant tumour microenvironment, as the tumour 
microenvironment plays a critical role in tumour progression and 
metastasis (reviewed in [62]). To ensure a more relevant 
microenvironment, the human cell lines were implanted orthotopically in 
the MFP of the mice. Furthermore, we aimed to generate more 
humanised pre-clinical models, by co-implanting the human breast 
cancer cell lines with cells of the human stroma i.e. human mesenchymal 
stem cells (MSCs). MSCs are important for tumour progression, as they 
contribute to tumour vascularisation, EMT and metastasis (reviewed in 
[62]). Promotion of breast cancer formation and metastasis by human 
MSCs in mouse models, have been described [72, 184].  
Tumour establishment was monitored manually by caliper 
measurements, a commonly used easy and non-invasive technique. 
Tumour growth was monitored by bioluminescent imaging; cell lines were 
transduced to express a plasmid construct that allowed constitutive 
expression of firefly luciferase, which was detected upon administration 
of its substrate, D-luciferin. As previously discussed, bioluminescent 
imaging is highly sensitive, and is suitable for detecting small numbers of 
cancer cells [116, 117]. Furthermore, the use of optical imaging has many 
advantages including non-invasive, quick and real-life monitoring of 
disease and drug response that minimizes the need of termination of the 
study at different time points for end-stage analysis, and hence reduces 
the number of animals being used  (reviewed in [185]). This study not 
RQO\ FRQWULEXWHG WR WKH ³UHGXFWLRQ´ RI DQLPDOV EHLQJ XVHG EXW DOVR WR
³UHILQHPHQW´Fontinual review of improvements in experimental design, 
techniques and husbandry to minimise adverse effects and improve 
welfare was undertaken), which comprise 2 of the 3Rs 
(https://www.nc3rs.org.uk/). 
To test whether EMT-related traits were induced, the xenografts were 
fixed for immunohistochemical analysis of EMT markers. Bigger tumours 
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were half fixed and half used for gene expression analysis of the EMT 
markers. 
 
5.1 Determining the effect of site of implantation on growth and 
phenotype of murine Xenograft models  
 
5.1.1. Bioluminescent MCF-7 tumour EMT / metastasis pilot in an 
orthotopic mammary fatpad model 
The study aimed to compare the ability to generate MCF-7 tumours at 
the implantation site, induction of EMT-related traits and metastatic 
growth via different initiation routes: MFP and sub-cutaneous (SC). 
Furthermore, this first study, aimed to assess the different methodologies 
used and to optimise the different analyses performed (e.g. correlation 
between bioluminescent signal and tumour weights), as a reference for 
subsequent studies. 
5.1.1.1 Tumour growth  
Bioluminescent MCF-7 cells were implanted in female MF1 nude mice in 
the MFP or SC and allowed to form primary xenografts. Xenograft 
formation was assessed by measuring the tumour volume, calculated 
using a calliper. Tumour growth was monitored by bioluminescent 
imaging every 1-2 weeks using the IVIS Spectrum. The MCF-7 cells were 
able to generate primary growth both at the MFP and SC sites after 1 
week (Figure 55). At midpoint of the study, two mice per group were 
terminated; the mice with the bigger tumour volume in each group 
(mouse 4 from group 1 and mouse 6 from group 2) and the mice with the 
second smallest tumour (mouse 2 from group 1 and mouse 8 from group 
2), in order to assess EMT at different time points i.e. midpoint of the 
study (day 67) and end of study (day 134).  
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The tumour volume in the two groups, as measured by calliper, followed 
the same pattern; primary xenografts were initially formed and then the 
tumour growth reached a plateau (Figure 56A). The difference in tumour 
volumes between the two groups was analysed using two-way ANOVA 
for each day. No significant differences in tumour growth were observed 
between the two groups. Looking at each mouse individually, the tumour 
volumes were similar in the two groups (ranged from 89.89 mm3 to 182.95 
mm3 at termination point), with the exception of mouse 4 in which the 
tumour volume reached the size of 506.25 mm3 (Figure 56B). Tumour 
growth was also monitored by bioluminescent readings, after 
administration of D-luciferin. The readings were misleading, due to 
variations of sensitivity of D-luciferin between the different time points. 
This was overcome in subsequent studies, by using the same batch of 
luciferin throughout the study. 
 
 
A B 
* * * * 
Figure 56. Representative images showing xenograft formation 
of bioluminescent MCF-7 cells. A. Group 1 = MFP; mice 1-4 (left to 
right) B. Group 2 = SC; mice 5-8 (left to right). Bioluminescent signal 
was measured as total flux (photons/second). The colour scale 
ranged from 2.297x107 (blue) to 8.55x108 (red). Pictures were taken 
at day 67 of the study (midpoint) using the IVIS Spectrum after 
administration of D-luciferin. The mice terminated at midpoint are 
demonstrated by a start.  
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Prior to termination, D-luciferin was administered, and the mice were 
imaged as normal. Following imaging, the mice were sacrificed, the 
xenografts were removed, weighed, and bioluminescent signal was 
measured (Figure 57A&B). Significant correlation was observed between 
the bioluminescent signal and tumour weights (Figure 57C), as 
determined by Pearson correlation coefficient (r=0.9576, p=0.0002). 
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Figure 57. Tumour growth of bioluminescent MCF7-cells in MF1 
nude mice  injected in the MFP (group 1) or SC (group 2). A. Mean 
tumour volumes (mm3) ± SEM in group 1 (red line) and Group 2 (blue 
line) as measured by a calliper. B. Tumour volumes (mm3) of individual 
mice (1-8) from each group (red lines=group 1and blue lines=group 2). 
The arrow indicates midpoint of the study where mice 2, 4, 6 and 8 were 
terminated. 
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Significant correlation was also observed between the tumour volumes 
(measured prior to removal) and the bioluminescent signal of the 
removed tumours (r=0.9850, p<0.0001) (Figure 57B).  The tumours were 
later fixed or cut in half (half was fixed for IHC staining and half was 
preserved in RNAlater for gene expression analyses). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Correlation of bioluminescence signal from tumours 
removed at termination of the study with tumour weight and 
tumour volumes. A. Correlation of tumour weights (mg) and 
bioluminescent signal (total flux p/s). Each point represents the weight 
and signal of an individual xenograft. (r=0.9170, p=0.0002). B. 
Correlation of tumour volumes (mm3) and bioluminescent signal. 
(r=0.9850, p<0.0001). N=8 (4 per group). Red=Group 1. Blue=Group 2. 
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5.1.1.2 Metastasis 
The mice were imaged after intermediate dissection in order to detect 
any signal in metastatic sites. No signal was detected in distant organs. 
The lymph nodes and spleens were removed and imaged individually. 
No signal, indicating metastasis, was detected in the spleens (Figure 58). 
 
 
 
 
 
 
 
Bioluminescent signal was only detected in the left LNs removed from the 
MFP group (Figure 59A, 59C, 59E & 59G). No signal was detected in the 
left LNs removed from the SC group or from the right LNs removed from 
either group (Figure 59). For those lymph nodes in which signal was 
detected, H&E staining was performed to reveal the structure of the 
lymph nodes and identify any tumour cells invading the lymph nodes. 
Normal structures were identified including capsule, adipose tissue and 
blood vessels (Figure 60), but no tumour cells were identified in either of 
the LNs. A representative example is shown in Figure 60; for all the other 
lymph nodes see appendix 10. The lymph nodes were also stained with 
anti-human cytokeratin, which only stains the tumour cells [186], in case 
the few tumour cells that had invaded the LNs were not detectable by 
H&E staining, but again no tumour cells were detected (data not shown). 
The left LNs are located very close to the MFPs (implantation site) and it 
is possible that the bioluminescent signal detected in the LNs was from 
MCF-7/fLuc cells that were not successfully removed, or perhaps tumour 
cells in transit state. 
 
1 2 3 4 
5 6 7 8
Figure 59. Bioluminescent images of spleens removed. Numbers 
indicate the mouse number. 1-4=MFP group and 5-6=SC group. Images 
were taken using the IVIS Spectrum, upon termination of the study.  
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5.1.1.2 Ex vivo analysis of EMT traits 
In order to check whether EMT was induced, the expression of the EMT 
markers E-cadherin and Vimentin was analysed in primary xenografts, 
both at the protein level by IHC and at the gene level by qPCR (in the 
available samples).  
A B C D 
E F G H 
I J K L 
M N O P 
Figure 60. Bioluminescent images of LHS and RHS LNs. Mouse 1, 
left (A) and right (B). Mouse 2, left (C) and right (D). Mouse 3, left (E) 
and right (F) Mouse 4, left (G) and right (H). Mouse 5, left (I) and right 
(J) Mouse 6, left (K) and right (L). Mouse 7, left (M) and right (N). Mouse 
8, left (O) and right (P).  
 
B 
Ca 
AdTi 
x5 
A 
BlVe 
LyNo 
x10 
Figure 61. H&E staining of lymph node 2 (LHS). A. x5 magnification. B. 
x10 magnification. Ca = capsule, LyNo = Lymph node, AdTi = Adipose 
tissue, BlVe = Blood vessel.  
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5.1.1.2.1 E-cadherin protein and gene expression 
The xenografts were stained with anti-human E-cadherin, which is 
expected to be reduced or lost upon induction of EMT, or an isotype 
control. As a reference for the staining (intensity and pattern), 
bioluminescent MCF-7 cells, cultured in normal cell culture conditions, 
were fixed and stained with the same antibody. The staining of the cells 
showed that most of the cells were positive for E-cadherin expression, 
and that the staining was located in the cell junctions and in the cytoplasm 
(Figure 61A). The same pattern was observed in in vitro cultured cells, 
when stained with the same antibody and imaged by IHC or IF. The 
staining confirmed that all the cells that were in contact expressed E-
cadherin, and that the staining was predominately membranous (Figure 
62B). All xenografts, with the exception of xenograft 8 which was mostly 
negative, stained positive for E-cadherin (Figure 62; for the isotype 
controls see appendix 11). The intensity and location of the staining was 
variable across the different xenografts (e.g. staining in xenograft 4 was 
located near the edges and was strong, while the staining in xenograft 1 
was located mostly in the core of the tumour and the intensity was weak). 
Unlike the MCF-7 cells cultured in vitro, not all the cells in the xenografts 
were positive. To assess the difference in staining between the two 
groups, the amount of E-cadherin staining both the percentage area 
stained and the H-Score. Pictures were taken (at x20 magnification), 6 
for each slide, using a Leica colour microscope. Images of low, medium 
and high levels of E-cadherin staining were selected in order to use these 
as a baseline for setting the ImageScope software DOJRULWKP³3RVLWLYH
3L[HO &RXQW Y´. The boundaries had been set (high positive=190, 
positive=130 and low positive=100) and the program was used to analyse 
all the pictures. Figure 63 shows the different boundaries, including 
negative tissues and necrotic areas i.e. red=high, orange=medium, 
yellow=low, blue=negative tissue and white=no tissue. Areas of necrosis 
were manually excluded from the analysis. The percentage of positive 
areas varied from 11% to 45%. No significant difference was observed 
between the two groups or the different time points of the study, as 
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determined by an unpaired t-test (Figure 64A-C). The H-scores varied 
from 14 to 69. No significant difference was observed in the H-scores 
between the two groups or the different time points of the study (Figure 
64D-F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
x10 
X40 
B 
x10 
x40 
Figure 62. E-cadherin staining of bioluminescent MCF-7 cells. A. IHC 
staining of MCF-7 cells fixed, suspended in agarose and embedded in 
paraffin with anti-human E-cadherin. B. Immunofluorescence staining of 
MCF-7 cells cultured in cover slip, stained with anti-human E-cadherin 
(green) and Dapi (blue). Pictures were taken using the Nikon Eclipse Ti 
microscope. Pictures were taken at 10x (left) and 40x (right) 
magnifications.  
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Figure 63. IHC staining of E-cadherin in mouse xenografts. A-D Mice 
1-4 from group 1 (MCF-7/fLuc cells in the MFP). E-H Mice 5-8 from group 
2 (MCF-7/fLuc cells SC). Pictures taken at x40 magnification.  
 
G H 
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A B 
C D 
E F 
Figure 64. Images showing analysis of E-cadherin staining using 
the ImageScope Software. Example of staining used to determine the 
boundaries between positive and negative (A), where red cells 
represent high staining intensity, orange cells represent medium 
staining intensity, blue cells represent negative density and yellow cells 
represent low intensity staining, matched to the original image (B). 
Boundaries were set as follows: high positive=190, positive=130 and 
low positive=100. Example of staining used to determine the boundaries 
between negative cells, shown in blue, and no tissue, shown in white 
(C), matched to the original image (D). Example showing manual 
exclusion of areas of necrosis (marked with green line) matched to the 
original image (F).  
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The xenografts stored in RNAlater (available xenografts only xenografts 
2, 3 and 4 from group 1) were mechanically homogenised using a mortar 
and pestle and collected with TRI-Reagent, the RNA was extracted, 
cDNA was synthesised and the gene expression levels of E-cadherin 
were analysed by qRT-PCR. Gene expression was compared with the 
baseline E-cadherin expression of the bioluminescent MCF-7 cells 
cultured in vitro. The gene expression was similar in the xenografts 2, 3 
and 4 (2-¨&7 values = 3.3, 3.0 and 3.19 respectively) and between 2.84 
and 3.12 folds lower than the control MCF7-fLuc cells (Figure 65). This 
Figure 65. Percentage of E-cadherin positive areas and H-scores in 
xenografts. A. Average percentage in all mice in group 1 and group 2 
(N=4 per group). B. Average percentage in mice terminated at day 67 
(N=2) and at day 134 (N=2) from group 1. C. Average percentage in mice 
terminated at day 67 (N=2) and at day 134 (N=2) from group 2. D. 
Average H-scores in all mice (N=4 per group). E. Average H-scores in 
mice terminated at day 67 (N=2) and at day 134 (N=2) from group 1. F. 
Average H-scores in mice terminated at day 67 (N=2) and at day 134 
(N=2) from group 1. Bars represent mean values. Error bars show ±SEM. 
Red bars = group 1 and blue bars = group 2. 
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showed that E-cadherin was downregulated when the cells were grown 
in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.1.2.2. Vimentin protein and gene expression 
The xenografts were stained with anti-human Vimentin which is 
upregulated upon induction of EMT. At this point, there was no more 
tissue left from xenograft 8, therefore it was not included in the analysis. 
Tissue from human colorectal cancer was used as a positive control for 
the staining (Figure 66A). All xenografts were negative for Vimentin. For 
the isotype controls see appendix 12. The gene expression of Vimentin 
was analysed and was compared with the baseline Vimentin expression 
of the bioluminescent MCF-7 cells. The 2-¨&7 value in the MCF-7 cells 
was 0.008 and the values ranged from 0.01 to 0.08 in the xenografts 
(Figure 67). The extremely low 2-¨&7 values indicate that the expression 
of Vimentin remained very low when the cells were implanted in vivo. 
 
Figure 66. E-cadherin gene expression in mouse xenografts and 
control cells (bioluminescent MCF-7 cells). Bars represent the 
average 2-¨&7 values and lower and upper limits as follows: MCF-7/fLuc 
= 9.40, Xenograft 2 = 3.34, Xenograft 3 = 3.00 and Xenograft 4 = 3.19. 
N=1. 
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Figure 67. IHC analysis of human anti-Vimentin in mouse 
xenografts. A. Positive control (human colorectal tumour). B-E 
xenografts 1-4 from group 1. F-H. Xenografts 5-7 from group 2.  
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5.1.2. Bioluminescent BT549 tumour EMT / metastasis pilot in an 
orthotopic mammary fatpad (MFP) model 
The study aimed to compare the ability to generate BT549 xenograft at 
implantation site and metastatic growth via different initiation routes; MFP 
and sub-cutaneous (SC), as well as to test the effect of matrigel on 
tumour growth. As explained previously, the tumour microenvironment 
plays an important role in tumour growth; therefore, the study aimed to 
determine whether there will be a difference in growth between orthotopic 
and SC sites. Furthermore, the use of matrigel has been shown to 
support the growth of BC cell lines, so the study aimed to explore whether 
matrigel would have an effect on tumour growth.  
Figure 68. Vimentin gene expression in Xenografts and control 
(bioluminescent MCF-7 cells). Bars represent the average 2-¨&7 
values and lower and upper limits as follows: MCF-7/fLuc = 0.008, 
Xenograft 2 = 0.011, Xenograft 3 = 0.015 and Xenograft 4 = 0.021. N=1. 
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Bioluminescent BT549 cells were implanted in female MF1 nude mice in 
the MFP (in culture medium) or SC (in culture medium or matrigel) and 
allowed to form primary xenografts. Xenograft formation was monitored 
by calliper measurements, and tumour growth was visualised by 
bioluminescent imaging every 1-2 weeks using the IVIS Spectrum. As 
shown in Figure 68, signal was detected at the beginning of the study, 
which then decreased and reached a plateau, in all the groups. As shown 
in the image of the bioluminescent reading at the end of the study, little 
signal was detected in the mice (Figure 69). In summary, the BT549 cells 
did not form tumours in either of the implantation sites tested, and the 
matrigel had no effect on growth. The tumour volumes were mainly 
unmeasurable throughout the study, showing that tumours were not 
formed. Therefore, no tissue was available at the end of the study for 
further examination.  
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Figure 69. Bioluminescent readings of BT549 cells implanted in 
MF1 nude mice. Each line represents a different group. Each point 
represents the average bioluminescent signal (total flux) on a logarithmic 
scale ± SEM. Readings were taken after administration of D-luciferin 
throughout the stuy. N=3 per group. 
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Figure 70. Representative images showing bioluminescent readings 
of BT549 cells in nude mice. A. Group 1 = MFP; mice 1-3 (left to right) 
B. Group 2 = SC with matrigel; mice 4-6 (left to right). C. Group 3 = SC 
no matrigel; mice 7-9 (left to right). Bioluminescent signal was measured 
as total flux (photons/second). The colour scale ranged from 5.19x104 
(blue) to 9.77x105 (red). Pictures were taken at the end of the study after 
administration of D-luciferin.   
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5.2 Assessing the effect of co-implanting epithelial with 
mesenchymal cells on growth, metastasis and EMT 
 
Tumour formation of bioluminescent MCF-7 was previously observed, 
but no substantial tumour growth was observed. Furthermore, no EMT or 
metastasis was observed, and no tumour formation at all was observed 
with the BT549 cells. As MSCs have been shown in the literature to 
promote tumour growth, BT549 were co-implanted with hMSCs and the 
effect of the MSCs on tumour growth was assessed. Although no 
significant difference was previously observed between the MFP and SC 
initiation, the MFP site was chosen for the subsequent studies, as it 
should provide a more relevant TME. 
 
5.2.1 BT549 tumour EMT / metastasis pilot in an orthotopic 
mammary fatpad (MFP) model ± Rag2-/- mice via co-implantation 
with MSCs 
The study aimed to test the ability to generate BT549 tumour at 
implantation site and metastatic growth via co-implantation with MSCs, 
as well as to test the effect of MSCs on the expression of S100A4. As the 
nude mice were no longer available at this point, the Rag2 mice were 
used. 
5.2.1.1 Tumour growth and metastasis  
BT549 cells were implanted in the MFP site of Rag2-/- mice either alone 
or with MSCs. The tumour growth was monitored as before. As shown in 
Figure 70, bigger tumours were formed when co-implanted with MSCs. 
,QPRXVH³%706&V´JURXSWXPRXUVZHUHIRUPHGHDUO\LQWKH
study and continue to grow until termination of the study. In mouse 3 
³%706&V´JURXSWKHWXPRXUVZHUHIRUPHGDQGVWDUWHGJURZLQJ
later in the study. On the other hand, small-sized tumours were formed 
LQ WKH ³%7 RQO\´ JURXS PLFH  DQG  DQG WKH WXPRXU YROXPH
decreased until the end of the study; in mouse 2 the tumour volume was 
undetectable by the end of the study. The study was terminated as the 
162 
 
mice did not recover from anaesthesia. This study showed that BT549s 
require the support of MSCs to form tumours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.1.2 S100A4 expression 
The activity of the S100A4 reporter had been validated in the BT549 cells 
(chapter 3). Briefly, under hypoxic conditions the S100A4 gene 
expression was upregulated, and this was associated with upregulation 
of the bioluminescent signal. Therefore, the expression of S100A4 was 
analysed in the BT549 mouse xenografts at the end of the study, to 
assess whether the BT549 cells expressed S100A4 at the protein levels. 
,WZDVVKRZQWKDWPRVWRIWKHFHOOVLQWKH[HQRJUDIWVIURPWKH³%7
06&V´JURXSH[SUHVVHG6100A4 (Figure 71). For the isotype controls 
see appendix 13. $VQRWXPRXUIRUPDWLRQZDVREVHUYHGLQ³%7RQO\´
group (or the xenografts were very small), it was not possible to stain for 
S100A4.  
Figure 71. Tumour volume formation of bioluminescent BT549 in 
Rag2-/- nice. Each line represents a different mouse. Blue lines 
represent mice from group 1 (BT549 only). Red lines represent mice 
from group 2 (BT549 + MSCs). Each point represents a calliper tumour 
volume (mm3) measurement. 
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In order to assess whether the S100A4 expression was due to the effect 
of MSCs, and to reproduce the effect of MSCs on growth, the study was 
repeated. In this study the imaging was less frequent in order to minimise 
the stress and avoid earlier termination of the study. The study also 
aimed to analyse the expression of S100A4 at different stages of tumour 
growth (early and late stages of tumour growth), in order to assess 
whether a change on the S100A4 expression was due to tumour 
progression and/or the effect of MSCs and determine whether the 
S100A4 reporter would be tested in BT549 mouse xenografts. The 
tumours did not grow in this study, even when the cells were co-implanted 
with MSCs; therefore it was not possible to stain for S100A4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 72. IHC analysis of S100A4 in the BT549 mouse xenografts 
co-implanted with MSCs. A. Xenograft from mouse 1. B. Xenograft 
from mouse 2.  
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5.2.2 Bioluminescent MCF-7 tumour EMT / metastasis pilot in an 
orthotopic mammary fatpad (MFP) model ± nude mice 
This study aimed to assess the effect of human MSCs in MCF-7 tumour 
formation, EMT and metastasis. Bioluminescent MCF-7 cells were 
implanted in the MFP of female MF1 nude mice with or without MSCs in 
matrigel, at a ratio of 2MCF-7:1MSCs. This ratio has been previously 
used in the lab in 3D assays, where it was shown that MSCs promoted 
the growth of MCF-7 cells.  
5.2.2.1 Tumour growth and metastasis 
The MCF-7 cells, implanted alone in the MFP, established tumours at the 
beginning of the study and then the tumour growth reached a plateau 
(Figure 72A-B), but as before, the tumours did not grow well. Bigger 
tumours were formed and the growth was significantly promoted when 
the MSCs were co-implanted with the MSCs, as assessed by a two-way 
ANOVA test (Figure 72). At the end of the study the mice were imaged 
after intermediate dissection in order to detect any signal in metastatic 
sites. The lymph nodes and spleens were removed and imaged 
individually. No signal, indicating metastasis, was detected in the 
spleens, lymph nodes or other sites (data not shown).   
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Figure 73. Tumour formation and tumour growth of bioluminescent 
MCF-7 cells in MFP mouse models. A. Tumour volumes (mm3) in 
group 1 (MCF-7 alone) and group 2 (MCF-7 + MSCs). B. Bioluminescent 
imaging (total flux; photons/second) in group 1 and group 2 as measured 
after administration of D-luciferin. Each bar represents the average 
volume (A) or average total flux (B) ± SEM. N=3 per group. Statistical 
analysis was performed with two-way Anova. *P0.05, **P0.01 and 
***P0.001. C. Representative image of bioluminescent imaging showing 
mice 1-6 (from left to right); mice 1-3 = group 1 and mice 4-6= group 2. 
The colour scale ranged from 2.10x107 (blue) to 1.93x109 (red).  
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5.2.2.2 Ex vivo analysis of EMT traits 
In order to check whether EMT was induced, or changes in the 
expression of the reporter markers were detected, the xenografts were 
stained with E-cadherin, Vimentin and S100A4. At the same time, the 
tumour histology was examined. The gene expression of E-cadherin and 
Vimentin was also analysed in the available xenografts. The gene 
expression of S100A4 was not analysed, because of the lack of primer 
sequences that allow species-specific detection of S100A4, as there is a 
high homology between the mouse and the human gene (93% homology 
according to http://atlasgeneticsoncology.org/).  
5.2.2.2.1 E-cadherin protein and gene expression 
As shown in Figure 73, the xenografts from group 1 (MCF-7 cells only, 
Figure 73A-C) were composed of few cancer cells and contained large 
areas of necrosis, while the xenografts from group 2 (MCF-7 with MSCs, 
Figure 73D-F) were composed mainly of cancer cells (Figures 73, 75, 76 
and 78).  
The xenografts were stained with anti-human E-cadherin or an isotype 
control to detect any unspecific/background staining. No background 
staining was observed (see appendix 14 for pictures of the isotype 
controls). The cancer cells in xenografts from group 2 had lower 
expression of E-cadherin compared with the cells in xenografts from 
group 1 (Figure 73D-F). The gene expression of the available xenografts 
from group 2 was analysed and compared with the gene expression of 
E-cadherin of the bioluminescent MCF-7 cells. The gene expression in 
the xenografts 4 and 5 was 6 and 5 times lower than the expression of 
the MCF-7 cells accordingly (Figure 74); an effect that was greater than 
when the MCF-7 cells were implanted in the MFP alone (Figure 65). In 
summary, co-implanting MSCs with MCF-7 resulted in lower E-cadherin 
expression, both at the gene and protein levels.  
 
 
 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A D 
B E 
C F 
Figure 74. IHC analysis of E-cadherin in MCF-7 mouse xenografts. A-
C. Xenografts from mice 1-3 (Group 1; MCF-7 alone). D-F. Xenografts 
from mice 4-6 (Group 2; MCF-7 + MSCs).  
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5.2.2.2.2 Vimentin protein and gene expression 
The xenografts were stained with anti-human Vimentin, or an isotype 
control. No background staining was observed (see appendix 15 for 
pictures of the isotype controls). While none of the xenografts from group 
1 expressed Vimentin (Figure 75A-C), patches of strong Vimentin 
expression was observed in all the xenografts from group 2 (Figure 75D-
E). To ensure that Vimentin was expressed by the tumour cells (MCF-7) 
and not by any residual MSCs, staining on sequential sections of 
Vimentin and Cytokeratin, which reacts with human breast epithelial 
tissue [186], was performed. The antibody used reacts with both luminal 
and basal cytokeratins including CK5, CK6, CK8, CK17 and possibly 
CK19. The matched pictures are shown in Figure 76. It is shown that 
Vimentin staining is localised in areas that were also stained with 
cytokeratin, confirming that Vimentin was expressed in the tumour cells.  
 
M
C F
-
7 /
fL
u
c
X e
n
o
g r
a f
t  4
X e
n
o
g r
a f
t  5
0
2
4
6
8
1 0
1 2
G
e
n
e
 
e
x
p
r
e
s
s
io
n
 
(2
-
' C
T
)
Figure 75. E-cadherin gene expression in mouse xenografts and 
control cells (bioluminescent MCF-7 cells). Bars represent the average 
2-¨&7 values and lower and upper limits as follows: MCF-7/fLuc = 10.22 
xenograft 4 = 1.64 and xenograft 5 = 1.91. N=1. 
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Figure 76. IHC analysis of Vimentin in mouse xenografts. A-C. 
Xenografts from mice 1-3 (Group 1; MCF-7 alone). D-F. Xenografts from 
mice 4-5 (Group 2;MCF-7 + MSCs).  
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A B 
C D 
F G 
Figure 77. Matched pictures of IHC staining of Vimentin and 
Cytokeratin in mouse xenografts. A. Vimentin staining in xenograft 4. 
B. Cytokeratin staining in xenograft 4. C. Vimentin staining in xenograft 
5. D. Cytokeratin staining in xenograft 5. F. Vimentin staining in xenograft 
6. G. Cytokeratin staining in xenograft 6.  
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The gene expression of Vimentin was higher in xenografts 4 and 5 (group 
2) compared to the control cells (in vitro-cultured MCF-7/fLuc cells) 
(Figure 77). The expression was 76 times higher in xenograft 4, and 165 
times fold higher in xenograft.  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2.2.3 S100A4 protein expression 
The xenografts were also stained with anti-human S100A4 or a control 
antibody. No background staining was observed (see appendix 16). No 
staining was observed in the xenografts from group 1 (Figure 22A-C). 
Most of the cells from the xenografts in group 2 expressed S100A4 
(Figure 78D-F). The staining was nuclear, cytoplasmic and membranous.  
 
In summary, MSCs promoted tumour growth of MCF-7 cells and induced 
EMT-like traits, including lower expression of E-cadherin, and higher 
expression of Vimentin and S100A4. On the other hand, MSCs did not 
result in metastasis. This model would be ideal to test the activity of the 
EMT reporters in vivo. Unfortunately, for reasons that were not in the 
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Figure 78. Vimentin gene expression in Xenografts and control 
(bioluminescent MCF-7 cells). Bars represent the average 2-¨&7 values 
and lower and upper limits as follows: MCF-7/fLuc = 0.0076, xenograft 
4 = 0.5627 and xenograft 5 = 1.2740. N=1. 
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DXWKRU¶VFRQWUROWKH0)-1 nude mice were no longer available for use. 
Therefore the study was repeated in a different mouse strain, in an 
attempt to generate similar data.  
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C F 
Figure 79. IHC analysis of S100A4 in mouse xenografts. A-C. 
Xenografts from mice 1-3 (Group 1; MCF-7 alone). D-F. Xenografts from 
mice 4-6 (Group 2; MCF-7 + MSCs).  
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5.2.3 Bioluminescent MCF-7 tumour EMT / metastasis pilot in an 
orthotopic mammary fatpad (MFP) model ± Rag2-/- ȖF-/- mice  
This study was performed in order to test whether the data produced in 
the nude mice would also be observed in the Rag2-/- ȖF-/- mice, before 
proceeding to test the EMT reporters. As previously, the mice received 
oestrogen. 
5.2.3.1 Tumour growth and metastasis 
The bioluminescent MCF-7 cells were implanted in the MFP site of the 
mice either alone or with MSCs at the same cell number and MCF7:MSC 
ratio used before. The tumour formation and growth was monitored by 
calliper measurements and bioluminescent imaging every 1-2 weeks as 
before. As shown in Figure 79, the MSCs had an effect on tumour 
formation/growth very early in the study. An increase in the tumour 
volumes and bioluminescent signal was observed early in the study 
(around day 20) (Figure 79). The bioluminescent signal in group 2 then 
reached a plateau until the end of the study, while a drop in the signal in 
group 1 was observed by the end of the study. A drop in the tumour 
volumes was observed in both groups.  In other words, the tumours did 
not grow well and metastasis was not observed.  
5.2.3.2 Ex vivo analysis of EMT traits 
The expression of E-cadherin, Vimentin and S100A4 was analysed in the 
xenografts by IHC. 
5.2.3.2.1 E-cadherin protein expression 
E-cadherin expression was detected in all the xenografts from both 
groups (Figure 80). The effect observed before (lower E-cadherin 
H[SUHVVLRQ LQ WKH ³0&)-06&V´JURXSZDVnot reproduced in this 
study. For the isotype controls see appendix 17. 
5.2.3.2.2 Vimentin protein expression 
The xenografts were stained for Vimentin. A positive control was included 
in the analysis to ensure that the staining was successful (Figure 81A). 
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No Vimentin expression was detected in either of the xenografts (Figure 
81C-E). The effect observed before (higher expression of Vimentin in the 
³0&)-  06&V´ JURXS ZDV QRW REVHUYHG ZLWK WKLV PRGHO )RU WKH
isotype controls see appendix 18. 
5.2.3.2.3 S100A4 protein expression 
The xenografts were stained for S100A4. A positive control was included 
in the analysis to ensure that the staining was successful (Figure 82A). 
No S100A4 expression was detected in either of the xenografts (Figure 
82C-E). The effect observed before (upregulation of 6$LQWKH³0&)-
  06&V´ JURXS ZDV QRW UHSURGXFHG LQ WKLV VWXG\ )RU WKH LVRW\SH
controls see appendix 19. 
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Figure 80. Tumour formation and tumour growth of bioluminescent 
MCF-7 cells in MFP mouse models. A. Tumour volumes (mm3) in 
group 1 (MCF-7 only) and group 2 (MCF-7 + MSCs). B. Bioluminescent 
imaging (total flux; photons/second) in group 1 and group 2. Each bar 
represents the average volume (A) or average total flux (B) ± SEM. N=2 
per group. Statistical analysis was performed with two-way Anova. 
*P0.05 and **P0.01.  
175 
 
In summary, MSCs did not induce any EMT-like traits in the xenografts 
formed in this strain of mice. Furthermore, the growth promotion effect 
observed in this study was not as great as observed before (Figure 72). 
This confirms that the EMT-like traits observed in the study with the MF1 
nude mice, were associated with MSC-induced tumour growth. As in the 
study with the MF1 nude mice an effect of the MSCs on tumour growth 
was observed at the early stages of the study (Figure 72), it was 
hypothesised that the MSCs may have depleted early in the study and 
therefore did not promote tumour growth. Thus, an additional study was 
designed in which MSCs would be co-implanted with the MCF-7 and 
LQMHFWHGDJDLQDIHZGD\VDIWHUWKHLQLWLDWLRQRIWKHVWXG\³06&VERRVW´ 
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Figure 81. IHC analysis of E-cadherin in mouse xenografts. A-B. 
Xenografts from mice 1-2 (Group 1; MCF-7 alone). C-D. Xenografts from 
mice 3-4 (Group 2; MCF-7 + MSCs).  
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E 
Figure 82. IHC analysis of Vimentin in mouse xenografts. A. Positive 
control (xenograft 6, Figure 81A). B-C. Xenografts from mice 1-2 (Group 
1; MCF-7 alone). D-E. Xenografts from mice 3-4 (Group 2; MCF-7 + 
MSCs).  
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E 
Figure 83. IHC analysis of S100A4 in mouse xenografts. A. Positive 
control (MDA-MB-231 xenograft from a study performed in house). B-C. 
Xenografts from mice 1-2 (Group 1; MCF-7 alone). D-E. Xenografts from 
mice 3-4 (Group 2; MCF-7 + MSCs).  
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 $VVHVVLQJ WKH HIIHFW RI ³06&V ERRVW´ LQ D bioluminescent 
MCF-7 tumour EMT / metastasis pilot in an orthotopic mammary 
fatpad (MFP) model ± Rag2-/- ȖF-/- mice 
 
This study aimed to overcome possible depletion of MSCs early in the 
study by injecting MSCs both at initiation and at later stages. Here, 
bioluminescent imaging was performed immediately after initiation of the 
study (rather than a week later as previously) to better determine the 
timing of the effect of MSCs.   
5.2.4.1 Tumour growth and metastasis 
Bioluminescent MCF-7 cells were co-implanted in the MFP of Rag2 mice 
as before. An equal amount of MSCs, as implanted initially, was injected 
in the mice at day 21. Tumour establishment and tumour growth was 
monitored by measuring the tumour volumes and bioluminescent signal. 
The tumours established early in the study and then reached a plateau, 
as indicated by the bioluminescent imaging (Figure 83A&C). Apart from 
GD\ZKHUH WKHVLJQDOZDVXQH[SHFWHGO\KLJKHU LQ WKH ³0&)-7/fLuc 
only group), there was significant different between the two groups, as 
assessed by a two-way Anova test (Figure 83A). Furthermore, there was 
no significant difference in the tumour volumes between the two groups 
(Figure 83B). Looking at the individual tumour volumes (Figure 83D) only 
the tumour in mouse 6 from the ³0&)-I/XF06&V´JURXSZDVJUHZ
substantially throughout the study. It is worth noting, there is a variation 
in the tumour YROXPHV LQ WKLV JURXS DV RSSRVHG WR WKH ³0&)-I/XF´
group, which might suggest a difference in the effect of MSCs in the 
different mice. At the end of the study, a post-mortem image was taken 
in order to detect any metastasis, but no metastasis was observed. Also, 
the tumours were removed, imaged and weighed. The bioluminescent 
signal was proportional to the tumour weight (Pearson r=0.8247, 
p=0.0118), but no significant difference was observed in either the 
bioluminescent signals or the tumour weights between the two groups 
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(data not shown). In summary, it was shown that the MSCs and the 
³06&VERRVW´GLGQRWKDYHDVLJQLILFDQWHIIHFWRQWXPRXUJURZWK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.4.2 Ex vivo analysis of EMT traits 
The expression of the EMT markers, E-cadherin, Vimentin and S100A4, 
was analysed in the xenografts by IHC.  
 
 
 
 
 
Figure 84. Tumour formation and tumour growth of bioluminescent 
MCF-7 cells in MFP mouse models. A. Bioluminescent measuments 
(total flux; photons/second) as measured after administration of D-
luciferin.  B. Tumour volumes (mm3). Each bar represents the average  
total flux (A) or volume (B) ± SEM. N=4 per group. Statistical analysis was 
performed with two-way Anova. *P0.05, **P0.01 and ***P0.001. C. 
Bioluminescence of individual mice. D. Tumour volumes of individual 
PLFH7KHDUURZLQGLFDWHVWKHGD\RI³06&VERRVW´ 
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5.2.4.2.1 E-cadherin 
E-cadherin expression was detected in all the xenografts from both 
groups (Figure 84). While all the cells within the tumours stained positive 
for E-cadherin, the density of the staining varied within the same 
xenograft i.e. both strong and weak signals were detected in the same 
sample. Furthermore, while in certain xenografts the staining was mostly 
strong (xenografts 1, 2, 3 and 5; Figures 84A, B, C and E), in others the 
signal was mostly weak (xenografts 4, 6, 7 and 8; Figures 384E, F, G, 
and H). No particular difference in pattern/intensity of staining was 
observed between the two groups, showing that MSCs did not a 
substantial effect on E-cadherin expression. Strong staining was also 
observed in xenografts 6; the only one that had the effect of MSCs on 
growth. For isotype controls see appendix 20.  
5.2.4.2.2 Vimentin 
The xenografts were stained for Vimentin. None of the xenografts 
expressed Vimentin (Figure 85), indicating that MSCs did not increase 
the expression of MSCs, as it was detected in a previous study (Figure 
75). A positive control was included, which was successfully stained, 
indicating that the technique worked. For isotype controls see appendix 
21. 
5.2.4.2.3 S100A4 
The xenografts were also stained for S100A4. For isotype controls see 
appendix 22. Expression of S100A4 was detected only in xenograft 6 
(Figure 86F); it was the only xenografts where an effect of MSCs was 
seen (both in tumour growth promotion and S100A4 expression). 
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Figure 85. IHC staining of E-cadherin in mouse xenografts. A-D Mice 
1-4 from group 1 (MCF-7/fLuc). E-H Mice 5-8 from group 2 (MCF-7/fLuc 
+ MSCs).  
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Figure 86. IHC staining of Vimentin in mouse xenografts. A-D Mice 
1-4 from group 1 (MCF-7/fLuc). E-H Mice 5-8 from group 2 (MCF-7/fLuc 
+ MSCs).  
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Summary and discussion 
 
  
A B 
C D 
E F 
G H 
Figure 87. IHC staining of S100A4 in mouse xenografts. A-D Mice 1-
4 from group 1 (MCF-7/fLuc). E-H Mice 5-8 from group 2 (MCF-7/fLuc + 
MSCs).  
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Summary and discussion 
In this chapter, the different in vivo studies were described, which were 
performed in order to assess the tumorigenicity of the BC cell lines, and 
generate a model of EMT and/or metastasis, to assess the activity of the 
S100A4 reporter.  
Initially, the tumorigenicity of the MCF-7 and BT59 cells was tested in 
different implantation sites. There was no significant difference in the 
growth between the two different sites for the MCF-7 cells and the BT549 
cells did not grow. Furthermore, no metastasis was observed. When 
MSCs were co-implanted with MCF-7 in an orthotopic nude model, the 
tumour growth was significantly upregulated and EMT-like traits were 
induced. When BT549 were co-implanted with MSCs, no significant 
tumour growth promotion was observed. In the Rag2 model, neither 
promotion of tumour growth was observed or EMT-like traits. It was 
hypothesised that the MSCs were depleted early in the study; therefore, 
DGLIIHUHQWVWXG\LQZKLFKD³06&VERRVW´ZDVLQFOXGHGZDVSHUIRUPHGLQ
the Rag2 mice. Here, no growth promotion was observed, but S100A4 
expression was detected in a particular xenograft, which was the biggest 
DQGEHORQJHGWRWKH³0&)-I/XF06&V´JURXS 
In the different studies, variation in the tumour growth was observed both 
between and within the different groups. In some cases, growth was only 
observed in a particular mouse. One possible explanation for this is the 
difference in the amount of oestrogen uptake by the mice. As explained 
earlier, oestrogen supports the tumour growth of MCF-cells [180]. In our 
studies the oestrogen (estradiol) was included in the diet; therefore, 
difference in the amount of food consumed by each mouse would result 
in differences in the oestrogen uptake. The reason for choosing to give 
the oestrogen in the diet rather than in the form of a pellet was based on 
previous experiments performed in house that showed that 
administration of estradiol resulted in well-documented side effects such 
as bladder calculi and urine scald. Another difference that could explain 
the variation in the results, concerns the technicality of implanting the 
cells in the MFP site.  In our studies, the cells were implanted into the 4th 
185 
 
mammary fad pad located in the abdomen, which is the most common 
technique used. This approach is based on the rationale that the 4th 
mammary pad is the largest and relatively easy to access, and is thus 
being assumed that the cells will be successfully implanted in the MFP. 
This technique is not guided by a microscope as opposed to an orthotopic 
implantation under direct vision (ODV), and can miss the targeted MFP 
entirely, resulting in intradermal, subcutaneous or intramuscular 
implantation [101].  
While MSCs promoted the tumour growth of MCF-7 cells in MF1 nude 
mice, they did not promote tumour growth in the Rag2 mice. The role of 
MSCs in tumour progression per se is controversial (reviewed in [187]). 
Many studies have shown that MSCs promote the tumour growth and 
metastasis of BC [72, 74, 184, 188], but inhibition of tumour growth has 
also been reported [189]. MSCs also induced EMT-like traits in the 
orthotopic MCF-7 models, including downregulation/loss of E-cadherin, 
upregulation of Vimentin, and upregulation of S100A4. MSC-induced 
EMT in BC associated with loss of E-cadherin and upregulation of 
Vimentin have been demonstrated in vitro [73]. To our knowledge, this is 
the first study in which hMSCs were co-implanted with MCF-7 cells and 
loss of E-cadherin and upregulation of Vimentin was observed. 
Furthermore, we showed that the MSCs increased the expression of 
S100A4, which plays an early role in EMT [121], and this was 
accompanied (in the case of nude mice) with the loss of E-cadherin and 
Vimentin. In the Rag2 mice, upregulation of S100A4 was only observed 
in one mouse WKDWEHORQJHGWRWKH³06&VJURXS´ZKLFKDJDLQLQGLFDWHG
MSC-induced expression of S100A4. In this case, no other EMT-like 
traits were observed, suggesting that the cells were maybe in an early 
stage of undergoing EMT.  
In summary, it was shown that MSCs have the ability to promote the 
tumour growth of MCF-7 cells and/or induce EMT-like like traits (loss of 
E-cadherin, upregulation of Vimentin and upregulation of S100A4), when 
co-implanted in the MFP of nude mice. MSCs can act as a progenitor for 
CAFs which are characterised by the expression of S100A4 [34]. 
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Induction of EMT in MCF-7 cells by CAFs associated with loss of E-
cadherin and acquisition of Vimentin has been previously reported [167, 
190]. Therefore, based on the findings, we propose that MSCs generated 
CAFs expressing S100A4 (and hence the S100A4 expression), which in 
turn induced EMT-like traits (E-cadherin downregulation/loss and 
upregulation of Vimentin).  
The S100A4 reporter will be tested in an orthotopic MCF-7 model, in 
which MSCs will be co-implanted and later injected in the study.  
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CHAPTER 6: RESULTS 4 ± Assessing the activity 
of the EMT reporter in vivo 
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This chapter describes the assessment of the in vivo activity of the 
S100A4 and its refinement.  
The activity of the reporter had been validated in MCF-7 and BT549 cells 
in in vitro models, under hypoxic conditions (Chapter 3). It was shown 
that S100A4 expression was upregulated under hypoxia and that the 
bioluminescent signal was also upregulated. In chapter 5, a number of in 
vivo studies were performed, in order to identify a model of EMT and/or 
metastasis or a model where changes in the S100A4 expression would 
be detected. It was shown that co-implanting the MSCs with the MCF-7 
cells in an orthotopic nude mouse model resulted in tumour growth 
promotion and induction of EMT-related traits, including upregulation of 
S100A4 expression. In Rag2 mice, expression of S100A4 was observed 
only in one xenograft, which belonged to the group in which MSCs were 
co-implanted and injected later in the study. The particular xenograft was 
also the biggest. Since the nude mice were not available to use, the study 
here was performed using the Rag2 mice, where MSCs were co-
LPSODQWHGZLWK06&VDQGDQ³06&VERRVW´ZDVUHFHLYHGDVEHIRUH 
The model was designed in way that the tumour growth and the activity 
of the S100A4 reporter was validated in the same mouse at different 
times, which avoids the need to sacrifice multiple groups of mice at 
different end-points; hence, the total number of animals needed is 
reduced. The tumour growth was monitored by fluorescent readings and 
the activity of the reporter was monitored by bioluminescent readings. 
The model was assessed by correlating the fluorescent and 
bioluminescent signal with the tumour volume. The activity of the reporter 
was assessed by measuring the bioluminescent signal and comparing 
with the ex vivo analysis of the S100A4 expression. To assess whether 
the reporter detected changes in EMT, ex vivo analysis of EMT markers 
was performed and this was correlated with reporter activity.  
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6.1 Design of the model 
The MCF-7 cells expressing the S100A4 reporter were transduced with 
a lentiviral vector constitutively expressing the fluorescent marker 
mCherry (pLVX-CMV-mCherry) and stable transductants were selected 
by Flow Cytometric Cell Sorting. The resulting cell line will be referred as 
³0&)6$-I/XFP&KHUU\´7KHFRQVWLWXWLYHH[SUHVVLRQRIP&KHUU\
allowed the tumour growth to be monitored. The activity of the S100A4 
reporter was monitored by bioluminescent imaging. The cell line (2x106 
cells /mouse) was co-implanted in the MFP of Rag2 mice with or without 
MSCs (1x106 FHOOVPRXVHDQGWKHPLFHUHFHLYHGD³06&VERRVW´[6 
cells/ mouse), as before. 
For more accurate readings, the images were adjusted to remove excess 
autofluorescence and the background fluorescent signal was subtracted 
from the signal in the tumours (Figure 87A). Occasionally, the resulting 
signal had a negative value. This was due to the fact that the machine 
generated artifacts when the values of the tumour and background signal 
were similar. The negative values were included in the graphs as zero. 
Following fluorescent imaging, the mice received D-luciferin and the 
bioluminescence signal was measured, to assess the activity of the 
reporter. A representative image showing fluorescent and bioluminescent 
images in the same mice is shown in Figure 87. 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Background 
Figure 88. Fluorescent and bioluminescent readings. A. Fluorescent 
measurements. Each circle represents the regions for measuring tumour 
signal and the dotted circle shows the background signal. B. 
Bioluminescent readings of the same group. Each circle represents the 
regions for measuring signal. Scale=total flux (p/s) 
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6.2 Tumour growth 
Tumour establishment and growth was monitored by fluorescent imaging 
and calliper measurements. At the beginning of the study, a discrepancy 
in the signal was observed between the two groups but no significant 
difference was observed between the two groups throughout the study 
(Figure 88A).  An increase in the fluorescent signal was observed at the 
beginning of the study (from day 7 to day 14) in both groups, then reached 
a plateau, increased at day 62 and then remained the same until the end 
of the study (Figure 88A). The average fold increase in the signal at the 
end of the study compared to day 7 was 11.7 (16.5 compared to day 0). 
Similar to the fluorescent signal, the tumour volumes increased at the 
beginning of the study, and then reached a plateau, then started to 
increase again (Figure 88B). Unlike the fluorescent signal, the tumour 
volumes kept increasing until the end of the study. The average fold 
increase in the volume at the end of the study compared to day 7 was 
13.5. No significant difference was observed between the two groups as 
assessed by a two-way Anova test. Looking at the individual mice, the 
fluorescent signal was similar between and within the groups (Figure 
89A). The tumour volumes of individual mice in group 1 ranged from 
13.5mm3 (mouse 3) to 167.4mm3 (mouse 1) (Figure 89B). A bigger 
variation was observed in group 2, where extremely low volumes were 
observed in mice 5 and 6, but big tumour volumes were observed in mice 
7 and 8. It is worth noting that in that the higher fluorescent signal and 
higher tumour volumes were observed in these mice (7 and 8), both of 
which belonged to the group in which MSCs were co-implanted (Figure 
89).  The tumour volumes were measured weekly, but for direct 
comparisons between the volume and the signal, only specific points are 
shown in the graphs.  
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Figure 89. Tumour formation and tumour growth of the reporter line 
in MFP mouse models. A. Fluorescent measuments (total flux; 
photons/second) B. Tumour volumes (mm3). Each bar represents the 
total flux (A) or volume (B) ± SEM. N=4 per group. Statistical analysis 
was performed with two-way Anova. *P0.05, **P0.01 and ***P0.001. 
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Figure 90. Tumour formation and tumour growth of the reporter 
line in MFP mouse models in individual mice. A. Fluorescent 
measurements (total flux; photons/second). B. Tumour volumes (mm3) 
in individual mice. Each point represents the total flux (A) or volume (B) 
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6.3 Measuring reporter activity  
The bioluminescent signal increased in the beginning of the study and 
then reached a plateau (Figure 90). Significant difference in the 
bioluminescent signal was observed only at day 96 (Figure 90A). The 
average fold increase in the signal at the end of the study compared to 
day 7 was 8.6 (71.3 compared to day 0). Looking at the readings from 
individual mice (Figure 90B), there was a peak in the signal in all the mice 
from group 2 at day 96, which dropped by the next imaging.  
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Figure 91. Bioluminescent readings measuring reporter activity. A. 
Average readings in group 1 and group 2. Each point represents 
average total flux ± SEM. N=4 per group. Statistical analysis was 
performed with two-way Anova. *P0.05, **P0.01 and ***P0.001. B. 
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6.4 Assessing/refining the model 
6.4.1 Correlation between tumour volumes and fluorescent signal 
As all the cells constitutively express mCherry, the fluorescent signal 
should serve as an indicator of tumour growth. To validate this, the 
relationship between the signal and the tumour volume was examined. A 
significant positive correlation was observed in mice 1, 2, 3, 7 and 8, as 
DVVHVVHGE\WKHSHDUVRQ¶VFRUUHODWLRQWHVW)LJXUH91A-C, G & H).  
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Figure 92. Correlation of fluorescent signal and tumour volume. 
Each point represents the tumour volume and fluorescent signal at different 
time-points throughout the study. A-H. Mice 1- U SHDUVRQ¶V FRUUHODWLRQ
coefficient. N=9 (overlapping values appear as single dot). ns=not significant.  
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When assessing this relationship in all mice from both groups at different 
time points a positive correlation between the fluorescent signal and the 
tumour volumes was only observed at on day 49 (Figure 92A) and day 
104 (Figure 92B). No significant correlation was detected in the other time 
points (data not shown). At day 49, a drop in the signal (Figure 92C) and 
an increase in the tumour volumes (Figure 92D) was observed. At day 
104, there was no change in the signal or tumour volumes compared to 
previous measurements (Figure 92C-D). 
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Figure 93. Correlation between fluorescent signal and tumour 
volume at different time points. A. Correlation analysis at day 49. B. 
Correlation analysis at day 104. Each point represents a different mouse. 
N=8. r=pearson correlation coefficient. p=P value.The days are pointed 
by the black arrows in the fluorescent (C) and tumour volume (D) graphs.  
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6.4.2 Correlation between tumour volumes and bioluminescent 
signal 
In previous chapters, it was shown that the bioluminescent signal of the 
cells expressing the S100A4 reporter was proportional to the cell number. 
Therefore, we wanted to assess whether the signal would change 
proportional to tumour growth. It was anticipated that the bioluminescent 
signal would not correlate with tumour volume upon activation of the 
reporter, since this would be independent of cell number and hence 
tumour volume (if tumour volume is an indicator of cell number). A 
significant positive correlation was observed between the signal and the 
tumour volumes in mice 1, 2, 8 and 9 (Figure 93A, B, G & H). No 
correlation was observed in mice 3, 4 and 6 (Figure 93C, D and F), while 
a negative correlation was observed in mouse 5 (Figure 93E). When 
assessing this relationship in all mice from both groups at different time 
points, a positive correlation between the bioluminescent signal and the 
tumour volumes observed in most days throughout the study, apart from 
day 7, day 35 and day 96 (Figure 94). At day 96, the signal in the group 
where MSCs were co-implanted was significantly higher than the group 
where the reporter cells were implanted without MSCs. This could imply 
that the reporter was activated, and therefore a relationship between the 
tumour volume and the signal would not be expected, as the reporter 
activity is not dependent on cell number.  
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Figure 94. Correlation of bioluminescent signal and tumour volume 
in individual mice. A-H. Mice 1-8. Each point represents the tumour 
volume and fluorescent signal taken on the same day throughout the 
study. N=9. r=pearson correlation coefficient. p=P value. ns=not 
significant. 
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Figure 95. Correlation between bioluminescent signal and tumour 
volume at different time points. Correlation analysis at day 14 (A), day 
21 (B), day 27 (C), day 49 (D), day 62 (E) and day 104 (F).  Each point 
represents a different mouse. N=8. r=pearson correlation coefficient. 
p=P value. The days are pointed by the black arrows in the 
bioluminescent (G) and tumour volume (H) graphs.   
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6.4.3 Correlation of reporter activity and S100A4 expression 
As shown by the bioluminescent readings, the bioluminescent signal was 
VLJQLILFDQWO\KLJKHULQWKH³0&)-7/S100A4-I/XFP&KHUU\06&V´group 
at day 96 (Figure 90A), which was not proportional to the tumour volume 
(Figure 94). An increase in the signal was observed in all the mice from 
this group on that day (Figure 90B). It was hypothesised that the reporter/ 
S100A4 gene was activated at this point. Although the signal was not 
LQFUHDVHGLQWKH³0&)-7/S100A4-I/XFP&KHUU\´JURXSRQWKDWGD\KLJK
signals were detected in mouse 1 and 2 throughout the study. To 
determine whether the S100A4-generated signal correlated with the 
expression of S100A4, the protein levels of S100A4 in the xenografts 
were analysed by IHC and correlated with the latest bioluminescent 
readings. Staining was observed in all xenografts apart from xenografts 
5 and 7 (Figure 95). For the isotype controls see appendix 23. While 
substantial staining was observed in some xenografts (e.g. xenograft 9; 
Figure 95A) only a few cells were stained in others (e.g. xenograft 15; 
Figure 95G). On the other hand, expression of S100A4 was not restricted 
to the group where MSCs were co-implanted, implying that the 
expression of S100A4 was not due to MSCs (or MSC-induced EMT). 
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Figure 96. IHC staining of S100A4 in mouse xenografts. A-D Mice 1-
4 from group 1 (MCF-7/S100A4-fLuc/mCherry). E-H Mice 5-8 from group 
2 (MCF-7/S100A4-fLuc/mCherry + MSCs). 
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C D 
E F 
G H 
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7KHDUHDVZKHUHVWDLQLQJZDVGHWHFWHGZHUHFDOOHG³S100A4 KRWVSRWV´
and they were used for scoring the expression of S100A4. The 
expression of S100A4 was determined by measuring the number of 
stained cells (number of features), using semi-automated quantitative 
computer assisted image analysis. The hotspots were detected using the 
LEICA DMLB microscope and the image analysis was performed using 
the Qwin programme (version 3.5.1). The picture was taken, the negative 
and positive areas (blue and brown respectively) were manually selected 
(example shown in Figure 96A-C), and the programme generated an 
output for the number of positive cells and other information (e.g. area of 
cells). During the selection of positive and negative areas, false positive 
data (e.g. dark blue cells and dirt) were manually excluded from the 
analysis and false negative data (brown cells not selected by the 
programme) were manually included in the analysis. For more accurate 
results the size (area) of the features was calculated (example shown in 
Figure 96D). We estimated that anything with a size less than 20µm2, 
was not a cell but an artifact, and excluded from the analysis. 
The total QXPEHURIVWDLQHGFHOOVLQWKH³S100A4 KRWVSRWV´ZDVFDOFXODWHG
for each xenograft (Table 11) and correlated to the bioluminescent signal 
detected in the last day of the study (day 104). A strong positive 
correlation was observed between the bioluminescent signal and the 
number of cells stained positive for S100A4, as assessed by the 
SHDUVRQ¶V FRUUHODWLRQ WHVW )LJXUH 97). This indicated that the reporter 
could detect the levels of S100A4 expression at protein levels.  
The number of hotspots varied between the xenografts (Table 11) and 
the proportion of stained to unstained cells within the hotspots was 
extremely low (varied from 0.0002% to 0.05% as estimated using the 
ImageScope programme). This would suggest that the reporter can 
detect small number of cells expressing S100A4..   
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Table 11. Expression of S100A4. Table shows the total number (sum) 
RI VWDLQHG FHOOV LQ WKH ³(07 KRWVSRWV´ IRU HDFK PRXVH [HQRJUDIW DV
calculated by a semi-automated quantitative computer assisted image 
analysis7KHQXPEHURI³(07 KRWVSRWV´YDULHGEHWZHHQWKH[HQRJUDIWV
from 1 to 5.  
 
Xenograft Total number of 
stained cells 
Number of hotspots 
1 114 3 
2 90 2 
3 5 1 
4 20 1 
5 0 0 
6 27 3 
7 0 0 
8 128 5 
 
 
 
A B 
C D 
385µm2 
59µm2 
105µm2 
95µm2 
487µm2 
15µm2 
26µm2 
28µm
35µm2 
86µm2 87µm2 
109µm2 
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6.4.6 Assessing EMT in the model 
In order to assess whether the reporter could detect EMT-related traits, 
the xenografts were stained for E-cadherin and Vimentin. For the isotype 
controls see appendices 24-25. Expression of E-cadherin was detected 
in all xenografts (Figure 98). The H-scores were calculated as described 
in chapter 5. No significant difference was observed between the two 
groups (Figure 99), as assessed by an unpaired t-test. Furthermore, 
there was no correlation between the S100A4 expression and the E-
FDGKHULQH[SUHVVLRQDVDVVHVVHGE\DSHDUVRQ¶VFRUUHODWLRQWHVW)LJXUH
100). Finally, no Vimentin expression was detected (Figure 101). In 
summary, no difference in the expression of the EMT markers (S100A4, 
E-cadherin and Vimentin) was observed between the two groups, 
indicating that MSC-induced EMT was not present at termination. 
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Figure 98. Correlation of bioluminescent signal from the S100A4 
reporter and S100A4 expression. Each point represents the signal at 
day 104 or number of positive cells for a particular mouse/xenograft 
(Table 11). 1 SHUJURXS U SHDUVRQ¶VFRUUHODWLRQcoefficient. p=P 
value.  
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Figure 99. IHC staining of E-cadherin in mouse xenografts. A-D Mice 
1-4 from group 1 (MCF-7/S100A4-fLuc/mCherry). E-H Mice 5-8 from 
group 2 (MCF-7/S100A4-fLuc/mCherry + MSCs).  
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Figure 100. E-cadherin H-score. Each bar represents the average H-
score for E-cadherin as detected by IHC and calculated using 
ImagScore for each group ± SEM. N=4 per group.  
0 5 0 1 0 0 1 5 0
0
5 0
1 0 0
1 5 0
N u m b e r o f s ta in e d  c e lls   (S 1 0 0 A 4 )
H
-
s
c
o
re
 
(E
-
c
a
d
h
e
ri
n
)
Figure 101. Correlation between E-cadherin and S100A4 
expression. Each point represents the H-score for E-cadherin and the 
corresponding number of stained cells for S1004 (Table 1) in each 
mouse xenografts. N=8 (4 per group).  
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Figure 102. IHC staining of Vimentin in mouse xenografts. A-D Mice 
1-4 from group 1 (MCF-7/S100A4-fLuc/mCherry). E-H Mice 5-8 from 
group 2 (MCF-7/S100A4-fLuc/mCherry + MSCs).  
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Summary and discussion 
In this chapter the activity of the S100A4 reporter was validated in an 
orthotopic MCF-7 mouse model, and the model itself was assessed. 
The model was designed to assess whether a fluorescent reporter could 
be used to measure tumour growth and to monitor the activity of the 
reporter by bioluminescent readings. It was shown that the fluorescent 
readings did not correlate with the tumour volume throughout the study, 
indicating that the fluorescent readings might not be very reliable for 
measuring tumour growth. The most possible explanation for this is the 
decrease sensitivity of the fluorescent measurements due to high 
autofluorescence. Autofluorescence is an intrinsic property of the cells; 
fluorescence emission arises from endogenous fluorochromes, such as 
NAPDH and Flavin [191]. In tissues, the autofluorescence originates 
mostly from the extracellular matrix. The molecules that contribute to 
autofluorescence emit fluorescence between 450 and 650nm [192], 
which covers the emission of mCherry used in this study, 620nm. Another 
possible explanation is the fact that dead cells tend to be really bright; a 
phenomenon that has been repeatedly observed in vitro (i.e. the 
apoptotic/rounded/floating cells appear very bright under the 
microscope).  While the fluorescent signal relies on excitation by an 
external light source, the bioluminescent signal does not require 
excitation and hence, the autofluorescence is minimised [116]. The 
bioluminescent signal is therefore a more reliable way to measure tumour 
growth. To minimise the problem of autofluorescence, it is suggested that 
a far-red fluorochrome (mPlum, emission  655nm) is used in future 
studies [193]. Furthermore, a different way of illuminating fluorescence is 
suggested. In this study the fluorescence was illuminated from the top 
(epi-illumination), but the IVIS Spectrum can also illuminate from the 
bottom (trans-illumination). While in epi-illumination the excitation and 
emission reside on the same side of the tissue within the animal, trans-
illumination involves illuminating the tissue from one side and detecting 
the emitted light that has passed [194]. In the latter, the measurements 
come from deep inside the tissue, through which each measurement is 
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an average of the tissue volume sampled by the bulk of tissue through 
which the light has passed. Furthermore, the sensitivity of epi-illumination 
is limited in the ability to probe deep tissues due to scattered light and 
autofluorescence; autofluorescence is mostly absent on trans-
illumination images. The trans-illumination technique became available 
since the study was carried out and therefore could not have been used 
throughout the study.  Another way to refine the model, is to transduce 
the cells with a dual reporter (or two different reporters) expressing 
Renilla and Firefly luciferase; suitable as they have different substrate 
and light output requirements [195].  
Even though the reporter measures the gene levels of S100A4, It was 
shown that the activity of the reporter (as measured by bioluminescent 
readings) correlated with the protein expression of S100A4. Due to the 
high homology between the mouse and human S100A4, it was not 
possible to analyse the gene expression levels. It could be implied that 
the gene was activated when the peak in the signal (at day 96) was 
observed, followed by translation of the protein. On the other hand, 
S100A4 expression (protein levels detected by IHC) was detected in 
xenografts in which this peak was not observed. There was an increase 
in the signal at the beginning of the study, which can imply that S100A4 
was expressed early in the study. Taken together with the data from the 
in vitro studies, it can be concluded with confidence that the S100A4 
reporter can detect the baseline gene expression of S100A4, the 
changes in the gene expression and the changes in protein expression 
both in vitro and in vivo. For more accurate and powerful results, the 
studies should be repeated using more animals, and the ex vivo analysis 
of S100A4 should be performed at early and late stages to capture the 
moment at which S100A4 was expressed. Furthermore, a bigger study 
will allow determining a cut off value for the bioluminescent signal for 
better refining the reporter/model.  
MSCs did not promote the tumour growth and did not alter the expression 
of the EMT markers, E-cadherin and Vimentin, suggesting that EMT was 
not induced. Furthermore, S100A4 expression was observed in 
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[HQRJUDIWVIURPERWKJURXSV³0&)-DORQH´DQG³0&)-7 co-implanted 
ZLWK06&V´VXJJHVWLQJWKDWWKHH[SUHVVLRQZDVnot induced by hMSCs. 
So, is S100A4 a good marker of EMT and is the S100A4 reporter an EMT 
reporter? S100A4 is expressed by tumour cells, immune cells and 
fibroblasts, and has different functions in cancer progression including 
cell regulation of cell motility, angiogenesis, invasion and metastasis 
(reviewed in [119]), and has been used as an early marker of EMT [121]. 
The expression of S100A4 can be induced by different factors involved 
in EMT (e.g. TGFȕDQGDWWKHWUDQVFULSWLRQDOOHYHOLWFDQEHUHJXODWHG
E\ GLIIHUHQW WUDQVFULSWLRQ IDFWRUV HJ ȕ-catenin) [120]. As previously 
discussed, S100A4 is also activated under hypoxic conditions [131, 132], 
and this was also supported by our data that showed upregulation of the 
S100A4 in hypoxic cultures. Therefore, it is clearly shown that the 
expression of S100A4 is regulated by different factors and in order to 
answer the question, further investigation is needed. For example in 
order to investigate whether the S100A4 expression related to hypoxia, 
hypoxia should be assessed in the xenografts and relate to the 
localisation of S100A4 expression. A common way to do this, is by 
injecting pimonidazole hydrochloride to the mice prior to termination, 
which is chemical compound that specifically binds to proteins in hypoxic 
cells and can be detected by IHC [196]. Hypoxia can also be detected by 
staining from HIF-1Į or glucose transporter 1 (Glu-1) [197]. Expression 
of S100A4 in the invasive areas of the tumour in our experiments can 
support the theory that S100A4 detected the EMT-like/early metastatic 
cells but again, this needs further investigation. If indeed the S100A4 
expression is involved in the early stages of EMT, this could explain why 
only a few cells expressed S100A4 and no changes in E-cadherin and 
Vimentin were observed. In vitro and in vivo models of EMT should be 
established and the expression of S100A4 should be correlated with the 
expression of EMT markers and functional assays of EMT (e.g. invasion 
assays) to further refine the model. 
In summary, the activity of the reporter was validated in vitro and in vivo, 
where the S100A4-generated bioluminescent corresponded/ correlated 
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with changes in the gene and protein levels of S100A4. The reporter 
could be potentially used for detecting early stages of EMT or hypoxic 
regions etc., upon further validation/ refinement of the model. 
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CHAPTER 7: DISCUSSION 
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Summary of findings 
EMT is thought to be involved in the early stages of metastatic BC, where 
cells in the invasive border of the tumour undergo EMT which allows them 
to metastasise. It is not clear though when EMT is happening, which cells 
are involved and what happens to those cells after they metastasis, and 
to our knowledge this has not been shown in real-time. This project aimed 
to generate inducible bioluminescent EMT reporters that would allow a 
real-time read-out of EMT in in vivo models, and to improve orthotopic 
and metastatic BC model by incorporating key elements of the tumour 
microenvironment. A bioluminescent EMT reporter could provide 
mechanistic insights to the EMT process and be used to identify potential 
targets against EMT, as well as be used to test drugs targeted at the 
process of EMT and metastasis.  
In summary, an inducible bioluminescent reporter, that measures the 
transcription of S100A4, was constructed and validated in MCF-7 cells 
both in vitro and in vivo, where it was shown that S100A4-generated 
bioluminescence associated/ correlated with S100A4 expression. Upon 
refinement of the in vivo model, the reporter/model could potentially be 
used for imaging the process of EMT and/or metastasis in real-time and 
for testing novel drugs targeted at theVH SURFHVVHV 7R WKH DXWKRU¶V
knowledge no drugs have been developed to target EMT in BC. 
Therefore, the model can be used for testing and monitoring drug 
response in real-time. 
 
Cell lines used: their significance and limitations 
Three main human BC cell lines were used (MCF-7, MDMAB231 and 
BT549) during this study. They were characterised according to the 
expression of EMT markers and CSC population, and, in agreement with 
the literature, MCF- FHOOV ZHUH GHILQHG DV ³HSLWKHOLDO´ ZLWK ORZ &6&
population anG0'$0%DQG%7ZHUHGHILQHGDV³PHVHQFK\PDO´
with high CSC population. These cell lines not only have different EMT 
phenotypes, but they represent different subtypes of BC; MCF-7 belong 
to Luminal and MDAMB231 and BT549 belong to Basal B subtypes [81]. 
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This allowed us to explore the EMT potential (or expression of the 
different EMT and CSC markers) in different in vitro and in vivo 
experiments that will be useful for future studies. For example, it was 
shown that the transcription of the S100A4 reporter was activated in 
MCF-7 and BT549 cells under hypoxic conditions in vitro and in in vivo 
models, but not in MDAMB231. As S100A4 is involved in the early stages 
of EMT, targeting S100A4 in these two cell lines might have therapeutic 
potential. Using cell lines that belong to different subtypes would be 
useful for testing the effects of new drugs targeted at the process of EMT 
and/or metastasis in different stages/subtypes of BC. There are of course 
many other available cell lines that could be used that represent other BC 
subtypes, that have not been explored here, including Basal A subtype 
[81]. The ultimate goal of the study was to develop models that could be 
used for patient-relevant drug testing of novel drugs targeted at the 
process of EMT. But, when using human BC cell lines the question of 
whether established cell lines represent the heterogeneity of human BCs 
still remains controversial. The pros and cons of using cell lines have 
been previously highlighted, and it has been suggested that primary 
cultures are more likely to provide more useful data since they are 
isolated directly from patients and represent the heterogeneity and 
genotype of the human tumours [198]. Indeed, studies have shown that 
when primary tumours are used as an orthotopic xenograft, there is a 
stronger predictive response value compared to cell lines [199, 200]. On 
the other hand, primary cultures are hard to get, are challenging to 
establish due to the high possibility of contamination, they have other 
limitations such as finite lifespan, slow population time, and their genetic 
manipulation is difficult [198].  Therefore, it might prove difficult to 
transduce primary cells with the S100A4 reporter, induce EMT, and 
generate a large amount of these cells for testing them in vivo.  
 
Inducing EMT in vitro and in vivo 
Different methods were attempted to induce EMT in MCF-7 in vitro but 
none of them were successful. Methods that alter a single factor (e.g. 
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overexpression of Twist) were tried, and then experiments that involve 
components of the tumour microenvironment (e.g. 3D cultures) were 
assessed. The techniques used here were an adaptation of the 
techniques used literature where induction of EMT in MCF-7 cells have 
been reported [69, 141, 155, 162, 164, 165, 168], but they were 
unsuccessful most likely because of differences in the cell density, length 
of the assay, dimensionality, and the origin, batch and passage number 
of the cell lines used. The fact that none of the methods worked, even 
those that included components of the tumour microenvironment, 
stresses the need for better models of EMT. EMT-related traits were only 
observed in vivo (co-implantation of MCF-7 and MSCs) in a certain 
setting but not in vitro (co-cultures of MCF-7 and MSCs). While MSCs 
induced tumour growth promotion and EMT-like traits in MF1 nude mice, 
they did not have an effect on MCF-7 cells implanted in the Rag2 mice or 
in MCF-7 cells in in vitro co-cultures. The role of MSCs in tumour growth 
and EMT is controversial. For instance, induction of EMT associated with 
decreased E-cadherin expression and increased expression of Vimentin, 
N-cadherin, Twist and Snail, has been reported in T47D, SK-Br3 and 
MDAMB231 cells co-cultured with MSCs [73], but not in MCF-7 cells 
[201] 7R WKH DXWKRU¶V NQRZOHGJH 06&-induced EMT has not been 
demonstrated in in vivo BC models. 
 
Xenograft models: their significance and limitations 
For the in vivo studies we chose orthotopic xenograft models, as 
orthotopic xenografts have a main advantage over other models (e.g. 
GEM models): they are useful for testing drugs targeting human 
molecules as they use human cell lines [87, 88]. On the other hand, they 
use human cell lines that are have been growing in plastic, which may 
have undergone selection and genetic drift such that they are 
genotypically and phenotypically very distant to real patient tumours. 
Furthermore, the xenografts are performed in immunocompromised mice 
WKDW GRQ¶W SURYLGH D VSHFLHV PDWFKHG 70( DQG WKH JHQHWLFV DQG
histology of the mouse xenografts do not recapitulate those of the human 
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tumours. More realistic pre-clinical models are thought to be achieved by 
grafting fresh cancer tissue (PDX) in immunodeficient mice, as well as by 
using humanised chimeric animals [202]. Such models preserve the 
heterogeneity of the human cancers, and more accurately represent the 
interactions between the cancer cells the TME.  
 
The role of hMSCs and related issues 
In our attempt to include a more relevant TME and humanise the 
xenograft models, we co-implanted human MSCs, but this did not entirely 
solved the issues of the xenograft models discussed above. Regarding 
the effect of MSCs on tumour growth, while certain authors reported that 
MSCs increased the tumorigenicity of BC cells in vitro [74, 188], others 
reported that MSCs inhibited the proliferation of MCF-7 cells [189]. This 
shows that the effects of MSCs on tumour growth are complex and may 
be context-dependent, which is supported by the studies performed in 
this project.  
It has been reported that MSCs promoted tumour growth and metastasis 
through generating an immunosuppressive environment [184], through 
paracrine signalling [72], through cellular interactions [188] and through 
generation of cytokine networks that regulate CSCs [74]. In this thesis, 
MSC-mediated growth and EMT was only observed in nude mouse 
models but not in Rag2 mouse models. A main difference between the 
two mouse strains lies in their immune system; the nude mice lack T cells, 
while the Rag2 mice lack T, B and NK cells and reduced macrophage 
and dendritic cell function [176-178]. As the Rag2 mice are more 
immunocompromised and lack a functional immune system, it would be 
expected that tumour formation (with or without MSCs) would be greater 
in these mice; which was not the case. In order to better understand why 
the MSCs did not have an effect on tumour growth in the certain models 
it is important to elucidate the fate and lifespan of the MSCs; MSCs are 
pluripotent stem cells that have the ability to proliferate and differentiate 
to other cells types when recruited to tumours (e.g. endothelial cells and 
CAFs) (reviewed in [187]). One way to explore this is to use fluorescently 
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labelled MSCs in vivo to image them and detect their location and 
lifespan, and then isolate the cells for further characterisation (e.g. isolate 
the cells with Flow Cytometric Cell Sorting and stain them for different 
cell-specific markers).  
Another point worth considering is the appropriate number/ratio of MSCs 
to use in. In this study 1x106 cells have been implanted in vivo  with MCF-
7 cells (2 MCF-7: 1 MSCs; same ratio in vitro), but others have used 
either more MSCs than MCF-7 (1:3 BC cells: 2 MSCs in co-cultures [73] 
and 1 BC cells: 20 MSCs in vivo [184]) or the same number of MSCs and 
BC cells  (1 BC cells: 1 MSCs in vivo [74]). The number of stromal cells 
recruited to tumours in the clinical scenario is not known; therefore, it is 
not clear what should be the correct number/ ration of cells to use in 
studies of this nature. Studies performed here and by others, 
demonstrate the need for better models to better understand and monitor 
the role, fate and lifespan of MSCs in BC progression.  
 
Using inducible bioluminescence reporters 
The use of optical reporters in this project, allowed imaging of the same 
animal repeatedly at different times, which avoided the need to sacrifice 
multiple groups of mice at different end-points; hence, the total number 
of animals needed was reduced. All in all, this study contributed to 1 of 
WKH5V³5HGXFWLRQ´(http://www.nc3rs.org.uk/).  
In order to visualise the process of EMT in real-time, inducible 
bioluminescent EMT reporters were constructed. While the activity of the 
S100A4 reporter was validated in MCF-7 and BT549 cells in hypoxia, it 
was not possible to validate this reporter in MDAMB231 cells or the E-
cadherin and N-cadherin reporters. As previously discussed, when 
designing such reporters and choosing the setting in which the reporters 
will be validated, it is important to consider the different TFs that bind to 
the promoters and their gene regulation in general. For validating the 
activity of the E-cadherin and N-cadherin reporters, alternative models 
should also be established. Hypoxia was used to validate their activity as 
it regulates their expression through induction of Twist1 [133, 134]. It has 
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been shown though that the methyltransferase SET8 is important for 
Twist-1 induced EMT as it acts as a dual epigenetic modifier on the 
promoters of the E-cadherin and N-cadherin genes   via its H4K20 
monomethylation activity [141]; therefore, overexpression of Twist1 and 
SET8 could be used to induce changes in the genes and for testing these 
reporters.  
 
$³JRRG´(07UHSRUWHU 
Upon validation of the S100A4 reporter in vitro, the reporter was tested 
in vivo, where the S100A4-generated bioluminescent correlated with the 
protein expression of S100A4. While the activity of the reporter was 
validated, the use of a bioluminescent reporter did not allow to 
localisation of the expression of S100A4 (suggested early EMT) in vivo. 
As stated HDUOLHUD³JRRG´(07UHSRUWHUVKRXOGDOORZLGHQWLILFDWLRQRID
small population of cells undergoing EMT in vitro and in vivo and/or 
metastasising in vivo. To overcome this, a fluorescent reporter could be 
developed, which would allow the use of high resolution live-cell imaging 
applications, such as intravital and confocal microscopy and implantation 
of tissue window devices [108]. On the other hand, low levels of EMT/ 
EMT reporter-generated fluorescent and drug efficacy might be difficult 
to detect using these systems; bioluminescence is more sensitive that 
fluorescencet as discussed before.  
None of the reporters generated was validated upon induction of EMT 
either in vitro or in vivo, which stresses the need of determining whether 
WKHUHSRUWHUVDUH³JRRG´(07UHSRUWHUV$³JRRG´(07UHSRUWHUVKRXOG
detect EMT-related traits both in vitro and in vivo, and the subset of cells 
that are undergoing EMT and metastasise.  Upon establishment of EMT 
models, the activity of the reporters should be tested upon induction of 
EMT, by comparing/correlating the EMT/reporter-generated 
bioluminescent with reporter gene expression. As our results showed 
upregulation of Vimentin in in vivo models (and some in vitro models) a 
Vimentin reporter might also be useful for future studies.  
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Future directions 
Future studies will involve repeating the in vivo study, in which MCF-7 
cells were co-implanted with MSCs in MF1 nude mice, as soon as the 
mice become available. The study will aim to repeat/ replicate the data; 
MSC-induced tumour growth and induction of EMT-related traits. Should 
this model of EMT be established, the S100A4 reporter (existing and new 
fluorescent version of the reporter) will be assessed. The activity of the 
reporter will be studied at different time points and be correlated with the 
expression of EMT and CSC markers, to provide a real-time read out of 
S100A4/ early EMT.  
For validation of the reporters in vitro upon induction of EMT, variations 
of the methods used will be attempted, including direct co-cultures of 
epithelial cells with BrCAFs, 3D co-cultures with MSCs or CAFs, and co-
cultures with both MSCs and BrCAFs. In these models different ratios of 
epithelial: stromal cells, and different batches/ sources of stromal cells 
will be explored. Alternative methods will also be attempted for the 
induction of EMT in vitro, such co-cultures with inflammatory cells (e.g. 
TAMs), and inhibition or downregulation of miRNAs (e.g. inhibition of the 
miRNA-200 family); the role of inflammatory cells and miRNAs on EMT 
has been discussed in the introductory chapter. The induction of EMT will 
be tested by assessing the changes in the morphology of the cells, the 
changes in the expression of EMT markers, enrichment of CSCs and 
functional assays (invasion and migration assays). For achieving 
induction of EMT and/or metastasis in vivo, different ratios of epithelial: 
MSCs will be explored and co-implantation with different numbers of 
BrCAFs will be attempted. EMT will be assessed ex vivo by staining for 
EMT and CSC markers (Vimentin, E-cadherin, N-cadherin, Twist, CD44, 
ALDH1 etc.). Furthermore, more BC cell lines will be included in future 
studies covering different clinical BC subtypes, as well as primary cells 
as soon as they become available. Similarly, apart from orthotopic 
xenograft models, the reporters will be tested in PDXs upon availability. 
As mentioned earlier, a fluorescent version of the reporters will be 
constructed and be used for visualising EMT in vitro (by confocal 
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microscope) and in vivo (using the IVIS system initially to test sensitivity 
DQGPRYLQJWRLQWUDYLWDOPLFURVFRS\LQFROODERUDWRUV¶ODE$SDUWIURPWKH
S100A4, E-cadherin and N-cadherin reporters, a Vimentin reporter will 
be constructed and tested and possibly others (e.g. Snail reporter). Other 
than the promoter-based reporters, other types of reporters will be tested 
that are based on post-transcriptional regulatory mechanisms such as 
splicing, miRNA-regulated gene regulation or translational regulation of 
EMT-related genes. For example, a bichromatic fluorescent reporter 
which has been used to detect epithelial to mesenchymal transitions 
[203, 204], which is available for use through a collaboration with Dr 
Sebastian Oltean, can be used to identify EMT in in vitro and in vivo 
models.  Briefly, the reporter is based on the alternative splicing of the 
fibroblast growth factor receptor 2 (FGFR2); in epithelial cells alternative 
cells leads to the expression of FGFR2(IIIb) isoform, while in 
mesenchymal cells it leads to the synthesis of FGFR2(IIIc) isoform. The 
dual reporter (EGFP and RFP) contains the exon IIIc and an intronic 
activator and repressor (ISAR) which activates IIIb and represses exon 
IIIc, in an epithelial-manner; inclusion of IIIc results in a fusion protein in 
frame with EGFP, while skipping this exon results in RFP expression. 
This reporter will be used to visualise and time EMT changes in real-time.  
 
Significance and potential use of S100A4 reporter 
The study aimed to use the S100A4 reporter for imaging the early stages 
of EMT in real-time. The reporter can also be used to provide mechanistic 
insights regarding the pathways and molecules involved. It is suggested 
in the literature that EMT occurs in a subset of tumour cells that acquire 
invasive abilities, enter the circulation and metastasise to distant parts, 
where they revert back through MET. To our knowledge this has not been 
shown in real-time. In vivo studies can be performed to image changes 
in the reporter in real-time, and in which mice will be sacrificed at different 
time points (i.e. when change in reporter activity is observed) for ex vivo 
analysis of EMT, CSC and metastatic markers. This could provide new 
LQVLJKWV DV WR ZKDW LV LQYROYHG LQ WKH GLIIHUHQW VWDJHV RI WKH ³(07-
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metastasis-0(7´SURFHVVBuilding up on this, the reporter could be used 
to identify new prognostic and predictive markers to stratify patients.  
Upon further validation and refinement, the S100A4 reporter can be used 
to identify drugs targeted at the EMT process. Once it is proven that the 
UHSRUWHULVD³JRRG´(07UHSRUWHUDQGin vitro and in vivo models of EMT 
are established, the S100A4 reporter can be used in high-
throughput screening (HTS) drug discovery to identify compounds that 
target EMT, by for example using a small compound library as previously 
reported [83]. It can also be used for testing drugs targeted at EMT. For 
example, the reporter gene and other key genes involved can be knocked 
down (e.g. by shRNA) and effect on EMT and metastasis can be 
evaluated in in vivo models in real-time. Clinically relevant drugs could 
then be developed to target early EMT and therefore metastasis.  
 
Conclusive remarks 
In summary, in this study a potential EMT reporter was constructed and 
validated in an epithelial BC cell line. The different in vitro and in vivo 
experiments performed stressed the need for improved models of EMT, 
and will guide future studies for improving pre-clinical BC models. 
Through the use of inducible reporters such as this EMT reporter, more 
detailed information on the activity of specific biological pathways during 
tumour development drug treatment can be gained, allowing selection of 
the most relevant models to be selected for specific studies. 
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APPENDICES 
 
Appendix 16WXG\SURWRFRO IRU ³Bioluminescent MCF-7 tumour EMT / 
PHWDVWDVLVSLORWLQDQRUWKRWRSLFPDPPDU\IDWSDG0)3PRGHO´ 
 
1. STUDY OBJECTIVE 
Comparison of ability to generate bioluminescent MCF-7 cell primary and 
metastatic growth via different initiation routes with hormone 
supplementation; 
2. REGULATORY GUIDELINES 
This study will be conducted under the UK Home Office Licence number 
PPL 40/3559, 19b (3). NCRI guidelines for the welfare and use of animals 
in cancer research, LASA good practice guidelines and FELASA working 
group on pain and distress guidelines will also be followed. 
3. TEST SUBSTANCE AND VEHICLE DETAILS 
N/A 
4. FORMULATION  
As above 
5. REASON FOR THE CHOICE OF SPECIES, ROUTE OF 
ADMINISTRATION AND DOSE LEVELS 
Immunodeficient mice have been used extensively to generate human 
tumour xenografts and remain the experimental method of choice for 
testing anti-tumour efficacy of new compounds prior to administration in 
man and hence are appropriate for the development and refinement of 
orthotopic models. Female MF-1 nude mice are appropriate due to the 
use of breast cancer cells and bioluminescent reporters. 
6. ANIMALS (species, strain, sex, number, source) 
8 MF-1 female nude mice at 4 to 6 weeks of age will be obtained from 
Harlan (or PRECOS via Harlan). 
6.1 Location of the Study 
The study will be located in the CSU Level 2 containment facility, BSU, 
University of Nottingham.   
6.2 Housing and Environment 
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Mice will be maintained in IVCs (Tecniplast UK) within a barriered unit 
illuminated by fluorescent lights set to give a 12 hour light-dark cycle (on 
07.00, off 19.00), as recommended in the United Kingdom Home Office 
Animals (Scientific Procedures) Act 1986.  The room will be air-
conditioned by a system designed to maintain an air temperature range 
of 21 ± 2ºC and a humidity of 55% + 10%.  
Mice will be housed in social groups during the procedure with irradiated 
bedding and provided with autoclaved nesting materials and 
environmental enrichment.  
6.3 Diet and Water 
Sterile irradiated 2919 rodent diet (Harlan Teklad UK, product code 
Q219DJ1R2) and autoclaved water will be offered ad libitum.   
6.4 Animal welfare 
An experienced technician will check the condition of the mice daily. 
Adverse effects will be noted and reported to the Named Animal Care 
and Welfare Officer (NACWO) and Named Veterinary Surgeon (NVS).  
Animals may be terminated at any time during the study if any 
unexpected adverse effects are noted according to Home Office Project 
Licence PPL 40/3559. See also 7.4.6. 
All efforts shall be made to image mice prior to termination and on Post 
Mortem to assess excised liver tumour burden by BLI. 
7. EXPERIMENTAL DESIGN 
7.1 Animal Identification 
Each animal will be earmarked and assigned a cage number which will 
appear on the data sheets. Ear markings will be as follows; pl (plain or 
no marking), 1r (1 notch in right ear), 1l (1 notch in left ear), 1r1l, 2r etc 
7.2 Group Sizes, Doses and Identification Numbers 
4 mice per group will be initiated. Once allotted to their treatment/initiation 
groups the mice will be given ID numbers from 1 to 8 that relate to the 
cage and earmarking in order to simplify optical imaging and data 
analysis. 
B Pilot study 
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There will be 4 groups with 4 mice per group initiated with MCF-7 Fluc 
cells as supplied by NN as follows; 
 
Group 1 Standard mammary fatpad (MFP) initiation plus dietary  
estradiol 
Group 2 Subcutaneous initiation with dietary estradiol 
7.3 Body Weights 
Animals will be weighed weekly from initiation for the duration of the 
study. 
7.4 Experimental Procedure 
7.4.1 Cell maintenance  
The MCF-7 Fluc cells are maintained in vitro in RPMI culture medium 
(Sigma, UK?) containing 10% (v/v) heat inactivated foetal bovine serum 
(Sigma, Poole, UK) & 2 mM L-glutamine (Sigma, UK) at 370C in 5% CO2 
and humidified conditions. Cells from sub-confluent monolayers are 
harvested with 0.025% EDTA, washed in culture medium and counted.  
Cells with viability of >90% will be re-suspended and will be seeded at 
2x106 cells  per T150 flask and incubated for 48 hours. On day of initiation 
cells are harvested from semi-confluent monolayers with 0.025% EDTA, 
washed twice in the culture medium and counted 3 times as above. Cells 
with viability of >90% will be re-suspended, for in vivo administration, in 
sterile standard formulation matrigel  at 1 to 2x106 cells/100ul (1 to 2 
x107 cells per ml). Cells will be aliquoted into sterile tubes and 
transported on ice to the F Floor facility for initiation within 30mins of 
arrival 
7.4.2 Tumour Initiation  
Mice will be initiated with 100ul of 1 to 2 x107/ml MCF-7 Fluc cells into 
the appropriate site. 
7.4.3 Monitoring/tumour measurement 
Tumour establishment and growth will be monitored during the 
experiment by caliper measurements twice weekly and 2D and 3D optical 
imaging, carried out under anaesthesia in an IVIS Spectrum, once weekly 
and at termination to provide an optical post mortem. 3D image 
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reconstruction if required and tumour measurements will be made using 
Living Image (4.3.1 build) software. 
Mice will be evaluated daily by an experienced technician until 
termination. 
7.4.3b Treatment 
Animals will be checked daily. The study will continue until tumours reach 
maximum permitted volume/mass as specified in Home Office Project 
Licence PPL 40/3559 and following NCRI guidelines. 
7.4.4  Termination 
Each mouse will continue on the study as described in 7.2, or until the 
tumour size (as measured bioluminescently and specified in the Home 
Office licence) or other clinical signs necessitate removal of that mouse 
from the study. Animals may be terminated at any time during the study 
if the tumour size becomes excessive (tumour burden should not exceed 
RIWKHDQLPDO¶VQRUPDOERG\ZHLJKWRUHVWLPDWHGERG\PDVVRUDQ\
adverse effects, as described below, are noted according to Home Office 
Project Licence PPL 40/3559. Mice will be weighed weekly. Prior to 
termination the mice will be given D-Luciferin substrate to enable the 
excised liver and spleen to be assessed for tumour burden via 
bioluminescent imaging. The mice will be terminated by an approved S1 
method. 
Terminal imaging will be carried out on the cadaver with the skin and 
muscle layers open to expose the primary site (sc or MFP) and adjacent 
lymphatics followed by the body cavity and then all dissected organs in 
dorsal and ventral orientations to assess tumour burden by 
bioluminescence. 
Lymph nodes with identifiable light emission will be preserved in cold 
media for dissagregation to extract cells that may have a metastatic 
phenotype. These cells will be re-passaged to develop a reliable 
metastatic model. If there is enough material some will be fixed for IHC 
analysis 
Other metastatic sites might be of interest ± a decision may be made on 
the day about their importance otherwise see below.  
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After imaging other organs of interest will be weighed and tumours or 
organ thought to contain tumour cells will be preserved half formalin fixed 
and half frozen. If tumour is too small then fix only. 
7.4.5   Adverse effects and humane end points 
Dosing of 
substances 
Adverse 
effects specific 
to the 
substance 
under test 
% 
Unkn
own 
Where supporting data cannot 
be provided in a similar model 
(mouse strain and tumour 
model) or dose level/frequency; 
short (14 days) pilot tolerability 
studies will be carried out (n=2 
per level) to assess novel 
preparations. Duration and dose 
of the substance will be selected 
to minimise frequency and 
adverse effects without affecting 
scientific outcome. 
Animals exhibiting adverse 
effects (e.g. loss of bodyweight 
20%, subdued behaviour 
patterns etc) will be referred to 
the named persons. Any which 
are fail to improve within a 
reasonable time will be killed by 
a schedule 1 method advice  
Subcutaneous 
initiation of 
tumour  
 
Although care is 
taken to position 
the tumour graft 
so that 
subsequent 
growth will take 
place on the 
flank to 
minimise 
disruption to 
movement, in 
<1% animals the 
<0.1% 
Where the experimental results will 
not be compromised the animal will 
be killed by a schedule 1 method. 
Where the loss of the animal would 
compromise the data with the 
resulting waste of the other animals 
in the study, the Named Veterinary 
surgeon, and if the adverse effects 
exceed or are likely to exceed 
moderate the Home Office 
Inspector, will be consulted. 
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tumour will 
develop in such 
a way that this 
occurs. 
  
 
Tumours may 
grow rapidly and 
suddenly 
exceed 
permitted size. 
 
 
 
 
<1% 
except 
during 
pilot 
studies 
when 
may 
approa
ch 
10% 
NCRI guidelines with regard to 
maximum permissible size and 
weight will be observed, if the 
tumour size suddenly (rather than 
gradually) approaches this, the 
animal will be humanely killed. Pilot 
studies will always be performed 
with new tumour lines to determine 
growth rates. 
 
 Ulceration <5% 
Injected cells grown 
subcutaneously have a tendency to 
ulcerate whilst the tumour is quite 
small. The animals will therefore be 
observed regularly as soon as 
growth is established, and the 
mouse will be Schedule 1 sacrificed 
and tumour passaged as soon as 
the skin covering the tumour 
appears to be stretched.  
 
 
Primary 
xenografts, 
particularly 
those from 
luminal sites 
e.g. 
oesophageal, 
gastric and 
colorectal, may 
contain residual 
bacterial 
contamination. 
 
 
<5% 
The Primary tissue is washed and 
incubated with antibiotic/antimycotic 
media overnight prior to 
implantation. 
Animals implanted with these 
tissue-types are treated 
prophylactically with an antibiotic 
under advice of the NVS. 
Any animals exhibiting symptoms of 
local (reddening of the implant site, 
infected wound) or systemic 
(subdued behaviour patterns, 
piloerection, intermittent abnormal 
breathing patterns, weight loss of 
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20%) infection will be immediately 
terminated by a Schedule 1 
method. 
 
 
Slow growing 
xenografts or 
those exhibiting 
a pronounced 
metastatic 
phenotype may 
result in 
metastatic 
tumour spread 
to a distant 
organ. 
 
 
 
<5% 
 
 
 
 
 
 
Symptoms may be specific to the 
metastasised organ e.g. lung 
(intermittent abnormal breathing 
patterns); in addition to general 
symptoms: subdued behaviour 
patterns, piloerection, weight loss of 
20%. Abdomen will be palpated to 
detect the presence of tumours as 
per NCRI Guidelines. Each specific 
experiment protocol will include the 
specific organs likely to be affected 
and associated clinical signs and 
specific humane endpoints 
Animals exhibiting such symptoms 
will terminated by a schedule 1 
method. 
 
Injection into  
the mammary  
fat pad  
 
Due to the 
location of the 
tumour (lower 
left mammary 
pad) 
subsequent 
growth may 
cause disruption 
to movement.  
 
 
up to 
100% 
NCRI guidelines with regard to 
maximum permissible size will be 
observed. If the tumour size and 
position affects normal animal 
behaviour, the animal will be 
humanely killed. Where the loss of 
the animal would compromise the 
data with the resulting waste of the 
other animals in the study, the 
Named Persons will be consulted. 
 
 
Injected cells 
grown 
subcutaneously 
(the fat pad is in 
effect a 
subcutaneous 
site) may 
ulcerate 
<5% 
Animals will be terminated by a 
Schedule 1 method.  
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independent of 
tumour size. 
The animals will 
therefore be 
observed 
regularly as 
soon as growth 
is established. 
 
 
 
Pronounced 
metastatic 
phenotype may 
result in 
metastatic 
tumour spread 
to a distant 
organ. 
 
 
 
% 
Unkno
wn 
To be 
determ
ined 
by 
initial 
pilot 
studies 
 
 
Symptoms may be specific to the 
metastasised organ e.g. lung 
(intermittent abnormal breathing 
patterns); in addition to general 
symptoms: subdued behaviour 
patterns, piloerection weight loss of 
20%. 
Animals exhibiting such symptoms 
will terminated by a schedule 1 
method. 
General and 
Terminal 
Anaesthesia 
Animals 
undergoing 
repeated 
anaesthesia 
events over a 
single day are at 
increased risk of 
dehydration and 
a drop in body 
temperature 
<1% 
 
 
Veterinary advice will be sought in 
order to ensure that animals are 
able to be re-hydrated between 
anaesthetic events. Body 
temperature will be maintained by 
the use of appropriate warming, 
with monitoring to confirm that this 
is achieved. 
Repeated anaesthetic events will 
require the Named Persons or their 
nominees to be notified in advance 
LQRUGHUWRHQVXUHDQLPDOV¶ZHOIDUH
is not unduly compromised, and will 
only be carried out when animals 
have returned to normal eating, 
drinking and mobility. No more than 
two sessions will be carried out in 
any one day, such daily sessions 
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8. DATA & STATISTICAL ANALYSIS 
Body weight and tumour measurement data will be recorded and 
reported in spreadsheet and graphical format. Images and videos will be 
provided as required on the appropriate medium. Statistical analysis will 
be performed if appropriate using either SPSS/Minitab/Prism 
programmes for the PC. Data will be provided to the sponsor as soon as 
possible, the final report will follow when completed. 
9.      FINAL REPORT 
A final report will be completed within 4-weeks of study completion, all 
data generated will be included as part of the therapy study report. 
10.    STORAGE OF DATA 
All documents relating to the study, including raw data, will be stored at 
PCO for 3 years after which time it will become the responsibility of the 
Sponsor. 
11.    Consumables excluding tech time and overheads 
20.00 to 45.00 per mouse depending on source 
175.00 Shipping cages, transportation and delivery  
¼NJ Mouse Chow ± estradiol supplemented  
12.    CHANGES TO PROTOCOL (to be signed off by PPL Holder) 
 
 
 
 
 
 
 
 
 
 
being no less than two days apart 
for two weeks or weekly for five 
weeks. 
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Appendix 2: Sequence of pLVX-S100A4promoter-fLuc 
 
 
 
 
 
«77$&$***$&$*&$*$*$7&&$*777$7&*$7AT^CGATAACTC
CCCTATTTCATGCCATTTCACCTCTAACTCTCCACCCCAACCTGGA
TTCTTCATTCCTGACACTCATCCCAACTTTAAATGGCCCCTCCTGAT
ACCCTCTCCGAACCTGAGATCTATCCGTGAGCCCCCACGCCTCAC
TGCCACTCCACTCCATCACTACCTCACCCAGGACCTTTCCCACTGA
CGTTCCTGAGGTGGTCCCAGAGCCTCCTTTGGGTGTGAGCCTGTT
CCCCTCCAGATCCCCCCGCCCCGACCCTGAGCCTTACTTGGCATG
GCAGACAGTACCGGGCATGGGGATCCCCACCCCAGTTTTTGTTTC
TGAATCTTTATTTTTTTAAGAGACAAGGTCCTCTGTGTTGCTCAGGC
TGGAGAGCAGTGGCTTGAGCATAGCCAACTGCAGTCTCGAACTCC
TGGGCTCAAATGATCCTCCTGTCTCAGCTTCCTGACTAGCTGGGA
CTACAGGCTACAGCCATGCTGCCCAGCTAATTAAAAAAAAAAATTG
TTTTTCCTTTTTATAGAGACAGAAGTCTCTCTATGTTGCCTAGGCTG
GTCTTGAACTCCTGGCCTCAGGCGATCCTCCCATCTCCCCCCTAG
CTTTTGTGTCACCACATTTCCAGGGCAATCTCCCACCTGTCACCCA
CCACCCCCTGCATCTCCTTTCCTAGGTCCCCATGGGACTACTCCCT
GTCCCCCATGCTCCAGGCACAGGCTGCCCCTTCCTCCACCTCTCT
AAAACTCAGGCTGAGCTATGTACACTGGGTGGTGCCCATCTCATC
CAGTCCCCTGCTAGTAACCGCTAGGGCTTACCCGTTACCCACGGG
TGCCCACCTGGGAACAGGAGGCTTGGTTCCACGGCTGGGCTGGT
GGAGGGTGCTGTGGCACTTACCGCATCAGCCCACAGCAGGAAGG
CAGTATCCGCTCTCCCCTGTCCCCTGCTATGGGCAGGGCCTGGCT
GGGGTATAAATAGGTCAGACCTCTGGGCCGTCCCCATTCTTCCCC
TCTCTACAACCCTCTCTCCTCAGCGCTTCTTCTTTCTTGGATTGGT
GAGTTGTGTTGC^TCGAGCTCAAGCTTCGAATTCTGCAGTCGACG
GTACCGCGGGCCCGGGATCTGGCCTCGGCGGCCAAGCTTGGCAA
Bold = Restriction enzymes (ClaI, XhoI) / Cloning sites 
Underlined = S100A4 promoter 
Box = Change from the original sequence (T to A)  
Double underlined = Firefly Luciferase 
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TCCGGTACTGTTGGTAAAGCCACCATGGAAGATGCCAAAAACATTA
AGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGA« 
 
 
Appendix 3: Sequence of pLVX-Ncadherin promoter-fLuc 
 
 
 
 
«ATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTC
GATTAGTGAACGGATCTCGACGGTATCGCCTTTAAAAGAAAAGGG
GGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATA
GCAACAGACATACAAACTAAAGAACTACAAAAACAAATTACAAAAAT
TCAAAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCAGTTTAT
^CGATGGCTCTAGGGGCTGGATTGCGGGTCCCCTCTGCTCCTTCT
TCGGGGCCGAGCAAGCTCGCGGGGGGTGTCCCCAGGCAGCAGG
AGGGTGAGGCAGGATAACTCCCAGGTTTTGCAGTTTTCTGTGCCT
TTCGCCCCTCGCATAGTACTTTGCTCCAATTTTTTTGTTTATTTCTG
CAGGGATGGGTCGCGAGTTTACAGTAGGAATTCTCACTCTGGTGT
CTTAGTTACGGGACTTGCCTCCACCTTACCCCACCCTGCACCCGT
GCGCCTCCCGGTGCTCAAGGGCTCTACTGTCCTATTGTCTTTATCC
CAGTCTGGAGTTGCCTCCTTTTCTTCTTCTCTTGCCCTCACAATATT
CTGTGTTCGTCCCACCTGGAAAGAAAATCTGGCCCTCTTGCCCGG
AGGAGTCTCTGCCGGTCAGCGCCTGCCTGTAGAACGAGTCTGGC
CTCTCACGCCTAGTATCTCCCCCGGGCGAGAAGTTCCGTTACGCG
GCTGCTCCTTTCTCTGTCCGGCTGCCTGTGCCCTATATGCGCCCC
GGGGGCGCCTTTGCCTGGAGCCTTCCGTACTTTTCATACCCTCGG
GAGAGAGCCAGCGAGCCTTTTCACTTAATCTCTACTAAGAGGCTC
CTCCGCGGCAGGAAGCACCTGCTCCAGTCCGGGCGCAGGTTCCC
TCGCCACTGCACGCTGCGGGTTCCCAGCCCGGGGGCAGCCCAAC
TTTCCGCCGCCTCCAACCCGAGGATGCCCCCAGGCTCCTCCCGA
Underlined = N-cadherin promoter 
Box = Change from original sequence (T to C) 
Bold = Restriction enzymes (ClaI, XhoI) / Cloning sites 
Double underlined = Firefly Luciferase 
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CCAGCCAGCCCAGGCCTGGAGGCCACTTCACACAGCCTCGGCCG
GGACCCTCTAGCTGGGCGGGTGCAGTGCCCTGGTCCCAAGTCGG
TCTCCGCCTGCCGTGGGGTCCCTCGAAGGTTGCGGGAAAGGGGC
GTGCCCACCCTCGCCGCGGGGCAGGAAAATCCACGGAGGGTCCC
CCTGCCTGTCGCCCTCGGGGCAAGGGGAGAGGTGCTCTACTGCC
AGCTGGCAGCCCCGAAAAGTGCGGACGCAGCTCGGAAGTGCCTG
CTCCGGGGGTGGAGACAGGTGGTGTGGATTACCCCGCTCCGTGG
TCTTCACGGGTCAGGGCCTGGCGCGCTCCGGCCCGCCGGGGGG
TGAGTGCTGCTGGGGCGGGGGCAGGGGCTGGACGGGGCTGGCC
TCCGCAGTCTCTCGCGCTTTCTCCCGCAACCCCTAGACGGTCGTG
GGCCGCCGCCGCGCGGAGCCCTGTCCATGGTGCGCCATGGTGC
GGCACGCCTGTCCCTGCCCGGCTCCACGCTCTCCTCCCGGGTCG
TGCTCTCTCACTTTGTCTCTCCCCACCCCTGCCTCCCAGGCCAGG
GTCCCAGCGTTCCTTTTCCCTTTCTTGGATTTCTTCTTTTGTTCTTT
AGTCTCCTACCGGTCTTTCTCCCTTCCCCCACTCGCCATCCGCCAC
TCGGCTCTCTCCTGACTCGGGGATTTCAGAACTATTAGACTAGACA
TTTTTGGCCTTTGCAGTTTTGGAGAGTGGATGGAATTCCTTCTAAC
TTGGGGGAGGAGACCTGCCAGTCACTTGCTAACAAAAGTACCTCC
TGTTATAAAACCGCCCTTTATTCTCCCAGCGCACACTCCTCATTCTT
TGACCTCCTGTCACTTCATTTATTGTTTCTTCTTTAAAAATGGGGTT
TATTAAAGAGGTTAGGCTGAAGGAGGAAGAAGGAAAAAAGTCCTG
CTTCTAAAGTATTTGAAGTTAAATGGAAGGCAAGACAAACTTAAAG
ACTCCTGTGTATTAGGATTTTTTTTTAACAAAGGAGATGTGATACAT
TTTTTACAAATCTTACTTTAAAAACACTAATTTTTGGACAGCATTGG
GTCGTCTTATTTACAGACAGTAAATCCTCAGTGTGAATCCAGCAGC
AGATGGTTATTTTCACAAACTTTTTCATCTAAAAGTGAGTTTTAATT
GAATACTGTGCAGCGAAGTTAGGACACGAAGAGACATTTGTTGGT
CATGAATACTGTGGGAAATCTATGTGTGTTACAAGTGGAGCACTCT
CATTTTCTGTTTTAGTCATCTGCCTTGAAGTCAGGTGTGAATTTTCT
GTCAGTTTTTTCTTAAGTGTTTCTAAAAATATCGTTTATAAGCATTAA
ATAATGTGCTTTTCCATTGTATGTTCTTTCTCAGTTTCTTCTATACCA
ATGTTGACTTTTTTAAACCTTCAGGAAAGGAGAAATTATAACTTTCT
CATCAAGTTATTTGGCAGTCCTCTAATTCATGAGTACAAGTCAAGC
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AGTAACATTGAATGATTTGAAAGGTCATTAGGAGTGGAAGCAGAGC
AGTTTACGCAACATGAGTTTTAGGGTTAAGTGCACCATGTGGATTG
TACAACTGAGATTAGAAATGACTTTGTGCTAATGGTCTGCTTTACA
CGCCCGAACAACAC^TCGAGCTCAAGCTTCGAATTCTGCAGTCGA
CGGTACCGCGGGCCCGGGATCTGGCCTCGGCGGCCAAGCTTGG
CAATCCGGTACTGTTGGTAAAGCCACCATGGAAGATGCCAAAAAC
ATTAAGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGACC
GCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGT
GCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGACAT
7$&&7$&*&&*$*7$&77&*« 
 
 
 
Appendix 4: Sequence of pLVX-E-cadherin promoter-fLuc 
 
 
 
 
 
«AAATTCAAAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCAG
TTTAT^CGATAAATTAGGCTGCTAGCTCAGTGGCTCATGGCTCACA
CCTGAAATCCTAGCACTTTGGGAGGCCAAGGCAGGAGGATCGCTT
CAGCCCAGGAGTTCGAGACCAGGCTGGGCAATACAGGGAGACAC
AGCGCCCCCACTGCCCCTGTCCGCCCCGACTTGTCTCTCTACAAA
AAGGCAAAAGAAAAAAAAAATTAGCCTGGCGTGGTGGTGTGCACC
TGTACTCCCAGCTACTAGAGAGGCTGGGGCCAGAGGACCGCTTG
AGCCCAGGAGTTCGAGGCTGCAGTGAGCTGTGATCGCACCACTG
CACTCCAGCTTGGGTGAAAGAGTGAGCCCCATCTCCAAAACGAAC
AAACAAAAAATCCCAAAAAACAAAAGAACTCAGCCAAGTGTAAAAG
CCCTTTCTGATCCCAGGTCTTAGTGAGCCACCGGCGGGGCTGGG
ATTCGAACCCAGTGGAATCAGAACCGTGCAGGTCCCATAACCCAC
CTAGACCCTAGCAACTCCAGGCTAGAGGGTCACCGCGTCTATGCG
AGGCCGGGTGGGCGGGCCGTCAGCTCCGCCCTGGGGAGGGGTC
Underlined = E-cadherin promoter 
Bold = Restriction enzymes (ClaI, XhoI) / Cloning sites 
Box = Change from original sequence (C to T) 
Double underlined = Firefly Luciferase 
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CGCGCTGCTGATTGGCTGTGGCCGGCAGGTGAACCCTCAGCCAA
TCAGCGGTACGGGGGGCGGTGCCTCCGGGGCTCACCTGGCTGCA
GCCACGCACCCCCTCTCAGTGGCGTCGGAACTGCAAAGCACCTGT
GAGCTTGCGGAAGTCAGTTCAGACTCCAGCCCGCTCCAGCCCGG
CCCGACCCGACCGCACCCGGCGCCTGCCCTCGCTCGGCGTCCCC
GGCCAGCCATGGGCCCTTGGAGCCGCAGCCTCTCGGCGCTGCTG
CTGCTGCTGCAGGTACCTCGGATCCCCTGACTTGCGAGGGACGC
ATTC^TCGAGCTCAAGCTTCGAATTCTGCAGTCGACGGTACCGCG
GGCCCGGGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTAC
TGTTGGTAAAGCCACCATGGAAGATGCCAAAAACATTAAGAAGGG
&&&$*&*&&$77&« 
 
 
Appendix 5: DNA sequence of Twist1 expressing vector 
 
 
 
 
 
 
 
 
 
«GCTTGGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCC
TGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGAC
GTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAA
TGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAA
GTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTA
AATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACT
TTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATG
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTT
GACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGG
AGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTA
Double underlined = CMV promoter 
Green = TWIST1 (Underlined = Exon 1, Bold = Part of Exon 2) 
Bold = Restriction enzymes (EcoRI & BamHI) / Cloning sites 
Italic = IRES 
Italic underlined = tdTomato 
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ACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGT
GGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCG
CCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACC
GACTCTACTAGAGGATCTATTTCCGGTG^AATTCGAGGTATAAGAG
CCTCCAAGTCTGCAGCTCTCGCCCAACTCCCAGACACCTCGCGGG
CTCTGCAGCACCGGCACCGTTTCCAGGAGGCCTGGCGGGGTGTG
CGTCCAGCCGTTGGGCGCTTTCTTTTTGGACCTCGGGGCCATCCA
CACCGTCCCCTCCCCCTCCCGCCTCCCTCCCCGCCTCCCCCGCG
CGCCCTCCCCGCGGAGGTCCCTCCCGTCCGTCCTCCTGCTCTCTC
CTCCGCGGGCCGCATCGCCCGGGCCGGCGCCGCGCGCGGGGGA
AGCTGGCGGGCTGAGGCGCCCCGCTCTTCTCCTCTGCCCCGGGC
CCGCGAGGCCACGCGTCGCCGCTCGAGAGATGATGCAGGACGTG
TCCAGCTCGCCAGTCTCGCCGGCCGACGACAGCCTGAGCAACAG
CGAGGAAGAGCCAGACCGGCAGCAGCCGCCGAGCGGCAAGCGC
GGGGGACGCAAGCGGCGCAGCAGCAGGCGCAGCGCGGGCGGC
GGCGCGGGGCCCGGCGGAGCCGCGGGTGGGGGCGTCGGAGGC
GGCGACGAGCCGGGCAGCCCGGCCCAGGGCAAGCGCGGCAAGA
AGTCTGCGGGCTGTGGCGGCGGCGGCGGCGCGGGCGGCGGCG
GCGGCAGCAGCAGCGGCGGCGGGAGTCCGCAGTCTTACGAGGA
GCTGCAGACGCAGCGGGTCATGGCCAACGTGCGGGAGCGCCAG
CGCACCCAGTCGCTGAACGAGGCGTTCGCCGCGCTGCGGAAGAT
CATCCCCACGCTGCCCTCGGACAAGCTGAGCAAGATTCAGACCCT
CAAGCTGGCGGCCAGGTACATCGACTTCCTCTACCAGGTCCTCCA
GAGCGACGAGCTGGACTCCAAGATGGCAAGCTGCAGCTATGTGG
CTCACGAGCGGCTCAGCTACGCCTTCTCGGTCTGGAGGATGGAG
GGGGCCTGGTCCATGTCCGCGTCCCACTAGCAGGCGGAGCCCCC
CACCCCCTCAGCAGGGCCGGAGACCTAGATGTCATTGTTTCCAGA
GAAGGAGAAAATGGACAGTCTAGAGACTCTGGAGCTGGATAACT
AAAAATAAAAATATATGCCAAAGATTTTCTTGGAAATTAGAAGAG
CAAAATCCAAATTCAAAGAAACAGGGCGTGGGGCGCACTTTTAA
AAGAGAAAGCGAGACAGGCCCGTGGACAGTGATTCCCAGACGG
GCAGCGGCACCATCCTCACACCTCTGCATTCTGATAGAAGTCTGA
ACAGTTGTTTGTGTTTTTTTTTTTTTTTTTTGACGAAGAATGTTTTTA
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TTTTTATTTTTTTCATGCATGCATTCTCAAGAGGTCGTGCCAATCA
GCCACTGAAAGGAAAGGCATCACTATGGACTTTCTCTATTTTAAA
ATGGTAACAATCAGAGGAACTATAAGAACACCTTTAGAAATAAAA
ATACTGGGATCAAACTGGCCTGCAAAACCATAGTCAGTTAATTCT
TTTTTTCATCCTTCCTCTGAGGGGG^GATCCCGCCCCTCTCCCTCC
CCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCG
GTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTG
GCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCA
TTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTT
GAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACA
AACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACC
TGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATAC
ACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGAT
AGTTGTGGAAAGAGTCAAATGGCTCACCTCAAGCGTATTCAACAAG
GGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGAT
CTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTA
AAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTT
GAAAAACACGATGATAATATGGTGAGCAAGGGCGAGGAGGTCATC
AAAGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCATGAAC
GGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCT
ACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGC
CCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCATGTAC
GGCTCCAAGGCGTACGTGAAGCACCCCGCCGACATCCCCGATTA
CAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGAT
GAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCCT
CCCTGCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGC
ACCAACTTCCCCCCCGACGGCCCCGTAATGCAGAAGAAGACCATG
GGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGGCGT
GCTGAAGGGCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCG
GCCACTACCTGGTGGAGTTCAAGACCATCTACATGGCCAAGAAGC
CCGTGCAACTGCCCGGCTACTACTACGTGGACACCAAGCTGGACA
TCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAGC
GCTCCGAGGGCCGCCACCACCTGTTCCTGGGGCATGGCACCGGC
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AGCACCGGCAGCGGCAGCTCCGGCACCGCCTCCTCCGAGGACAA
CAACATGGCCGTCATCAAAGAGTTCATGCGCTTCAAGGTGCGCAT
GGAGGGCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGG
GCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAG
GTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTC
CCCCCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCCCGC
CGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAA
GTGGGAGCGCGTGATGAACTTCGAGGACGGCGGTCTGGTGACCG
TGACCCAGGACTCCTCCCTGCAGGACGGCACGCTGATCTACAAGG
TGAAGATGCGCGGCACCAACTTCCCCCCCGACGGCCCCGTAATG
CAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTA
CCCCCGCGACGGCGTGCTGAAGGGCGAGATCCACCAGGCCCTGA
AGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCAAGACCATCT
ACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTACTACGTGG
ACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCG
TGGAACAGTACGAGCGCTCCGAGGGCCGCCACCACCTGTTCCTG
TACGGCATGGACGAGCTGTACAAGTGAACGCGTCTGGAACAATCA
ACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACT
$7*77*&7&&7777$&*&7$7*7**$7$« 
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Appendix 6:  Immunofluorescence staining of mono-cultures for E-
cadherin.  
A. Image of cells stained with the secondary antibody only taken with the 
FITC channel. B. Image of cells stained with the isotype control taken 
with the FITC channel. Image of cells stained with the E-cadherin 
antibody taken with the brightfield channel (C), the Dapi channel (D) and 
the FITC channel (E). F. Merge picture of cells stained with E-cadherin 
of the Dapi and FITC channels. Dapi shows the nuclei of the cells and 
FITC shows the expression of the secondary antibody (AF 488) bound to 
the isotype control or E-cadherin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
E F 
Brightfield/Dapi/FITC (Secondary antibody/E-cadherin) 
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Appendix 7: Immunofluorescence staining of co-cultures for E-cadherin. 
A. Image of cells stained with the secondary antibody only taken with the FITC 
channel. B. Image of cells stained with the isotype control taken with the FITC 
channel. Image of cells stained with the E-cadherin antibody taken with the 
brightfield channel (C), the HcRed channel (mCherry MSCs), the Dapi channel 
(E) and the FITC channel (F). Merge picture of cells stained with E-cadherin of 
the Dapi and FITC channels (G) or the Dapi, FITC and HcRed (H). Dapi shows 
the nuclei of the cells and FITC shows the expression of the secondary antibody 
(AF 488) bound to the isotype control or E-cadherin.  
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E F 
G H 
E F 
G H 
Brightfield/Dapi/FITC (Secondary antibody/E-cadherin)/ 
HcRed (mCherry MSCs) 
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Appendix 8: IF staining of mono-cultures for Vimentin. A. Image of 
cells stained with the secondary antibody only taken with the FITC 
channel. B. Image of cells stained with the isotype control taken with the 
FITC channel. Image of cells stained with the Vimentin antibody taken 
with the brightfield channel (C), the Dapi channel (D) and the FITC 
channel (E). F. Merge picture of cells stained with E-cadherin of the Dapi 
and FITC channels. Dapi shows the nuclei of the cells and FITC shows 
the expression of the secondary antibody (AF 488) bound to the isotype 
control or Vimentin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
E F 
Brightfield/Dapi/FITC (Secondary antibody/Vimentin) 
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Appendix 9. IF staining of co-cultures for Vimentin.  
A. Image of cells stained with the secondary antibody only taken with the FITC 
channel. B. Image of cells stained with the isotype control taken with the FITC 
channel. Image of cells stained with the Vimentin antibody taken with the 
brightfield channel (C), the HcRed channel (mCherry MSCs), the Dapi channel 
(E) and the FITC channel (F). Merge picture of cells stained with Vimentin of the 
Dapi and FITC channels (G) or the Dapi, FITC and HcRed (H). Dapi shows the 
nuclei of the cells and FITC shows the expression of the secondary antibody 
(AF 488) bound to the isotype control or Vimentin.  
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C D 
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G H 
Brightfield/Dapi/FITC (Secondary antibody/E-cadherin)/ 
HcRed (mCherry MSCs) 
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Appendix 10: H&E staining of LNs 
A. Lymph node 1 (LHS). B. Lymph node 3 (LHS). C. Lymph node 4 
(LHS).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
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Appendix 11: Isotype controls for E-cadherin staining 
A-D. Mice 1-4 from group 1 (MCF-7/fLuc cells in the MFP). C-H Mice 5-
8 from group 2 (MCF-7/fLuc cells SC). Control antibody = Mouse IgG1 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
E F 
G H 
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Appendix 12. Isotype controls for Vimentin staining 
A. Positive control (human colorectal tumour). B-E xenografts 1-4 from 
group 1. F-H. Xenografts 5-7 from group 2. Isotype control = Mouse IgG1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 13: Isotype controls for S100A4   
A B 
D C 
E F 
G H 
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A. Xenograft from mouse 1. B. Xenograft from mouse 2. Control = Rabbit 
serum. 
 
 
 
 
  
A B 
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Appendix 14: Isotype controls for E-cadherin staining  
A-C. Xenografts from mice 1-3 (Group 1; MCF-7 alone). D-F. Xenografts 
from mice 4-6 (Group 2; MCF-7 + MSCs). Isotype control = Mouse IgG1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A D 
B E 
C F 
247 
 
Appendix 15: Isotype controls for Vimentin staining 
A-C. Xenografts from mice 1-3 (Group 1; MCF-7 alone). D-F. Xenografts 
from mice 4-5 (Group 2;MCF-7 + MSCs). Isotype control = Mouse IgG1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A D 
B E 
C F 
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Appendix 16: Isotype controls for S100A4 staining 
A-C. Xenografts from mice 1-3 (Group 1; MCF-7 alone). D-F. Xenografts 
from mice 4-6 (Group 2; MCF-7 + MSCs). Control = Rabbit serum 
  
 
 
 
 
 
 
 
 
A D 
B E 
C F 
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Appendix 17: Isotype controls for E-cadherin staining 
A-B. Xenografts from mice 1-2 (Group 1; MCF-7 alone). C-D. Xenografts 
from mice 3-4 (Group 2; MCF-7 + MSCs). Isotype control = Mouse IgG1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C D 
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Appendix 18: Isotype controls for Vimentin staining 
A. Positive control (xenograft 6, Figure 81A). B-C. Xenografts from mice 
1-2 (Group 1; MCF-7 alone). D-E. Xenografts from mice 3-4 (Group 2; 
MCF-7 + MSCs). Isotype control = Mouse IgG1. 
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Appendix 19: Isotype controls for S100A4 staining 
A. Positive control (MDA-MB-231 xenograft from a study performed in 
house). B-C. Xenografts from mice 1-2 (Group 1; MCF-7 alone). D-E. 
Xenografts from mice 3-4 (Group 2; MCF-7 + MSCs). Control = Rabbit 
serum. 
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Appendix 20: Isotype controls for E-cadherin staining  
A-D. Xenografts from mice 1-4 (Group 1; MCF-7/fLuc). E-H. Xenografts 
from mice 5-8 (Group 2; MCF-7/fLuc + MSCs). Isotype control = Mouse 
IgG1 
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Appendix 21: Isotype controls for Vimentin staining  
A-D. Xenografts from mice 1-4 (Group 1; MCF-7/fLuc). E-H. Xenografts 
from mice 5-8 (Group 2; MCF-7/fLuc + MSCs). Isotype control = Mouse 
IgG1 
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Appendix 22: Isotype controls for S100A4 staining  
A-D. Xenografts from mice 1-4 (Group 1; MCF-7/fLuc). E-H. Xenografts 
from mice 5-8 (Group 2; MCF-7/fLuc + MSCs). Isotype control = Rabbit 
serum 
 
  A B 
C D 
E F 
G H 
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Appendix 23: Isotype controls for S100A4 staining 
A-D. Mice 1-4 from group 1 (MCF-7/S100A4-fLuc/mCherry). E-H Mice 5-
8 from group 2 (MCF-7/S100A4-fLuc/mCherry + MSCs).. Control 
antibody = Rabbit serum 
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C D 
E F 
H G 
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Appendix 24: Isotype controls for E-cadherin staining 
A-D. Mice 1-4 from group 1 (MCF-7/S100A4-fLuc/mCherry). E-H Mice 5-
8 from group 2 (MCF-7/S100A4-fLuc/mCherry + MSCs).. Control 
antibody = Mouse IgG1 
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Appendix 25: Isotype controls for Vimentin staining 
A-D. Mice 1-4 from group 1 (MCF-7/S100A4-fLuc/mCherry). E-H Mice 5-
8 from group 2 (MCF-7/S100A4-fLuc/mCherry + MSCs).. Control 
antibody = Mouse IgG1 
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